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Frontotemporal dementia (FTD) is a clinically, genetically and pathologically heterogeneous 
disorder characterised by a change in language, behaviour and personality, which can also be 
accompanied by the signs of motor neuron disease (MND). Further, it is considered to be the 
second most common form of presenile dementia. Pathologically, it is characterised by atrophy 
of the frontal and anterior temporal lobes. In 2006, TDP-43 was identified as the major component 
of the ubiquitinated neuronal inclusions found in both frontotemporal lobar degeneration (FTLD) 
and MND. However, the role of TDP-43 in the neurodegenerative process of FTLD and MND is 
not yet fully understood. Identifying the TDP-43 protein network could assist in understanding 
TDP-43’s pathological mechanism in neurodegeneration.   
In this study, I screened for candidate TDP-43-binding proteins in the brain and spinal cord tissue 
of FTLD and MND cases using immunohistochemistry. Striking inclusions were detected with 
hnRNP-E2 in the brain of 16 out of 30 FTLD-TDP cases which do not carry the C9orf72 mutation. 
The hnRNP-E2 pathology is significantly related to the TDP-43 pathological subtypes A and C.  
Furthermore, hnRNP-E2 inclusions colocalised with 84.5% of TDP-43 inclusions and with 67% of 
ubiquitin inclusions that were also seen in the brain tissue of the FTLD-TDP cases found to exhibit 
hnRNP-E2 pathology. hnRNP-E2 inclusions were not detected in any of the other 
neurodegenerative diseases examined in this study, which suggests the close relation of hnRNP-
E2 to the pathology of TDP-43.  
In order to explore the mechanistic connection between TDP-43 and hnRNP-E2 as well as the 
possible role of this interaction in TDP-43 pathogenesis, cell biology techniques were utilised to 
manipulate the levels of TDP-43 and hnRNP-E2 expression in the HEK293T cell line. The 
knockdown of hnRNP-E2 caused a significant reduction in the TDP-43 levels; however, the 
interaction was not confirmed. Yet, the hnRNP-E2 interacted with the TDP-43 in the stress 
granules of HeLa cells under combined osmotic and oxidative stress. At this point, it remains 
unclear how and why hnRNP-E2 interacted with TDP-43 in a subset of FTLD-TDP cases. 
However, the results presented here demonstrate that the role of hnRNP-E2 in TDP-43 
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Chapter 1 Introduction 
1.1 Frontotemporal Dementia and Motor Neuron Disease 
1.1.1 Overview 
Frontotemporal dementia (FTD) is the third most common type of dementia in all age groups as 
well as the leading type of dementia in presenile cases after Alzheimer’s disease (AD) and 
dementia with Lewy bodies (DLB). The most prominent characteristic of frontotemporal lobar 
degeneration (FTLD) is atrophy of the frontal and temporal lobes, which renders it an umbrella 
term for a group of neurodegenerative diseases characterised by behavioural changes or 
language deficits (Miyoshi, 2009, Bang et al., 2015). Arnold Pick (1892) was the first to describe 
FTLD in a patient with presenile dementia, aphasia and lobar atrophy. Two decades later, Alois 
Alzheimer (1911) recognised the characteristic pathological association of Pick bodies and hence 
named the clinicopathological entity Pick’s Disease. From that point, Pick’s disease was used as 
a synonym for FTLD until 1982, when Mesulam described a language subtype of the disorder that 
is now defined as primary progressive aphasia (Bang et al., 2015). According to the predominant 
clinical presentation, FTD can be classified into three major clinical subtypes, namely the 
behavioural variant (bvFTD) and two forms of primary progressive aphasia (PPA), that is, the non-
fluent variant (nfvPPA) and the semantic variant (svPPA) (Mackenzie and Neumann, 2016). The 
clinical diagnosis of FTD is challenging due to the similarities of the associated behavioural 
changes to those seen in psychiatric disorders. 
Abnormal protein aggregation in the neuronal cytoplasm is a key feature of most 
neurodegenerative diseases and a number of disease-specific pathological proteins were 
identified decades ago, for example, tau protein, which composes the neurofibrillary tangles of 
Alzheimer’s disease. However, the protein composition of the ubiquitinated inclusions found in 
motor neuron disease (MND) and FTLD-U (the most common form of frontotemporal dementia) 
was not identified until 2006, when the trans-activation response DNA-binding protein-43 (TDP-
43) was identified as the major component of these inclusions (Neumann et al., 2006b, Arai et al., 
2006, Kwiatkowski et al., 2009, Vance et al., 2009), which led to the novel molecular classification 
of FTLD. In this chapter, I will discuss the clinical features and clinical classification of FTLD as 
well as the FTLD pathological and molecular classification according to recent findings. 




areas for therapeutic development. Finally, a brief overview of the heterogeneous nuclear 
ribonucleoproteins (hnRNPs) will be presented.   
 
1.1.2 Clinical features of FTD  
Clinically, FTD is classified into three types, namely the behavioural variant frontotemporal 
dementia (bvFTD), the semantic variant primary progressive aphasia (svPPA) and the non-fluent 
variant primary progressive aphasia (nfvPPA). FTLD is further classified into frontal lobar 
degeneration, Pick FTLD and FTLD with motor neuron disease (FTLD-MND). MND refers to a 
group of diseases wherein the upper and/or lower motor neurons are affected. FTLD is often 
associated with MND, specifically with the narrower spectrum of MND known as amyotrophic 
lateral sclerosis (ALS). The prevalence of FTLD ranges from 3% to 26% in most studies (Lambert 
et al., 2014, Hodges et al., 2003, Kansal et al., 2016). It has been estimated by the World Health 
Organization (WHO) (2017) that dementia rates will double every year, reaching 135.5 million 
cases in 2050. The epidemiology of FTD is summarised in Table 1. The chance of survival in FTD 
varies among the different FTLD phenotypes, with FTLD with MND having the shortest average 
survival period of 2.5 years while the survival period ranges from 8–12 years among the rest of 
the FTLD phenotypes (Kansal et al., 2016). The survival rate is not affected by either age or 
gender, and the effect of education was found to be equivocal. Further, the survival heterogeneity 
is not completely explained by the heterogeneity of the FTLD phenotypes (Kansal et al., 2016).   
 
 
Table 1: Epidemiology of frontotemporal dementia (Bang et al., 2015) 
 Age Prevalence 
Patients with early dementia <65 3–26% 
US general population 45–64 12–22 per 100,000 
UK general population  45–64 3–26 per 100,000 








The diagnostic criteria for FTD outline the clinical symptoms, imaging features and genetically 
confirmed diagnosis. Applying these diagnostic criteria increases the possibility of identifying 
related neuropathology. As frontotemporal dementia progresses, global cognitive impairment 
develops and the symptoms of the three clinical variants can converge. Over time, patients 
develop motor deficits, including parkinsonism and MND. At the end stage of the disease, patients 
experience difficulty moving, feeding and swallowing, and death is typically caused by pneumonia 
or other secondary infections (Bang et al., 2015). The emphasis of this study is on the FTLD-MND 
spectrum; however, a brief review of the clinical aspects of other types of FTLD will be performed. 
 
1.1.2.1 Behavioural variant frontotemporal dementia (bvFTD) 
The most pronounced early symptoms of this type of FTD include personality changes, 
disinhibition and apathy. The behavioural disinhibition can result in socially inappropriate 
behaviour and/or impulsive or careless actions. It can also include the development of new 
criminal behaviours, for example, theft, and a tendency to make embarrassing personal remarks. 
The decreased inhibition can also lead to inappropriate fiscal decisions that can result in financial 
ruin. Further, patients usually have reduced libido, although they may make inappropriate sexual 
comments. Apathy can be mistaken for depression, since it manifests as a decreased interest in 
social interaction, work, hobbies and hygiene. Patients also show lower responsiveness to 
emotions and the needs of other people as well as a loss of sympathy and empathy towards their 
relatives and friends. Additionally, they can show stereotyped behaviours such as repetitive 
movements or the repetitive use of verbal phrases. Increased consumption of sweet foods or 
binge eating can be a reflection of hyperorality in patients with the behavioural variant of FTD. 
The course of this disease type is very slow, with the progression of the cognitive deficit taking 
years and normal positron emission tomography (PET) and magnetic resonance imaging (MRI) 
scans often being seen at the outset. Some of these patients suffer primary psychiatric disorders, 
while others may have a slow sporadic or genetic form of FTLD. The pathogenesis of the 






1.1.2.2 Primary progressive aphasia (PPA) 
The initial phase of this type of FTD includes a gradual, progressive decline in linguistic skills. 
During the first few years, the language deficit can impact the naming of objects, language 
production, syntax or word understanding as detected through conversations or language 
assessment, which has a significant detrimental effect on daily living activities. If the patient 
presents with visuospatial or episodic visual memory impairments, then Alzheimer’s disease 
should be considered. Patients usually show no behavioural disturbance during the initial phase 
of this type of FTD (Mesulam, 2001, Bang et al., 2015).   
 
1.1.2.2.1 Semantic variant primary progressive aphasia (svPPA) 
Semantic dementia is a syndrome characterised by semantic aphasia and associative agnosia, 
which is an inability to interpret sensations and therefore an inability to identify objects (Neary et 
al., 1998). The semantic loss leads to impaired word finding and comprehension, which mainly 
results from the asymmetrical degeneration of the anterior temporal lobes and amygdala (Seeley 
et al., 2005). The left temporal lobe (semantic) variant is approximately three times more common 
than the right temporal (behavioural) type of FTD. During the initial phase of the disease, the other 
language domains are spared and patients retain fluent speech and correct grammar. Further, 
the people and object recognition deficits extend beyond the visual and tactile domain to olfactory 
and gustatory clues. With disease progression, behavioural changes may manifest, including 
emotional withdrawal, irritability, insomnia and strict or selective eating. In the left temporal lobe 
variant, the right side functions are heightened. Therefore, patients will develop visual 
compulsions, for example, repetitive playing with puzzles and painting. Yet, patients with the right 
lobe variant can develop verbal compulsions involving words and symbols, such as writing 
telephone numbers and letters or playing solitaire (Bang et al., 2015).   
 
1.1.2.2.2 Non-fluent variant primary progressive aphasia (nfvPPA) 
The main characteristic of this type of FTD is laboured, slow and stuttered speech production with 
the misuse or omission of grammar. Speech and sound errors are often made by patients, 
including substitutions, insertions, deletions, transposition and distortion. Although patients 
experience no trouble in understanding simple sentences, they can misunderstand sentences 




prominent impairment in terms of the spoken language. Object knowledge and single word 
recognition are not affected in this type of FTD (Bang et al., 2015, Gorno-Tempini et al., 2011).   
 
1.1.2.3 Frontotemporal dementia with motor neuron disease (FTLD-MND) 
Dementia in MND patients has been intermittently reported over the last 100 years. However, the 
concept of an FTLD-MND interrelationship has only fully emerged during the last decade as more 
pathological and genetic discoveries have enforced their specific association. Nowadays, FTLD-
MND is recognised as a dementia syndrome that presents a unique set of diagnostic and 
management challenges. Some 10–15% of MND patients are diagnosed with FTD, although mild 
cognitive impairment can be recognised in a higher proportion of MND patients (Burrell et al., 
2016, Mitsuyama and Inoue, 2009). Further, 40% of FTD patients develop mild MND symptoms 
(Burrell et al., 2011). MND symptoms arise more frequently in patients with the behavioural variant 
of FTD when compared to the semantic or non-fluent variant primary progressive aphasia.  
Typically, patients will present with upper and lower motor neuron signs. The upper motor neuron 
signs include hyperreflexia, spasticity and extensor plantar response, while the lower motor signs 
include muscular atrophy, weakness and fasciculation. FTD patients also present with clinical 
features of corticobasal syndrome, which is characterised by asymmetrical parkinsonism, 
sensory-motor cortical dysfunction, dystonia and alien-limb syndrome. In addition, FTD patients 
can display the clinical features of supranuclear palsy syndrome, which is characterised by 
postural instability with a tendency for falling and decreased eye movement velocity. Apathy, 
impulsivity and executive behavioural dysfunction are all common in FTLD-MND patients (Burrell 
et al., 2011, Bang et al., 2015, Hsieh et al., 2016). The diagnostic criteria for the FTD clinical 















Figure 1: Diagnostic criteria for the clinical diagnosis of FTD (Bang et al., 2015).  
 
 
1.1.3  Pathological subtypes of FTLD 
Neuronal loss, microvacuolar changes and gliosis of the frontal lobes, anterior temporal lobes, 
insular cortex and anterior cingulate gyrus represent the common gross anatomy characteristics 
of FTLD. Advances in immunohistochemistry and molecular biology techniques have led to the 
further classification of the FTLD spectrum disorders according to the predominant 
neuropathological protein deposition in the brain of FTLD patients. Three main pathological 
categories of FTLD have been identified. The majority of FTLD cases are characterised by 




the TAR DNA-binding protein with a molecular weight of 43 kDa (TDP-43) (FTLD-TDP) or, more 
rarely, the protein fused in sarcoma (FUS) (FTLD-FUS). A very small proportion of FTLD cases 
have a ubiquitin-only or p62-only positive pathology or even lack aggregate pathology altogether. 
Some 40% of FTLD cases are familial, with one-third to one-half of the familial cases following an 
autosomal dominant inheritance pattern. A number of mutations that are linked to FTLD have 
been identified, including within the following genes: MAPT, TARDBP, VCP, CHMP2B and 
C9orf72 (DeJesus-Hernandez et al., 2011b, Renton et al., 2011, Kabashi et al., 2008, Baker et 
al., 2006, Cruts et al., 2006a, Johnson et al., 2010, Skibinski et al., 2005). The pathological 
subtypes of FTLD will be briefly reviewed in this chapter, although a more detailed review of 
FTLD-TDP will be presented in Chapter 4. The continuum of ALS and FTD is represented 
according to their overlapping symptoms, common genetic mutations and underlying pathology 
in Figure 2.  
 
 
Figure 2: (A) Represents the continuum of ALS and FTD as a broad neurodegenerative disorder spectrum, 
with the disorders presenting as extremes of a spectrum of overlapping clinical symptoms (ALS in red and 
FTD in purple). The major identified genetic causes of ALS and FTD are plotted according to the ratio of 
known mutations that give rise to ALS or FTD. (B) Represents the proportion of pathological protein 
inclusions in ALS and FTD according to the major protein aggregation. The inclusions of TDP-43 and 
FUS/TLS in ALS and FTD reflect the pathological overlap between ALS and FTD. The figure is adapted from 






Tau is a microtubule-associated protein coded by the MAPT gene on chromosome 17q21 and 
some 36–50% of FTLD cases show tau pathology (Bang et al., 2015, Ling et al., 2013). Tau 
promotes the assembly and stability of the microtubules, thereby maintaining neuronal integrity 
and axoplasmic transport (Lee and Leugers, 2012). Low levels of tau are expressed in the glial 
cells; however, it is predominantly expressed in the axons. The tau gene contains 16 exons, while 
there are six tau isoforms expressed in the adult human brain via the alternative splicing of exons 
2, 3 and 10. The accumulation of abnormal hyperphosphorylated tau characterises a group of 
neurodegenerative diseases referred to as the tauopathies, which include FTLD-Tau. The tau 
aggregates differ in terms of the isoform content and the degree of phosphorylation among the 
tau disorders, which is believed to explain the variation in the morphology of inclusions and 
cellular specificity (Lee and Leugers, 2012). The most common subtypes of FTLD-Tau are Pick’s 
disease, progressive supranuclear palsy (PSP) and corticobasal degeneration (CBD). Pick’s 
disease constitutes 5% of all dementia cases and 30% of all FTLD-Tau cases. Pick’s disease is 
characterised by the knife-edge atrophy of the frontal, temporal and cingulate gyrus, while the 
parietal lobe is better preserved (Bang et al., 2015); (Mackenzie and Neumann, 2016, Lee and 
Leugers, 2012). Pick’s disease more commonly presents as the behavioural variant of FTD or the 
non-fluent variant of primary progressive aphasia and it is usually not accompanied by MND 
(Piguet, 2013). The histological characteristics of Pick’s Disease include severe neuronal loss, 
swollen neurons (Pick cells) and large spherical argyrophilic cytoplasmic inclusions in the neurons 
(Pick bodies). Pick bodies are most numerous in layers 2 to 4 of the neocortex and they mainly 
contain the 3R tau isoform. Pick bodies can also be detected in the granule and pyramidal cells 
of the hippocampus (Kovacs et al., 2012). 
CBD accounts for about 35% of all FTLD-Tau cases and it mainly presents with bvFTLD, nfvPPA 
or both (Kim et al., 2012, Bang et al., 2015). It is characterised by bradykinesia, dystonia, rigidity, 
alien-limb phenomenon, apraxia and cortical sensory signs. Asymmetrical and focal cerebral 
cortex atrophy, depigmentation of the substantia nigra and atrophy of the globus pallidus are the 
typical gross features of a CBD patient’s brain. The main histopathological feature is the presence 
of ring-shaped collections of short cell processes, which are known as astrocytic plaques, due to 
the accumulation of pathological tau in the distal processes of the astrocytes (Sha et al., 2006). 




pathology, coiled bodies and ramified astrocytes to be characteristic of CBD. The pathology is 
predominant in the cerebral cortex and white matter and it is restricted to the basal ganglia, 
diencephalon and midbrain in the subcortical regions (Dickson et al., 2002).    
PSP accounts for approximately 31% of all cases of FTLD-tau (Josephs et al., 2011). The cortical 
atrophy is milder than in CBD, although the subcortical atrophy is more severe in PSP at 
subcortical levels, specifically the globus pallidus, subthalamic nucleus and brainstem nuclei. The 
histopathological characteristics include neuronal granular inclusions, globose tangles and tufted 
astrocytes (Rebeiz et al., 1968, Bang et al., 2015).  
Globular glial tauopathy (GGT) is a rare 4R tauopathy, which has previously been reported under 
a variety of different terminologies, including sporadic multiple system tauopathy with dementia.  
Clinically, GGT may present as bvFTLD with or without extrapyramidal signs, primary lateral 
sclerosis or as a combination of the two (Ahmed et al., 2013). The tau pathology in GGT is 
widespread in the white matter, with oligodendrocyte and astrocyte inclusions that have a 
distinctive globular morphology. The tau pathology in the neurons is mainly represented by diffuse 
immunoreactivity or globular inclusions (Mackenzie and Neumann, 2016). 
Argyrophilic grain disease (AGD) is a sporadic 4R tauopathy that usually presents as mild 
amnestic dementia, slowly progressive dementia and late onset dementia (Tolnay and Frank, 
2007). AGD patients rarely present with bvFTD despite the presentation of the kind of emotional 
and personality changes that are common in AGD (Tsuchiya et al., 2001, Ishihara et al., 2005). 
The histopathological hallmark in AGD is the presence of small dot-like spindle-shaped structures 
(grains) that are tau immunoreactive and argyrophilic. The grains are most abundant in the 
temporal limbic neocortex and amygdala; however, they may extend to the adjacent temporal 
neocortex. The grain structures are thought to represent degenerating dendrites (Mackenzie and 
Neumann, 2016).  
Another type of FTLD-Tau is caused by MAPT mutations, which result in autosomal dominant 
FTLD and parkinsonism associated with chromosome 17 (FTLD-17). About 10% of all familial 
FTLD cases are caused by MAPT mutations. The mutations are either deletions or missense in 
exons 1, 9, 10, 11, 12 or 13 or in the intron following exon 10. FTLD-17 patients usually present 
with atypical parkinsonism with a combination of personality and behavioural changes and 
cognitive dysfunction. The neuropathological hallmark of FTLD-17 is the presence of glial 




inclusion morphology, biochemistry and anatomical distribution overlap with those of the sporadic 
tauopathies, as do the clinical features among families in relation to specific mutations (Wszolek 
et al., 2006, Ghetti et al., 2011). Generally, mutations in exons 9, 11, 12 and 13 cause dementia 
and they are predominantly neuronal inclusions in the form of either Pick bodies with 3R tau 
composition or AD-like neurofibrillary tangles (NFT) with both 3R and 4R tau isoforms. In contrast, 
mutations affecting the alternative splicing of exon 10 lead to neuronal and glial pathology that 
resembles PSP and CBD with a relatively increased 4R tau isoform. The clinical presentation is 
commonly associated with prominent parkinsonism (Mackenzie and Neumann, 2016).  
 
1.1.3.2 FTLD-TDP 
Aggregates containing the transactive response DNA-binding protein with a molecular weight of 
43 kDa (TDP-43) account for approximately 50% of all cases of FTLD (FTLD-TDP). TDP-43 is a 
414 amino acid DNA/RNA-binding protein that is involved in multiple aspects of RNA processing, 
including transcription, splicing, transport and RNA stabilisation (Buratti et al., 2010). TDP-43 has 
been identified as the major component of the ubiquitin-positive, tau-negative inclusions detected 
in FTLD cases referred to as FTLD-U and most cases of ALS (Arai et al., 2006); (Neumann et al., 
2006b). The pathological aggregates of TDP-43 show abnormal modifications of TDP-43 that 
include ubiquitination, hyperphosphorylation and N-terminal truncation (Neumann et al., 2006b); 
Hasegawa et al., 2008; (Neumann et al., 2009a, Hasegawa et al., 2008). The major pathological 
hallmark of FTLD-TDP is the loss of the normal diffuse nuclear staining of TDP-43 and the 
presence of TDP-43-immunoreactive neuronal cytoplasmic inclusions (NCI) and dystrophic 
neurites (DN). TDP-43 neuronal intranuclear inclusions (NII) can also be present, particularly in 
cases with a positive familial history due to progranulin mutations. In addition, TDP-43 inclusions 
are ubiquitin- and p62-immunoreactive in the absence of other proteins associated with other 
neurodegenerative diseases. Furthermore, the TDP-43 pathology demonstrates glial cytoplasmic 
inclusions (GCI) in the oligodendrocytes (Neumann et al., 2007a), delicate wispy neurites 
(Hatanpaa et al., 2008) and diffuse neuronal cytoplasmic staining (pre-inclusions) (Brandmeir et 
al., 2008). Typically, TDP-43 inclusions are abundant in the frontotemporal neocortex and the 
granule cells of the dentate gyrus of the hippocampus; however, subcortical pathology is not 
uncommon (Geser et al., 2009, Josephs et al., 2009). Figure 3 demonstrates the identified 




hippocampus of FTLD-U cases. Figure 4 shows the biochemical signature of pathological TDP-
43 as discovered by Neumann et al. (2006).  
 
Figure 3: Spectrum of FTLD-U neuropathology as detected by anti-TDP-43 in the frontal cortex of different 
types of FTLD-U (A–D). TDP-43 strongly stains the ubiquitin inclusions in the hippocampal dentate granule 
neurons (E and F). The clearing of nuclear TDP-43 (arrows) in ubiquitin-bearing neurons when compared to 
that of normal neurons (*) (E and F). TDP-43 lentiform inclusion (H), round TDP-43 inclusion (G) and 
intranuclear TDP-43-positive inclusion and Lewy body-like round inclusions in the motor neurons of the 
spinal cord (I). Scale bar in (A) corresponds to 50 μm [(A) to (D) and (G)], 25 μm [(E) and (F)] and 20 μm 




Figure 4: The biochemical signature of pathological TDP-43 in sporadic and familial FTLD-U. (A) 
Immunoblots of sequential extracts from the frontal cortex of FTLD-U types 1 and 2 with rabbit anti-TDP-43 
showed pathologic ∼25-kD bands (*), 45-kD bands (**), and high Mr smear (***) in the urea fraction. Lane 1, 









The variation in the morphology and cortical laminar distribution of the TDP-43 inclusions led to 
the further classification of FTLD-TDP into four major subtypes (types A, B, C and D) (Sampathu 
et al., 2006, Mackenzie et al., 2011b). The histopathological classification of FTLD-TDP was 
described by two different groups depending on the morphology and distribution of the ubiquitin-
positive, tau-negative inclusions in FTLD cases (Sampathu et al., 2006, Mackenzie et al., 2006).  
In 2011, a new harmonised classification was proposed by the authors of the original papers 
(Mackenzie et al., 2011b). Briefly, type A FTLD-TDP is characterised by crescentic or oval NCI 
and numerous short DN that are primarily concentrated in layer 2 of the neocortex. Lentiform NII 
can be seen; however, they are not a consistent feature of this subtype. Type B FTLD-TDP is 
characterised by a moderate number of NCI throughout all the cortical layers and very few DN. 
Type C has very few NCI and elongated DN in the upper cortical layers. Type D FTLD-TDP refers 
to the pathology associated with VCP mutations and it is characterised by frequent lentiform NII 
and numerous short DN (Mackenzie et al., 2011b). The pathological subtypes of FTLD-TDP cases 
have been correlated with the clinical phenotypes of FTLD-TDP. In addition, the identified genetic 
mutations provided a good marker for the underlying pathology seen in the distinguished FTLD-
TDP subtypes (Sieben et al., 2012a). Table 2 summarises the correlation between the FTLD-TDP 
pathological subtypes, clinical phenotypes and genetic mutations identified as underlying causes 
of FTLD-TDP.   
 
Table 2: Correlation between the FTLD-TDP subtypes’ neuropathological characteristics, clinical 









Type A GRN, C9orf72 bvFTD (PNFA) 
Many NCI and DN in superficial 
cortical layers (layer II) 
NII in superficial cortical layers GCI. 
Type B C9orf72 FTD-MND bvFTD 
NCI throughout the entire cortical 
thickness. NCI in the hypoglossal 
nucleus and ventral horn of the spinal 
cord. Pre-inclusions. 
Type C  SD (bvFTD) Long DN in superficial cortical layers. Few NCI and NII. 
Type D VCP IBMPFD Many NII and DN throughout the entire cortical thickness. Few NCI. 
 
The presentation of FTD varies among the FTLD-TDP subtypes. FTLD-TDP is considered to be 
the most common FTLD molecular subtype, accounting for approximately 50% of all FTLD cases. 




A represents only a small proportion of the bvFTD cases with or without MND. Yet, two-thirds of 
nfvPPA and 25% of bvFTD cases were identified as FTLD-TDP type B based on the pathology 
(Seeley et al., 2008, Kim et al., 2012). Approximately 90% of all svPPA (left temporal involvement) 
or temporal variant bvFTD (right temporal involvement) cases were recognised as type C FTLD-
TDP (Mackenzie et al., 2011b, Rohrer et al., 2010). Figure 5 summarises the relationship between 
the clinical FTD presentation and the underlying neuropathology.   
 
 
Figure 5: Relationship between the clinical FTD presentation and the underlying FTLD neuropathology. For 
each clinical subtype on the left, the bar is divided to show the approximate proportion of cases that are 
underpinned by the indicated disease neuropathology. Profound neuropathological heterogeneity exists for 
many clinical subtypes, particularly bvFTD and PNFA. This figure is based on data from Josephs et al. 
(2011). The diagram is adapted from (D'Alton and Lewis, 2014).   
 
1.1.3.2.1 Granulin gene mutation (GRN) 
Progranulin is a secreted growth factor with many functions that is cleaved in order to generate 
the pro-inflammatory granulin subunits (De Muynck and Van Damme, 2011). Mutations in the 
GRN gene were identified in 2006 as the cause of 5–20% of all FTLD cases and they form the 
basis of families with autosomal-dominant FTLD linked to chromosome 17 that are not due to 
MAPT mutations (Cruts et al., 2006b). The GRN pathogenic mutations all result in null alleles, 
which leads to decreased levels of functional progranulin (haploinsufficiency). The clinical 
presentation varies significantly, even among members of the same family. Patients with GRN 




exceptionally rare with GRN mutations (Mackenzie, 2007a). The TDP-43 pathology is consistent 
with FTLD-TDP type A with abundant subcortical pathology, particularly in the striatum, and it is 
often associated with hippocampal sclerosis and numerous delicate DN (Cairns et al., 2007, 
Mackenzie, 2007a).   
 
1.1.3.2.2 C9orf72 expansion mutations 
The abnormal expansion of a GGGGCC (4G2C) hexanucleotide repeat in a non-coding region of 
the C9orf72 gene was identified in 2011 as the most common genetic cause of familial and 
sporadic forms of both FTD and ALS, as well as the basis of most families in which both FTLD 
and ALS are present (DeJesus-Hernandez et al., 2011a, Renton et al., 2011). The clinical 
presentation is commonly associated with bvFTLD; however, a wide range of neurological 
features are now recognised, including memory deficits, extrapyramidal movement disorders, 
psychosis and nfvPPA (Hsiung et al., 2012). The clinical features may vary tremendously among 
members of the same family, with carriers of the C9orf72 expansion mutation presenting with the 
typical features of ALS or FTLD or a combination of both. The pattern of neocortical TDP-43 
pathology is most commonly type B (Figure 2g and h); however, a subset of cases (usually older 
patients without clinical ALS) show features more consistent with FTLD-TDP type A or a 
combination of types A and B (Hsiung et al., 2012, Mann et al., 2013). C9orf72 cases demonstrate 
a unique and highly specific feature in addition to the TDP-43 pathology, namely the presence of 
NCI and NII that are negative for TDP-43; however, they are immunoreactive for ubiquitin and 
p62 (DeJesus-Hernandez et al., 2011a, Al-Sarraj et al., 2011). These inclusions are now known 
to be the result of the unconventional repeat-associated non-ATG-initiated (RAN) translation of 
the hexanucleotide repeat, which is triggered when it is massively expanded (Mori et al., 2013a, 
Gendron et al., 2013). Five different dipeptide repeat proteins (DPR) are generated by various 
reading frame translations that occur in the sense and anti-sense RNA strands: glycine-alanine 
(GA), glycine-arginine (GR), glycine-proline (GP), proline-alanine (PA) and proline-arginine (PR). 
GP is generated by translation in both directions. All the TDP-43-negative inclusions in all C9orf72 
cases are labelled by antibodies to the DPRs; however, the GA, GP and GR peptides generated 
from the sense transcripts are more abundant, while the PA and PR, which are generated from 
the antisense transcripts, are relatively rare (Davidson et al., 2016, Gomez-Deza et al., 2015, 




the regional pattern of TDP-43 pathology and it is highly consistent among cases regardless of 
the clinical features. The DPR pathology, including NCI, dot-like NII and short DNs, is abundant 
in all regions of the cerebral neocortex, limbic cortex and cerebellar cortex, whereas it is more 
variable and modest in the thalamus, basal ganglia and upper brainstem.   
The DPR pathology is extremely rare in the lower brainstem and spinal cord (Schludi et al., 2015, 
Mackenzie et al., 2013, Davidson et al., 2014). An additional consistent feature of C9orf72 
expansion cases is the presence of intracellular RNA aggregates. These RNA foci are present in 
the nuclei of approximately 50% of neurons in specific anatomical regions and they are rarely 
seen in the cytoplasm of neurons or in glial cells. The RNA foci are composed of sense and 
antisense DPR transcripts; however, the role of these RNA foci in the pathogenesis of C9orf72 
FTLD-TDP remains unclear. Further, the relative significance of TDP-43 in relation to DPR in the 
pathogenesis of FTLD-TDP in C9orf72 expansion cases is a source of much debate (Davidson 
et al., 2014, DeJesus-Hernandez et al., 2011a, Mackenzie and Neumann, 2016, Lee et al., 
2013b).  
 
1.1.3.2.3 Valosin-containing protein (VCP) mutations  
VCP is a member of the AAA-ATPase gene superfamily, which functions as a molecular 
chaperone in specific cellular activities that are directly or indirectly regulated by the UPS. 
Mutations in the VCP cause a rare familial syndrome in which inclusion body myopathy, Paget’s 
disease of the bone and FTD with variable penetrance are seen (IBMFD) (Kimonis et al., 2008). 
The pathology of TDP-43 in cases with VCP mutations is specific to FTLD-TDP type D and it is 
characterised by numerous NII and DN in the neocortex as well as an absence of pathology in 
the hippocampus (Mackenzie and Neumann, 2016).   
 
1.1.3.2.4 TARDBP mutations 
Transactive response DNA-binding protein (TARDBP) is the gene encoding the TDP-43 protein. 
Many different mutations in the TARDBP have been identified in many populations with different 
geographical origins (Sreedharan et al., 2008, Van Deerlin et al., 2008). Over 40 pathogenic 
mutations in the TARDBP have been identified; however, they are considered to be rare causes 
of the disease because they comprise only about 4% of familial ALS (fALS) cases and 1.5% of 




they cause single amino acid substitutions in the C-terminus that alter the protein-protein 
interaction and hence do not affect nucleic acid binding (Mackenzie et al., 2010b). The TARDBP 
mutations are mostly linked to a pure-ALS clinical presentation; however, they have been found 
in familial and sporadic FTLD cases (with and without MND), in bvFTLD associated with 
supranuclear palsy and in parkinsonism. Although TARDBP mutations have been reported in 
cases of clinical FTLD presentation, most of these reports lack a neuropathological evaluation. 
The pattern of TDP-43 pathology in cases with TARDBP mutations is unusual, with complete 
sparing of the hippocampal dentate fascia and the presence of NCI, NII and DN predominantly in 
the subcortical regions, while DN are mostly present in the neocortex (Borroni et al., 2009, Kovacs 
et al., 2009, Mackenzie and Neumann, 2016). 
 
1.1.3.2.5 Other mutations associated with FTLD-TDP 
Mutations in many other genes that have been identified as rare causes of ALS have also been 
identified in FTLD patients, including sequestosome 1 (Kovacs et al., 2016), ubiquilin-2 (Deng et 
al., 2011), TANK-binding kinase 1 (Gijselinck et al., 2015) and optineurin (Shen et al., 2015). 
There are currently insufficient data concerning the pattern of TDP-43 pathology with these 
mutations; however, it was reported that the TDP-43 pathology for a patient with a TANK-binding 
kinase 1 mutation is inconsistent with FTLD-TDP type A or B (Mackenzie and Neumann, 2016).  
 
1.1.3.3 Fused in sarcoma FTLD (FTLD-FUS) 
FTLD-FUS accounts for 5–10% of all FTLD cases. It is predominantly associated with early-onset 
FTLD with severe disinhibition and, in some cases, with psychosis and behavioural abnormalities; 
however, language deficits are absent in FTLD-FUS patients (Mackenzie et al., 2011a). 
Anatomically and histopathologically, FTLD-FUS is characterised by severe striatal atrophy and 
abundant FUS-immunoreactive inclusions in the dentate gyrus (Roeber et al., 2008). FUS was 
initially discovered as a component of the fusion oncogenes, which cause specific types of human 
cancer. FUS belongs to the heterogeneous nuclear ribonucleoprotein (hnRNP) family and it is 
involved in many aspects of RNA and DNA processing, including transcription and transport 
(Calvio et al., 1995, Chaudhury A, 2010). The normal physiological functions of FUS in the brain 
are not yet fully understood; however, functional studies have suggested that it is involved in RNA 




Mutations in the FUS were discovered in 2009 to cause a small percentage of ALS cases (ALS-
FUS) (Vance et al., 2009, Kwiatkowski et al., 2009). The clinical and pathological overlap between 
FTLD and ALS as well as the high level of similarity in the functional homology between TDP-43 
and FUS suggested FUS as a candidate pathological protein in the 5–10% of FTLD cases that 
are not characterised by tau or TDP-43. Several subsequent studies showed that the 
characteristic cellular inclusions seen in the majority of the tau/TDP-negative FTLD subtypes were 
FUS-immunoreactive (Neumann et al., 2009b). In addition, FUS was also recognised in neuronal 
intermediate filament inclusion disease (NIFID) (Neumann et al., 2009c), basophilic inclusion 
body disease (BIBD) and atypical FTLD-U (aFTLD-U) (Munoz et al., 2009). Subsequently, it was 
demonstrated that FUS inclusions can also contain Ewing’s sarcoma (EWS) and TATA-binding 
protein-associated factor 15 (TAF15) (collectively, FUS, EWS and TAF15 are known as the FET 
protein family). FTLD-FUS inclusions have also been shown to contain transportin 1 (TRN1), 
which is the protein responsible for the nuclear import of the FET proteins (Brelstaff et al., 2011, 
Neumann et al., 2011, Neumann et al., 2012). Indeed, it has been suggested by one research 
group that aFTLD-U, NIFID and BIBD could be classified under the broad nomenclature of FTLD 
with FET-positive inclusions (FTLD-FET) (Rademakers et al., 2012). Recently, evidence has been 
provided that the accumulated FET proteins in FTLD are modified after they are translated, which 
may be related to the pathogenesis of FTLD-FET. The most common abnormal post-translation 
modifications include the reduced methylation of the arginine residue in the arginine-glycine rich 
region, which is adjacent to the nuclear localisation signal and results in the abnormal binding of 
FET to TRN1 (Dormann et al., 2012) and may hence explain why the FET proteins colocalise with 
FUS in FTLD. Yet, mutations that selectively disrupt the nuclear localisation signal of FUS result 
in the weak binding of FUS to TRN1, which in turn results in the abnormal accumulation of FUS 
in the cytoplasm in ALS-FUS (Dormann et al., 2010, Neumann et al., 2011). The role of the post-
translation modification of FET proteins in FTLD cases is currently unknown (Mackenzie and 





1.2 TDP-43 and TDP-43 Proteinopathy 
1.2.1 Background 
TDP-43 is a 414 amino acid nuclear factor protein with a molecular weight of 43  
kDa, which is encoded by the TARDBP gene on ch1p36.2. It consists of five coding exons and 
one non-coding exon. Structurally, it is characterised by two RNA recognition motifs known as 
RRM1 and RRM2 (RRM1: ~aa 106–175 and RRM2: ~aa 191–262) that have the capability to 
bind nucleic acids. TDP-43 also has a nuclear localisation sequence (NLS) and a nuclear export 
signal. In addition, it contains a glycine-rich C-terminal region (~aa 274–413), which allows it to 
bind single-stranded DNA, RNA and proteins (Mackenzie et al., 2010b, Hasegawa et al., 2011, 
Ayala et al., 2005). The C-terminal tail of TDP-43 resembles that of the heterogeneous 
ribonucleoproteins and it interacts with other hnRNP proteins. The C-terminal domain is essential 
for the exon skipping and splicing inhibitory function of TDP-43. TDP-43 is widely expressed, 
highly conserved and predominantly localised to the nucleus; however, it is continuously shuttling 
between the nucleus and cytoplasm. This process is partly regulated by the nuclear export signal 
motifs and nuclear localisation signal (Winton et al., 2008, Da Cruz and Cleveland, 2011, Warraich 
et al., 2010, Sephton et al., 2012). TDP-43 can regulate the stability of its own mRNA, which 
provides an autoregulation mechanism for its own levels. In addition, TDP-43 influences diverse 
cellular functions by means of regulating the splicing and stability of many other transcripts 
(Polymenidou et al., 2012, Ayala et al., 2011b). A schematic presentation of human TDP-43 is 
provided in Figure 6.   
Initially, TDP-43 was cloned as a human protein that binds the TAR DNA of human HIV-1 acting 
as a transcription repressor (Ou et al., 1995). Subsequently, it was identified as part of a complex 
involved in splicing the cystic fibrosis transmembrane conductance regulator gene as well as the 
apoA-II gene (Buratti et al., 2001, Mercado et al., 2005). Nuclear TDP-43 plays an important role 
in the regulation of RNA splicing and microRNA biogenesis modulation (Xu, 2012). In addition, it 
has been suggested that TDP-43 is also involved in other cellular processes such as cell division 
and apoptosis (Braun RJ, 2011). Approximately 30% of cellular TDP-43 resides in the cytoplasm 
with nuclear efflux, which is regulated by stress and activity. TDP-43 is an important component 




role in neuronal plasticity through regulating local protein production in the dendrites (Diaper et 
al., 2013, Alami et al., 2014).  
Under cellular stress, TDP-43 is involved in the production of stress granules through the 
formation of complexes in order to sequester mRNAs redundant for survival (Colombrita et al., 
2009, Scotter et al., 2015). It is crucial to more fully understand the normal functions and 
interactions of TDP-43, since these could prove the key to understanding the pathogenesis of 
disease and hence lead to the development of effective therapeutic targets.    
 
 
Figure 6: Schematic presentation of human TDP-43, which comprises four known functional domains: a 
nuclear localisation sequence, two RNA recognition motifs known as RRM1 and RRM2 and a C terminal 
glycine-rich domain that mediates protein-protein interactions (Chen-Plotkin et al., 2010). 
 
 
1.2.2 TDP-43 proteinopathy 
TDP-43 was identified as the major component of the ubiquitinated neuronal inclusions in ALS 
and FTLD in 2006 (Neumann et al., 2006b). Subsequently, TDP-43-positive inclusions were 
shown to be present in 97% of familial or sporadic ALS cases, except for those caused by 
mutations in the SOD1 or FUS (Mackenzie, 2007b, Maekawa et al., 2009, Suzuki et al., 2012). 
The abnormally accumulated TDP-43 in ALS and FTLD-TDP cases is detergent resistant, 
hyperphosphorylated, ubiquitinated and cleaved (Arai et al., 2006, Neumann et al., 2006b). Five 
abnormal phosphorylation sites were identified at serine residues in the C-terminal region 
(Hasegawa et al., 2008). The neuropathological examination of FTLD-TDP and ALS cases has 
revealed the clearance of nuclear TDP-43 and the accumulation of both hyper-phosphorylated 
full-length TDP-43 and TDP-43 fragments of 18-26kDa (Hasegawa et al., 2011). The TDP-43 
proteinopathy can spread from the spinal cord, cortical motor neurons and glia to other cortical 





1.2.3 Role of TDP-43 in neurodegeneration 
The precise mechanism by which TDP-43 mislocalisation and aggregation causes 
neurodegeneration has not yet been fully elucidated. The shift of TDP-43 from the nucleus to the 
cytoplasm suggests that the loss of normal TDP-43 nuclear function may be a key mechanism 
leading to the degeneration of neurons. Knockdown studies support this hypothesis in terms of 
the induced morphological nuclear defects, dysregulation of the cell cycle, increased cell death 
and altered neurite outgrowth (Mackenzie et al., 2010b, Lagier-Tourenne et al., 2010, Strong et 
al., 2007).  
In vitro studies have suggested that the accumulation of TDP-43 in cellular inclusions can also 
induce a toxic gain of function, which is independent of the normal biological function of the protein 
(Johnson et al., 2008). Several studies have shown that the C-terminal fragment of TDP-43 is 
more insoluble than full-length TDP-43, with a tendency to aggregate and become ubiquitinated, 
phosphorylated and toxic to cells (Igaz et al., 2009, Zhang et al., 2009). However, one study 
suggested that the cytoplasmic aggregates bind the full-length TDP-43, leading to depletion from 
the nucleus (Nonaka et al., 2009). Yet, a pure toxic effect has been suggested by one research 
group due to the retention of normal nuclear expression (Zhang et al., 2009). In vitro studies 
expressing the mutant TDP-43 in cultured cells support the toxic effect of the C-terminal 
accumulation hypothesis (Sreedharan et al., 2008, Barmada et al., 2010). The pathogenic 
mechanism of TDP-43 proteinopathy remains unresolved due to the inconsistencies found among 
the available in vivo and in vitro models as well as the fact that none of these models properly 
replicate all the features of the human disease. Indeed, current results suggest multiple disease 
mechanisms are likely to contribute to neuronal death (Scotter et al., 2015). Further discussion 






The term ‘heterogeneous nuclear ribonucleoproteins’ is a collective term for the proteins that 
associate with the pre-mRNAs (also known as heterogeneous nuclear RNAs according to their 
size heterogeneity and cellular location). The hnRNAs or pre-mRNAs are the products of the 
primary protein-coding transcripts produced by RNA polymerase II. Although the hnRNP proteins 
bind the hnRNAs, they are not stable components of the other classes of RNP complexes, for 
example, small nuclear RNA proteins (snRNPs) (Dreyfuss, 1993, Shyu and Wilkinson, 2000). At 
least 20 major hnRNPs along with other minor hnRNPs have been found in human cells (HeLa 
cells). The major hnRNPs are designated hnRNP-A1 through hnRNP-U and they have a 
molecular weight range from 34–120 kDa. The definition of hnRNPs does not distinguish between 
the different proteins according to their structure, function, tissue specificity, abundancy, steady 
state sub-nuclear localisation or the time they join the complexes. Therefore, splicing factors as 
well as traditional hnRNPs such as hnRNP A1 or H are components of the hnRNP complex so 
long as they bind directly and co-purify with the same hnRNAs. In this context, the hnRNP 
complexes are usually large and diverse and they contain numerous proteins that are highly 
dynamic and show various protein abundances (Markovtsov et al., 2000, Dreyfuss, 1993). 
Structurally, the hnRNP proteins contain one or more of a small number of RNA-binding motifs, 
which are also known as RNA recognition motifs (RRM), in addition to one or more protein-protein 
interaction and protein localisation domains and KH domains (Burd, 1994). The hnRNPs play 
important roles in several cellular functions, including transcription regulation, gene splicing, 
telomere-length maintenance and RNA processing (Michelotti et al., 1996, Hoek et al., 1998). 











1.4 Aims of this Study 
The present study aims to: 
1. Investigate the expression of potential TDP-43 binding partners in brain and spinal cord 
tissue from neurodegenerative disease cases with TDP-43 pathology using 
immunohistochemistry. 
2. Further examine the expression of any proteins that show potential interaction with TPD-
43 in other neurodegenerative disease cases in order to confirm whether their expression 
is specifically linked to TDP-43 pathology or is also seen in other neurodegenerative 
mechanisms. 
3. Explore the regional specificity of any specific protein pathology by conducting 
immunohistochemistry in several regions of the brain. 
4. Investigate the relationship and possible colocalisation between the identified proteins 
and TDP-43 aggregates using double immunofluorescence techniques. 
5. Biochemically characterise the identified proteins in the brain tissue of TDP-43 cases 
using the solubility fractionation of brain tissue and Western blotting. 
6. Investigate the interaction between the identified proteins and TDP-43 in cell lines using 





Chapter 2 Materials and Methods 
2.1 Human Tissue Samples 
2.1.1 Case selection and tissue preparation  
Post-mortem brain tissue was obtained from the MRC London Neurodegenerative Diseases Brain 
Bank at the Institute of Psychiatry, Psychology and Neuroscience, King’s College London (KCL). 
For each case, at the time of donation, one brain hemisphere was fixed in buffered formalin. Then, 
a neuropathological diagnosis was performed and the tissue was processed as formalin-fixed 
paraffin-embedded (FFPE) blocks for histopathological studies. The neuropathological 
assessment was performed according to the standard criteria. The other hemisphere was 
sectioned and specific brain areas were isolated by an expert before being placed individually 
into plastic bags, then labelled and sealed appropriately and stored at -80˚C. 
Post-mortem brain tissue was obtained from 111 cases: 30 cases of FTLD with TDP-43 
aggregates (FTLD-TDP) without the C9orf72 expansion (comprising 15 FTLD-TDP type A, six 
FTLD-TDP type B and nine FTLD-TDP type C). Additionally, 23 FTLD-TDP cases with the 
C9orf72 expansion were used (of which 15 were identified as FTLD-TDP subtype B and three as 
subtype A, the remainder could not be accurately subtyped). In addition, four FTLD/ALS with tau 
aggregates (FTLD-Tau, ALS-Tau), four  Pick’s disease, one FTLD with ubiquitin and progranulin 
mutations (FTLD-U-PRGN), three ALS with the FUS mutation (FUS-ALS), three ALS with the 
SOD1 mutation, 13 sporadic ALS (sALS), one ALS with P62 aggregates, two FTLD/ALS with the 
TARDBP mutation, one ALS with chronic inflammatory demyelinating polyneuropathy (CIDP), two 
dementia with Lewy bodies (DLB), one argyrophilic grain disease (AGD), one spinocerebellar 
ataxia (SCA), one Huntington’s disease,  and seven Alzheimer’s disease cases were examined. 
Fourteen healthy controls without a history of neurological problems or psychiatric disorders and 
without any significant pathology (matched for gender, age and post-mortem delay) were also 





Table 3: Demographic details concerning all the cases used in this study, including the experiments each case was involved with (PMD: post-mortem delay, IHC: immunohistochemistry, 
dIF: double immunofluorescence) 








IHC Exp dIF Western blotting 



















4 063/12 BBN_4568 FTLD-TDP A M 59 36 4 hnRNP-E2   
5 120/11 BBN_15306 FTLD-TDP A M 71 14 8 hnRNP-E2   
6 172/12 BBN_10245 FTLD-TDP A M 87 31 10 hnRNP-E2, UBQLN2, hnRNP-M, hnRNP-C1/C2, hnRNP-Q 
  

















11 334/09 BBN_15302 FTLD-TDP A M 81 11 24 hnRNP-E2     
12 033/08 BBN_15292 FTLD-TDP A F 56 35 10 hnRNP-E2, UBQLN2, hnRNP-M, hnRNP-C1/C2, hnRNP-Q 
    
13 047/07 BBN_15287 FTLD-TDP A F 74 70 8 hnRNP-E2     
14 097/09 BBN_16282 FTLD-TDP A M 78 n/a n/a hnRNP-E2     




16 030/06 BBN_6230 FTLD-TDP B M 71 43.5 n/a hnRNP-E2     
17 157/12 BBN_4249 FTLD-TDP B M 86 45 6 hnRNP-E2, UBQLN2, hnRNP-M, hnRNP-C1/C2, hnRNP-Q 
    





19 058/12 BBN_4590 FTLD-TDP B F 73 54 8 hnRNP-E2, UBQLN2, hnRNP-M, hnRNP-C1/C2, hnRNP-Q 
  
20 244/07 BBN_15289 FTLD-TDP B M 68 46 4 hnRNP-E2   
21 432/12 BBN_11067 FTLD-TDP B M 81 31 8 hnRNP-E2, UBQLN2, hnRNP-M, hnRNP-C1/C2, hnRNP-Q 
  
22 013/10 BBN_15303 FTLD-TDP C M 69 6 12 
hnRNP-E2, UBQLN2, hnRNP-
M, hnRNP-C1/C2, hnRNP-Q, 
hnRNP-G/RBMX 
hnRNP-E2 vs TDP-





23 022/07 BBN_15286 FTLD-TDP C M 68 120 7 hnRNP-E2, hnRNP-G/RBMX 
hnRNP-E2 vs TDP-
43 and hnRNP-E2 
vs ubiquitin 
   
24 061/13 BBN_15200 FTLD-TDP C M 69 16 11 hnRNP-E2, UBQLN2, hnRNP-M, hnRNP-C1/C2, hnRNP-Q 
    
25 301/10 BBN_15304 FTLD-TDP C M 80 45 20 
hnRNP-E2,UBQLN2, hnRNP-
M, hnRNP-C1/C2, hnRNP-Q, 
hnRNP-G/RBMX 
hnRNP-E2 vs TDP-
43 and hnRNP-E2 
vs ubiquitin 
   
26 350/08 BBN_15295 FTLD-TDP C M 82 14 16 hnRNP-E2, hnRNP-G/RBMX 
hnRNP-E2 vs TDP-
43 and hnRNP-E2 
vs ubiquitin 
   
27 409/08 BBN_15297 FTLD-TDP C M 78 n/a 12 hnRNP-E2, UBQLN2, hnRNP-M, hnRNP-C1/C2, hnRNP-Q 
    
28 163/07 BBN_15288 FTLD-TDP C M 80 6.5 12 hnRNP-E2, UBQLN2, hnRNP-M, hnRNP-C1/C2, hnRNP-Q 
    
29 295/07 BBN_15290 FTLD-TDP C M 66 54 8 hnRNP-E2     




31 088/00 BBN_15270 FTLD-TDP C9orF72 B F 57 16 n/a 
hnRNP-E2,UBQLN2, hnRNP-








32 403/08 BBN_15296 FTLD-TDP C9orF72 B F 70 15.5 12 hnRNP-E2 
    
33 019/95 BBN_16651 FTLD-ALS C9orF72 B M 51 64 7 hnRNP-E2 
    
34 050/98 BBN_16458 FTLD-ALS C9orF72 B M 70 40 n/a hnRNP-E2 
    
35 068/05 BBN_6227 FTLD-ALS C9orf72 B M 55 76 31 
hnRNP-E2, UBQLN2, hnRNP-
M, hnRNP-C1/C2, hnRNP-Q 
    
36 069/02 BBN_6198 FTLD-ALS C9orf72 B M 58 11 15 hnRNP-E2 
    
37 095/05 BBN_10306 FTLD-ALS C9orf72 B M 64 68 11 hnRNP-E2 
    
38 112/99 BBN_16438 FTLD-ALS C9orf72 A F 58 12 61 hnRNP-E2 
    
39 117/91 BBN_16969 FTLD-ALS C9orf72 B F 57 12 12 hnRNP-E2 
    





41 144/12 BBN_4253 FTLD-ALS C9orf72 B F 59 21 10 
hnRNP-E2, UBQLN2, hnRNP-





42 151/08 BBN_6251 FTLD-ALS C9orf72 B M 62 73.5 14 hnRNP-E2 
  





44 157/04 BBN_15713 FTLD-ALS C9orf72 B M 57 22.5 35 
hnRNP-E2, UBQLN2, hnRNP-





45 163/09 BBN_15300 FTLD-ALS C9orf72 A M 79 35 5 
hnRNP-E2,UBQLN2, hnRNP-
M, hnRNP-C1/C2, hnRNP-Q 
    
46 174/08 BBN_6252 FTLD-ALS C9orf72 B F 43 69 14 hnRNP-E2 
    













49 229/06 BBN_16380 FTLD-ALS C9orf72 F 59 34.5 17 hnRNP-E2 
    
50 290/10 BBN_16223 FTLD-ALS C9orf72 M 55 19 17 hnRNP-E2 
    
51 311/07 BBN_6242 FTLD-ALS C9orf72 F 39 69.5 18 hnRNP-E2, hnRNP-G/RBMX 
    
52 315/07 BBN_15291 FTLD-ALS C9orf72 A M 56 18.5 11 hnRNP-E2 
    
53 400/08 BBN_16304 FTLD-ALS C9orf72 B M 59 46 10 hnRNP-E2 
    
54 008/10 BBN_9933 Alzheimer’s disease F 98 25 9 hnRNP-E2 
    
55 012/10 BBN_9934 Alzheimer’s disease M 70 60 19 hnRNP-E2 
    
56 200/10 BBN_4182 Alzheimer’s disease F 81 23 18 hnRNP-E2 
    
57 207/10 BBN_4183 Alzheimer’s disease F 79 40 8 hnRNP-E2 
    
58 247/05 BBN_9801 Alzheimer’s disease F 90 23 20 hnRNP-E2 
    
59 315/09 BBN_9927 Alzheimer’s disease F 90 35 18 hnRNP-E2 
    
60 346/09 BBN_9930 Alzheimer’s disease M 101 48 12 hnRNP-E2 
    
61 347/08 BBN_2924 AGD M 82 20 8 hnRNP-E2     
62 247/07 n/a CIDP ALS M 70 5days 14 hnRNP-E2     
63 020/08 BBN_16337 DLB M 85 29.5 18 hnRNP-E2     
64 263/05 BBN_10290 DLB M 78 41 25 hnRNP-E2     
65 155/06 BBN_15283 FTLD-U-PRGN M 70 57 22 hnRNP-E2 
    
66 063/08 BBN_6245 FUS ALS F 35 13 5 hnRNP-E2     
67 086/01 BBN_6189 FUS ALS F 35 24 39 hnRNP-E2     




69 420/12 BBN_11070 HUNTINGTON'S DIS M 65 36 8 hnRNP-E2 
    
70 237/12 BBN_10214 P62-ALS M 65 33 10 hnRNP-E2     
71 008/06 BBN_10282 Pick’s dis M 72 6 19 hnRNP-E2     
72 009/06 BBN_10281 Pick’s dis M 61 23 21 hnRNP-E2     
73 048/02 BBN_15776 Pick’s dis M 66 17 3 hnRNP-E2     
74 258/06 BBN_15285 Pick’s dis M 67 16.5 7 hnRNP-E2     
75 058/08 BBN_6244 sALS M 55 33 22 hnRNP-E2     
76 059/01 BBN_6187 sALS M 70 73 75 hnRNP-E2     
77 075/06 BBN_10272 sALS M 87 70 22 hnRNP-E2     
78 091/08 BBN_6248 sALS M 66 38 8 hnRNP-E2     
79 148/04 BBN_15715 sALS M 74 34 40 hnRNP-E2     
80 226/03 BBN_6219 sALS M 49 32.5 33 hnRNP-E2     
81 249/09 BBN_6267 sALS M 68 5 18 hnRNP-E2     
82 142/06 BBN_16392 SOD1 ALS F 61 13.5 21 hnRNP-E2     
83 284/13 BBN_19995 TARDBP mutation M 57 48 9 hnRNP-E2 
    
84 151/10 BBN_6273 Tau-ALS F 75 38 3 hnRNP-E2     
85 067/00 BBN_15268 Tau-FTLD F 58 31 13 hnRNP-E2     
86 074/00 BBN_15269 Tau-FTLD M 67 35 9 hnRNP-E2     
87 247/06 BBN_15284 Tau-FTLD F 62 30.5 9 hnRNP-E2     
88 348/08 BBN_6257 TDP-ALS F 69 64 14 hnRNP-E2     
89 329/07 BBN_6243 sALS M 67 70 11 hnRNP-E2     
90 136/02 BBN_15766 SCA F 74 33 53 hnRNP-E2     
91 034/06 BBN_10276 SOD 1 ALS M 47 13.5 18 hnRNP-E2     
92 101/96 BBN_16553 SOD1 ALS F 46 5 14 hnRNP-E2     




94 251/09 BBN_6268 sALS M 78 2 18 hnRNP-E2     
95 257/11 BBN_6280 sALS M 75 38 9 hnRNP-E2     
96 274/05 BBN_10285 sALS M 42 41 23 hnRNP-E2     




98 047/02 BBN_15777 CNT F 87 21.5 150 hnRNP-E2     














102 066/00 BBN_15621 CNT M 61 53 14 hnRNP-E2     









105 130/09 BBN_16277 CNT M 54 30 8 hnRNP-E2, hnRNP-G/RBMX     
106 149/01 BBN_15791 CNT M 95 44 20 hnRNP-E2     
107 150/01 BBN_15790 CNT M 40 40 25 hnRNP-E2     
108 272/09 BBN_16256 CNT M 62 ~80 18 hnRNP-E2, hnRNP-G/RBMX     
109 308/09 BBN_16251 CNT M 66 52 7 hnRNP-E2, UBQLN2, hnRNP-M, hnRNP-C1/C2, hnRNP-Q 
    
110 158/14 BBN_22991 CNT F 73 27 6 hnRNP-E2, UBQLN2, hnRNP-M, hnRNP-C1/C2, hnRNP-Q 
    




Paraffin sections were obtained from the frontal cortex, temporal lobe, hippocampus, cerebellum 
and spinal cord. After the tissue selection, 7 µm sections were cut using a microtome. The 
sections were floated in a 37˚C water bath and then mounted onto glass slides (Superfrost™). 
Each slide was labelled with the case number and the region of the brain or spinal cord used. The 
slides were left to dry on a 37˚C hot plate. Once dry, the slides were incubated in a 60˚C oven 
overnight and then kept in a 37˚C oven until used for immunohistochemistry or double-labelling 
immunofluorescence experiments.  
 
2.1.2 Immunohistochemistry (IHC) 
The sections were dewaxed by twice submerging them into fresh xylene for 5 minutes each time. 
Then, they were dehydrated by twice submerging them into absolute ethanol for 5 minutes each 
time. The endogenous peroxidase enzymes were blocked by placing the sections in 200 ml of 
methanol containing 5 ml of 30% aqueous hydrogen peroxide solution for 30 minutes. The 
blocking of the endogenous enzymes is essential for reducing the interaction with the ABC/HRP 
solution used later in the protocol. The slides were washed for 10 minutes under running tap 
water, then rinsed with distilled water for 2 minutes and placed into 1x TBS (Tris-buffered saline). 
The TBS stock was made by mixing 604.5 g of Trizma base and 900 g of sodium chloride in 10 L 
distilled water. The pH was adjusted to 7.6 using 1M HCL. 
The antigen retrieval step is important for recovering the antigens that may have been altered by 
the fixation process. The antigen retrieval step was performed using the extended citrate method.  
The slides were submerged in a citrate buffer containing 14.7 g of sodium citrate diluted in 5 L 
distilled water with a pH of 6.0. The slides were microwaved on full power for 8 minutes followed 
by being simmered twice for 6 minutes each time. Afterwards, the slides were cooled down under 
running tap water and washed in TBS twice for 5 minutes each time. A piece of wax was used to 
circle around the sections, creating a hydrophobic barrier to ensure the solutions stayed on the 
sections during the incubations. Normal serum blocking was carried out to block non-specific 
binding as follows. For the primary polyclonal antibodies raised in rabbits, the sections were 
incubated in normal swine serum (NSS) diluted with TBS (1:10) for 20 min. For the monoclonal 
antibodies raised in mice, the sections were incubated with normal rabbit serum (NRS) diluted 
with TBS (1:10) for 20 min. The sections were then drained and the primary antibody applied 
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according to the optimal dilution obtained via the optimisation experiments (with 1:100 NSS for 
the polyclonal antibodies or 1:100 NRS for the monoclonal antibodies in TBS). 250 µl was added 
to each section and they were incubated overnight at 4˚C. Details concerning the primary 
antibodies used throughout the study and the optimal dilutions for each specific experiment are 
provided in Table 4. A negative control slide was incubated in each experiment with 1:100 NSS 
or NRS (depending on the antibody used) in TBS. 
 
Table 4: Details of the antibodies used for the screening of TDP-43 binding partners in FTLD-TDP cases 
and specific optimal experimental dilutions 
Antibody Source Experiment/Optimal dilution 
TDP-43 10782-2-AP (Proteintech) Rabbit polyclonal WB/1:1000 dIF/1:250 
UBQLN2 (M03), clone 5F5 (Abnova #H00029978-M03) Mouse monoclonal IHC/1:500, dIF/1:150 
hnRNP-M 95-RE36 (Santa Cruz. sc-134360) Mouse monoclonal IHC/1:500 
hnRNP-C1/C2 (H-105) sc-15386, Santa Cruz Rabbit polyclonal IHC/1:500 
hnRNP-Q (I8E4) sc-56703, Santa Cruz Mouse monoclonal N/A 
hnRNP-E2-23 G: (sc-101136, Santa Cruz) Mouse monoclonal IHC/1:500, dIF/1:250, WB/1:500 
PCBP2 (WH0005094M7 - clone 5F12 Sigma-Aldrich) 
(hnRNP E2) Mouse monoclonal IHC/1:500, dIF/1:250 
hnRNP-E2/PCBP2 (M07), clone 5F12 Abnova 
(H00005094-M07) Mouse monoclonal IHC/1:500, WB/1:500 
RBMX (H-80): (sc-48796, Santa Cruz) (hnRNP G) Rabbit polyclonal IHC/1:500 
hnRNP-E1 (E-2) (sc-137249, Santa Cruz) Mouse monoclonal IHC/1:500 
Ubiquitin (Dako, z0458) Rabbit polyclonal dIF/1:200 
Phosphorylated pTDP-43 (pS409/410-2); 1:1500, Cosmo 
Bio Ltd, Tokyo, Japan) Rabbit polyclonal dIF/1:250, WB/1:2000 
IHC: immunohistochemistry, dIF: double-labelling immunofluorescence, WB: Western blotting. 
 
 
On the second day, the slides were washed twice in TBS for 5 min each wash. The secondary 
antibodies were applied as follows. For the polyclonal rabbit primary antibodies, swine-anti-rabbit 
biotinylated immunoglobulin (SAR) obtained from Dako Ltd and diluted in TBS 1:100 was applied 
at 250 µl/section for 45 minutes. For the monoclonal mouse primary antibodies, rabbit anti-mouse 
biotinylated immunoglobulin (RAM) obtained from Dako Ltd and diluted in TBS 1:100 was applied 
at 250 µl/section for 45 minutes. The avidin-biotin complex horseradish peroxidase (ABC) solution 
was prepared by adding 2 drops of reagent (A) and 2 drops of reagent (B) (ABC kit obtained from 
Vectastain) to 5 ml of TBS. The slides were washed twice in TBS for 5 minutes each wash and 
then the ABC solution was added to the sections and incubated for 45 minutes. During this time, 
the 3,3’-diaminobenzidine tetrahydrochloride (DAB) solution was prepared by adding 1 DAB tablet 
(Sigma D5905) to 20 ml of TBS and allowing to dissolve. The solution was filtered and then 
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activated by adding 10 µl of 30% H2O2 (once activated, DAB should be used within 2 hours). The 
sections were washed twice in TBS (5 min each wash) and the activated DAB solution was added 
in order to allow visualisation by chromogenic precipitation of the oxidised DAB. This serves as 
an amplification of the antigen signal in the tissue. The sections were incubated with DAB for up 
to 10 minutes. The sections were washed in running tap water for 10 minutes and then counter-
stained with haematoxylin for 20 seconds to visualise the nuclei and the overall structure of the 
tissue. Next, they were washed in running tap water again before being dipped into acid alcohol 
(2 sec intervals) and returned to running tap water. The sections were then washed in distilled 
water for 2 minutes. The sections were dehydrated by submerging the slides into a series of 
different concentrations of ethanol: 70% alcohol for 2 minutes, followed by 2 minutes in 95% 
ethanol and then absolute alcohol twice for 2 minutes. The slides were submerged into fresh 
xylene four times for 2 minutes each time, before coverslips were added using Ralmount glue 
(formulation Raymond A. Lamb, BDH).. The sections were visualised using a bright field 
microscope with an attached camera (Zeiss Axioplan microscope and AxioCam MRc 5 megapixel 
Zeiss camera) and the images were captured using AxioVision software (AxioVision Rel. 4.7. Carl 
Zeiss).  
 
2.1.3 Double-labelling immunofluorescence 
In this study, a double-labelling immunofluorescence (dIF) method was used to detect the 
colocalisation of two antigens in the same tissue. The experiments were conducted according to 
a modified protocol supplied by the Brain Bank at KCL. The dewaxing and antigen retrieval steps 
were similar to those of the IHC protocol detailed above. The normal serum blocking was 
performed by incubating the sections with normal goat serum (NGS) diluted 1:10 in phosphate 
buffer saline (PBS) solution.  
All the primary antibodies were diluted in PBS with a pH of 7.4 and then incubated for 60 minutes. 
The primary antibodies for both antigens were mixed in the diluted solution; however, they had to 
be raised in different species, that is, one antibody is monoclonal and raised in mice, while the 
second antibody is polyclonal and raised in rabbits. The details of the primary antibodies used in 
this study and their optimal dilutions will be described in the following chapters. The sections were 
washed with PBS twice for 5 minutes each wash. Then, the sections were incubated with 
fluorophore secondary antibodies for 45 minutes.  
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The secondary antibodies used were Alexa Fluor® goat anti-rabbit, which was used to label the 
polyclonal primary antibodies, and Alexa Fluor® goat anti-mouse, which was used to label the 
monoclonal primary antibodies (Alexa Fluor® 488 Goat Anti-Mouse IgG [Invitrogen] and Alexa 
Fluor® 568 Goat Anti-Rabbit IgG [Invitrogen]). The colour of the fluorescence was chosen as 
green (488 nm) or red (568 nm) for each antibody. The sections were covered with foil in order to 
protect them from light and avoid the activation of the fluorescence. Following incubation, the 
sections were washed three times in PBS (5 min each wash). Next, the sections were incubated 
with Sudan Black for 10 minutes to quench the natural autofluorescence seen in human brain 
tissue. The Sudan Black was prepared by adding 0.15 g to 50ml of 70% ethanol (prepared at 
least 45 min in advance with constant mixing and filtering). The sections were washed eight times 
with PBS, for 5 minutes each wash. The slides were mounted using Vectashield with DAPI (Vector 
Laboratories Ltd, Petersfield, UK) and then coverslipped. All the sections were visualised using 
an inverted fluorescence microscope (Zeiss Axiovert S100, Gottingen, Germany). There were 
further modifications made for some experiments, which will be discussed alongside the results 
of each experiment.  
 
2.1.3.1 Inclusions counting 
Slides were visualised using the inverted fluorescence microscope (Zeiss Axiovision). TDP-43, 
ubiquitin and hnRNP-E2 inclusions were counted in the frontal cortex sections from 1 FTLD-TDP 
type A case (case #2) and 4 FTLD-TDP type C cases (case #22, #23, #25 and #26).  Depending 
on the section size, 8-10 fields from each slide were selected and the number of inclusions were 
counted in each field (the number of inclusions seen in the red channel were counted manually 
using a hand-held counter, the fluorescence channel was then switched to green and the number 
of inclusions seen counted, the number of these inclusions that colocalised was also recorded).  
Further details about the number of inclusions and percentage calculations will be provided in the 




2.1.4 Western blotting 
2.1.4.1 Human brain tissue fractionation for Western blotting 
The aim of this fractionation protocol is to determine whether the protein forms soluble or insoluble 
aggregates. Different detergents of increasing strengths were used to release different cellular 
components. Two fractionation protocols were used. One uses sarkosyl detergent, while the other 
uses RIPA detergent for protein extraction. For both protocols, approximately 100 mg of frozen 
cortical grey matter from the frontal cortex (Brodmann area 9) of each case was dissected from 
the white matter and meninges at 4°C. 
RIPA Protocol: Each brain tissue sample was homogenised using approximately 30 strokes of 
the glass douncer in 1 ml of ice-cold high-salt buffer containing 750 mM of NaCl, 10 mM of NaF 
and ‘complete protease inhibitor cocktail tablets’ (Roche, 1 tablet per 50 ml of buffer). 200 µl of 
the homogenate was retained as the lysate fraction of the sample. The remaining homogenate 
was transferred into ultrafuge tubes and then spun for 30 minutes at 44,000 rpm in the ultrafuge 
at 4°C (Beckman Ultrafuge). The supernatant was removed and stored at -20°C as the high-salt 
fraction of the sample. The pellet was washed twice by resuspension in 1 ml of the high-salt buffer 
and then spun at 44,000 for 20 minutes at 4°C. The previous steps were repeated using a Triton 
buffer containing 750 mM of NaCl, 10 mM of NF and 1% Triton X-100 (supernatant saved as the 
Triton fraction) and then an RIPA (radioimmunoprecipitation assay) buffer containing 1% NP-40, 
0.5% sodium deoxycholate and 0.1% SDS (supernatant saved as the RIPA fraction). The RIPA 
buffer is effective for protein extraction because it contains three non-ionic and ionic detergents; 
however, this detergent combination may prove relatively incompatible with certain downstream 
applications. Finally, the pellet was resuspended in a urea buffer containing 7 M of urea, 2 M of 
thiourea, 4% CHAPS, 30 mM of Tris-HCL pH 8.5 and vortex for 15 minutes. All the buffers were 
made up in 250 ml of stock buffer containing 50 mM of Tris-HCL, 150 mM of NaCl and 5 mM of 
EDTA with a pH of 7.4. All the fractions were stored at -20°C until used for Western blotting.  
Sarkosyl Protocol: The brain sample from each case was homogenised using approximately 30 
strokes of the glass douncer in 1 ml of ice-cold low-salt (LS) buffer, which contained 10 M of Tris 
pH 7.5, 5 M of EDTA (ethylenediaminetetraacetic acid), 1 M of dithiothreitol, 10% sucrose and a 
cocktail of protease inhibitors (Roche, 1 tablet per 50 ml of buffer). The homogenate was 
transferred into ultrafuge tubes and then spun for 30 minutes at 18,000 rpm in the ultrafuge at 
4°C (Beckman Ultrafuge). Next, 2x the sample buffer (0.5 m of Tris-HCL pH 6.8, 2% SDS, 10% 
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glycerol and 100 mg of bromophenol blue diluted in dH2O) was added to the supernatant and the 
samples were vortexed for 10 seconds, boiled for 10 min at 100°C and then saved at -20°C. The 
pellet was washed twice by resuspension in 1 ml of the same buffer and spun at 44,000 for 20 
minutes at 4°C. The supernatant was discarded. The pellet was resuspended in 1 ml of ice-cold 
high-salt Triton buffer that exhibited the same composition as the LS buffer with the addition of 
1% Triton X-100 and 0.5 M of NaCl. The samples were sedimented at 44,000 rpm for 30 min at 
4°C. The supernatant was saved with 2x the sample buffer, vortexed and boiled for 10 min at 
100°C and then saved at -20°C as the HS fraction. The pellet was washed twice in the HS buffer 
as per the previous washes. The pellet was resuspended in 1 ml of ice-cold Triton buffer that 
contained 30% sucrose made up by adding 3 g of sucrose to 10 ml of Triton X-100. The 
supernatant was saved as the TX fraction at -20°C after adding 2x the sample buffer and boiling 
at 100°C for 10 min. The pellet was resuspended in the sarkosyl buffer containing the LS buffer 
plus 1% N-Lauroylsarcosine and 0.5 M of NaCl. The samples were sonicated for a few seconds 
and then vortexed for 1 hour at room temperature. The samples were sedimented at 44,000 rpm 
for 30 min at 4°C and the supernatant was saved as the SARK fraction. The remaining pellet was 
resuspended in 200 µl of urea buffer containing 7 M of urea, 2 M thiourea, 4% 3[(3cholamidopro-
pyl)dimethylammonio]-1-propanosulphonate (CHAPS) and 30 M of Tris-HCLpH8.5. The samples 
were vortexed for 20 min at room temperature. Some 200 µl of 2x the sample buffer was added 
to each sample and centrifuged at 14,000 rpm for 10 min at 10°C. The supernatant was saved as 
the urea fraction at -20°C (without boiling).   
 
2.1.4.2 Gel electropheresis  
Specific proteins were detected using the Western blotting technique, which uses gel 
electrophoresis to separate proteins by their electrophoretic mobility according to their size, 
conformation, length and change of molecules. The Western blotting technique is comprised of 
three steps. The first step is size separation, while the second step involves the transfer of the 
proteins from the gel to a nitrocellulose or polyvinylidene difluoride (PVDF) membrane. Finally, 
the proteins are marked with an appropriate primary antibody, which is later probed with a 
fluorescent secondary antibody. The fluorescence is then visualised digitally (LI-COR Odyssey®) 
or via enhanced chemiluminescence (ECL). 
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The Western blots were performed using an SDS-PAGE polyacrylamide gel NuPAGE R Novex 
R 10% Bis-Tris buffering agent. This specific gel has a neutral pH, which minimises any protein 
modification. It is also the best option for the separation of medium- to small-sized proteins under 
denaturing conditions. The NuPAGE R Novex R gel comes in either 26 or 12 loading wells. The 
number of wells was chosen according to the sample number used for each experiment.   
The gel separation range depends on the buffer solution used for the Western blot. The MOPS 
(morpholino propanesulphonic acid) running buffer was used for the Western blots in this study.  
The composition of the 20x NuPAGE R MOPS SDS running buffer includes 50 mM of Tricine, 50 
mM of Tris base and 1% SDS (pH 8.24). The 20x MOPS running buffer was diluted to 1x using 
double distilled water and then added to the gel tank. Although the MOPS buffer is designed to 
resist the high temperatures the gel encounters, ice was used in the tank to cool the gel down 
during the electrophoric separation.  
For the RIPA fractionation protocol, the samples were diluted into 2x sample buffer before loading 
onto the gel. The 2x sample buffer was comprised of the following: 62.5 mM of Tris-HCL pH 6.8, 
2% SDS, 10% glycerol and 0.01% bromophenol blue in 50 ml of distilled water. The total lysate 
and HS fractions were prepared by adding 25 µl of each sample to 25 µl of the HS buffer and 50 
µl of the 2x sample buffer (1:5 dilution). The Triton and RIPA fractions were prepared by adding 
50 of µl of the sample to 50 of µl the 2x sample buffer (1:1 dilution). The urea fraction was prepared 
by using 10 µl of the sample with 10 µl of the 2x sample buffer (1:1 dilution).   
The sarkosyl samples were allowed to thaw at room temperature and the urea fraction was spun 
for 15 min at 14,000 rpm at 4°C before loading into the gels. Some 1–2 µl of protein ladder (Bio-
Rad) was loaded into a separate well on the gel as a reference for the protein sizes. The ladder 
contained ten Strep-tag® recombinant proteins that ranged in size from 10 kDa to 250 kDa. Figure 
7 presents an illustrative image of the protein ladder used throughout the experiments. The gel 




Figure 7: Representative blot of Precision Plus Protein™ Dual Color Standards (Bio-Rad). 
 
 
2.1.4.3 Protein transfer to the nitrocellulose membrane (iBlot) 
The samples can be visualised on the gel as they are diluted in the bromophenol blue sample 
buffer. The samples should travel in equal lines from each well down to the gel. Once the line 
reaches the bottom of the gel (after approximately 90 minutes), the run is stopped and the gel is 
transferred onto a nitrocellulose membrane so the proteins can be probed with specific antibodies 
for band detection. 
The nitrocellulose membrane is composed of 100% pure nitrocellulose with approximately 0.2 µm 
pores (Invitrogen). The gel was equilibrated into a 2x diluted transfer buffer (Invitrogen) for 5 min 
at room temperature on a plate shaker. The transfer buffer (Invitrogen) contained 5 mM of Bicine, 
25 of mM Bis-Tris (free base) and 1 mM of EDTA (pH 7.2) all dissolved in 100 ml of ultrapure 
water. The transfer buffer was diluted down to 2x containing 10% methanol with double-distilled 
water. Approximately 25 ml was used for each gel.   
The Invitrogen (iBlot_R) transfer device was used for the gel transfer. The device utilises high 
field energy, high currents and shortened distance electrodes to transfer the proteins from the gel 
to the nitrocellulose membrane. The device runs for 7 min, during which the proteins are 




2.1.4.4 Protein detection on the blot 
Ponceau S staining was applied to the membrane following the transfer. Ponceau S staining is 
designed for the rapid, reversible staining of any protein band on the nitrocellulose membrane, 
which allows for confirmation that the proteins were transferred to the membrane from the gel. 
Any excess Ponceau stain was removed by washing in water and the membrane was taken for 
antigen blocking. To reduce the non-specific binding of the proteins on the blot, antigen blocking 
was carried out using 5% skimmed milk, which was comprised of 2.5 g of skimmed milk powder 
(FLUKA Skim Milk Powder for microbiology #70166) in 50 ml of 1x TBS-T containing 0.01% 
Tween-20 (Calbiochem). The blocking milk solution was added to the blot in a plastic bottle and 
then left on a roller for 20 min at room temperature.   
The primary antibodies were diluted in 1% skimmed milk in 1x TBS-T and the blot was incubated 
overnight on a roller at 4°C. The primary antibodies used in this study were the polyclonal rabbit 
TDP-43 10782-2-AP (Proteintech) and the PCBP2 mouse monoclonal (M07) clone 5F12 
(Abnova). The next day, the blot was washed three times with TBS-T (10–20 min each wash) on 
a roller at room temperature. The blot was then incubated with the secondary antibodies obtained 
from Thermo Scientific (Goat anti-Rabbit IgG [H+L] Secondary Antibody, DyLight 680 conjugate, 
and Pierce Goat anti-Mouse IgG [H+L] Secondary Antibody, DyLight 800 conjugate) diluted to 
1:5000 in 1% milk for 2–3 hours on a roller at room temperature (tubes covered in tin foil to protect 
the blot from light). The blot was then washed three times with TBS-T as previously described. 
The blot was visualised using the LI-COR Odyssey® scanner and the bands were analysed 
according to both the sample fraction and the band size. The blots were also probed with a loading 
control antibody in order to ensure that the increase or decrease in the size of the bands seen in 
the individual cases was not due to differences in the sample loading. The loading control used 
was rabbit GAPDH (Sigma, G8795). The density of the bands was measured using ImageJ 1.47v 





2.2 Cell Biology 
2.2.1 Cell lines and tissue culture 
Two cell lines were used in this study. Human embryonic kidney 293 (HEK-293T) cells were used 
for the overexpression, knockdown and immunoprecipitation experiments, while HeLa cells 
(derived from cervical cancer cells) were used for the immunocytochemistry experiments in order 
to investigate the accumulation of TDP-43 and hnRNP-E2 in stress granules. The HeLa cells were 
chosen for this purpose because they have a larger cytoplasm and they show better survival for 
the co-transfection and stress experiments than other cell lines, for example, SHSY5Y and CV1 
cells.   
The cells were grown in vitro in 75 cm2 cell culture flasks with 8 ml of growing media. The growing 
media used was DMEM (Dulbecco’s modified Eagle’s medium) with GlutaMAX and high glucose 
(4.5 g/L), which was obtained from Life Technologies. Foetal bovine serum (FBS) was added to 
the media to make up a final concentration of 10% FBS. Antibiotics were added to the media as 
100 U/mL of penicillin and 100 µg/mL of streptomycin so as to protect the cells from bacterial 
infections. The cells will continue to grow in this media until they cover the available surface area 
(confluence) or the growing media is depleted of nutrients. Therefore, the cells were subcultured 
to prevent them from dying. In order to subculture the cells, they needed to be in a suspension. 
All the reagents and media used for the subculturing were warmed in a water bath to 37ºC. After 
aspirating the media from the flask completely, the cells were washed with 4 mL of DPBS 
(Dulbecco’s phosphate-buffered saline) obtained from Life Technologies to wash off the media 
and any dead floating cells. After aspirating the DPBS, 1 mL of the protease enzyme (trypsin) 
was added to the cells and incubated for 2 minutes at 37ºC. Trypsin will release the adherent 
cells from the surface of the flask in order to allow them to be resuspended in fresh media. Once 
the cells fell off the surface, they were resuspended in 7 mL of fresh warm media. Some 1 mL of 
the cell suspension was passaged into a new flask and 7 mL of fresh warm media was added. 
The flask was labelled with the passage number and date and then placed back in the incubator. 
The rest of the cell suspension was used for the planned experiments as needed or else discarded 
appropriately. The cells’ transfection for overexpression and knockdown will be detailed in 




2.2.2 Western blotting  
The cells were harvested in 1x SDS load buffer (50 mM of Tris-HCl pH 6.8, 2% SDS, 10% glycerol 
and 12.5 mM of EDTA without bromophenol blue or reducing agents) with 1x complete proteinase 
inhibitor (PI) (Roche) and 1x phosphatase inhibitors (PhosSTOP) and then boiled for 10 minutes. 
The protein concentrations within the harvested cell samples were quantified using the Bio-Rad 
DC protein assay (Bio-Rad, Hemel Hempstead, UK) against a bovine serum albumin (BSA) 
standard. After analysing the sample’s concentration, only 5 µg of proteins from each sample was 
loaded onto the polyacrylamide gel electrophoresis (PAGE) for Western blotting. The samples 
were diluted to 5 µg using the harvesting buffer and 2x the loading buffer (125 mM of Tris-HCL 
pH 6.8, 4% SDS, 20% glycerol and 0.02% bromophenol blue dissolved in double-distilled water 
with 1 mM of dithiothreitol [DTT]). Fresh PI and PhosSTOP were added to the loading buffer.   
The PAGE Western blotting technique was used to separate the different sized proteins in the 
samples. The NuPAGE_R Novex_R 10% Bis-Tris (buffering agent) gel was used in this study. 
Further, 20x MOPS composed of 50 mM of Tricine, 50 mM of Tris base and 1% SDS (pH 8.24) 
was used as the gel running buffer. The MOPS was diluted to 1x with distilled water and then 
added to the Western blotting tank. Ice was also added to reduce the temperature during the gel 
running.   
The samples were loaded onto the gel and 1–2 µl of the Bio-Rad ladder (Precision Plus Protein™ 
Dual Color Standards #161-0374) was added to the gel as a reference for detecting the protein 
sizes. The gel was run at 150 mV for approximately 90 minutes. When the samples reached the 
bottom of the gel, the Western blot was stopped and the gel was removed. The gel was then 
incubated for 5 minutes in a transfer buffer on a plate shaker at room temperature. The transfer 
buffer was made up by diluting the Invitrogen transfer buffer, which contains 25 mM of Bicine, 25 
mM of Bis-Tris (free base) and 1 mM of EDTA pH 7.2, to 2x NuPAGE_R containing 10% methanol 
with distilled water. The gels were then transferred onto nitrocellulose membrane (Invitrogen) 
using the iBlot gel transfer system (Life Technologies iBlotTM).  
The blots were stained with Ponceau S rapid stain to ensure the protein was successfully 
transferred from the gel to the membrane. The Ponceau S staining was then washed off using 
tap water. The blots were blocked in TBS with 0.05% Tween 20 (TBS-T) and 5% non-fat dried 
milk (NFDM, Sigma-Aldrich) for 20 min. The blots were probed overnight at 4°C with the primary 
antibodies. The blots were then washed with 1x TBS-T three times (15–20 minutes each wash) 
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on a roller at room temperature. The secondary antibodies (IRDye® 800CW Goat anti-Mouse IgG 
[H + L], 925-32210, and VRDye™ 549 Goat anti-Rabbit IgG [H + L], 926-54020, LI-COR 
Biotechnology, Cambridge, UK) were added at a 1:5000 dilution in TBS-T plus 1% NFDM and 
then incubated while rolling for 3 hours at room temperature. After the 3 hours, the blots were 
washed with 1x TBS-T three times for 15–20 minutes each wash. The blots scanned on the LI-
COR Odyssey® gel scanner (LI-COR Biotechnology).   
The quantitative analysis of the blots was performed by measuring the density of the lanes and 
bands using ImageJ 1.47v software. In order to measure the density of the bands using ImageJ, 
a rectangular shape should be drawn around the band. The shape, size and location of the first 
selection will serve as a guide for the rest of the lanes on the gel. The density of the bands is 
plotted as curves. The peak of each band was detected by a straight line connecting the start and 
the end of the curve peak. The area underneath each curve was measured using the wand tracing 
tool in the ImageJ 1.47v software and presented as a number. Figure 8 presents an example of 





Figure 8: An illustrative example of the Western blot band quantification using the ImageJ 1.47v software. A 
rectangular shape is drawn around the bands and the density of the bands is presented as curves. The area 
underneath the peaks of the curves is measured using the selected tool and then translated into numbers. 
  
2.2.3 Immunocytochemistry and stress experiments 
Coverslips were added to a 24-well plate and then coated with poly-D-lysin (PDL) by incubating 
for 1 hr. The coverslips were rinsed twice with 500 µl of PBS before the cells were plated. The 
HeLa cells were plated on coverslips at 50,000 cells/well and left in the incubator to recover for 
24 hrs. After this time, the cells were transfected with non-transgenic Flag-tagged hnRNP-E2 and 
HA-tagged (wild type) WT TDP43 plasmids, which will be described further in Chapter 5. After 48 
hrs transfection time, the cells were exposed to different stress conditions in order to encourage 
the formation of stress granules. Some cells were treated with 0.5 mM of sodium arsenite for 30 
minutes, while some were treated with 600 mM of sorbitol for 1 hr and others were treated with 
both 600 mM of sorbitol for 1hr and 0.5 mM of sodium arsenite for 30 minutes. As a control 
condition, other transfected cells were not exposed to any stressful conditions. The sodium 
arsenite and sorbitol were diluted in DMEM and then added to the cells after removing the media 
from the wells. Once the incubation time was up, the cells were fixed by removing the media and 
adding 500 µl/well of 4% PFA (paraformaldehyde) for 10 minutes and then replacing it with PBS. 
57 
 
The primary antibodies were diluted in an immunobuffer, which contained PBS with 1% donkey 
serum and 0.2% Triton TX-100. The primary antibodies were added to the coverslips as required 
for each experiment and then incubated on a plate rocker overnight at 4ºC. Next, the primary 
antibodies were removed and the coverslips were washed three times with PBS. The secondary 
fluorescent antibodies used were donkey anti-mouse 488 and donkey anti-rabbit 549 (Life 
Technologies). They were diluted in the same immunobuffer and then added to the coverslips 
and incubated for 3 hours on a plate rocker at room temperature. They were covered in order to 
protect them from the light. The secondary antibodies were removed and the coverslips were 
washed by adding and removing 500 µl/well PBS during each wash. DAPI (1.25 ug/ml) was added 
to the coverslips for 30 seconds and then washed with PBS. The coverslips were mounted using 
Fluorescence Mounting Medium (Dako Omnis) on microscopic slides and left to dry underneath 
an opaque object to prevent light exposure. The Leica confocal SP system was used to visualise 
high-resolution images. The processing of the images was performed using ImageJ 1.47v 
software.  
 
2.2.4 Immunoprecipitation (pull-downs) 
The cells were transfected as further described in Chapter 5. The cells were harvested using ice-
cold IP buffer that contained 50 mM of Tris pH 7.4, 150 mM of NaCl and 1% Triton TX-100 with 
protease and phosphatase inhibitors. The samples were centrifuged for 30 seconds at 14,000 
rpm at 4ºC. The supernatant was transferred into new tubes and the pellets were discarded. Some 
of the supernatant was saved as lysate to be used as an input for each sample. For the IP, the 
primary antibodies were added to each sample as required (with 20 µl of Invitrogen Protein G 
Dynabeads) and incubated on a roller at 4ºC for 4 hrs. Afterwards, the Eppendorf tubes containing 
the samples were attached to a magnet in order to allow the migration of the magnetic beads to 
the side of the Eppendorf tube. Some 20 µl of the supernatant was removed as the flow-through 
(FT), which was diluted with 20 µl of the 2x loading buffer containing 62.5 mM of Tris-HCL pH 6.8, 
2% SDS, 10% glycerol and 0.01% bromophenol blue with 1 mM of dithiothreitol (DTT), proteinase 
inhibitors (1 tablet per 50 mL) and PhosSTOP (1 tablet per 50 mL). The samples were boiled for 
10 minutes. The rest of the supernatant was discarded and the beads were washed three times 
with 500 µl of IP buffer by removing the Eppendorf tubes from the magnet, inverting them and 
spinning them in a pulse centrifuge for a few seconds. For the final wash, a 10 µl pipette was 
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used to ensure all the grit was removed. Following the washes, 20 µl of the 2x loading buffer with 
DTT was added to the beads and boiled for 10 minutes. The samples were loaded onto gels for 
Western blotting as previously described. The volume of the samples loaded onto the gels was 
as follows: 4 µl of the lysate and flow-through and 12 µl of the IP buffer in a 26-well gel or 9 µl of 





Chapter 3 Screening for TDP-43-Binding Proteins 
3.1 Introduction 
In 2006, TDP-43 was identified as the major component of the ubiquitinated protein aggregates 
in FTLD (FTLD-U), FTLD-U with MND (FTLD-MND) and ALS (Neumann et al., 2006a). Many 
studies have examined the role of TDP-43 in neuronal degeneration in order to understand the 
pathology of these diseases and establish appropriate therapeutic targets. TDP-43 belongs to the 
hnRNP family of proteins; therefore, it interacts with many proteins involved in the biogenesis of 
mRNA and other cellular and nuclear functions. A list of candidates TDP-43 interacting proteins 
was previously established in our lab using the stable isotope labelling with amino acids in cell 
culture (SILAC) method (Stalekar et al., 2015). The aim of the SILAC project was to identify the 
proteins down- and up-regulated by TDP-43 RNAi knockdown and overexpression in order to 
define the associated network pathways involved in TDP-43 pathology. The SILAC method 
depends on the incorporation of amino acids with substituted stable isotopic nuclei (e.g.13C, 
15N), which allows the direct comparison of changes in protein expression between two samples 
(Mann, 2006, Ong et al., 2002). The SILAC method involves growing two populations of cells in 
two different media, one containing normal amino acids (light medium) and the other containing 
a heavy amino acid, for example, 13C instead of 12C. After the incorporation of either the light or 
heavy amino acids into the peptides, the SILAC method distinguishes two proteomes by the 
molecular weight of the light or heavy amino acid that is used during the growth of the two cell 
populations. The SILAC method’s amino acid replacement would be achieved after five cell 
doublings in all proteins, including proteins with insignificant turnover. Therefore, there will 
ultimately be two populations of cells, namely population A labelled with light amino acids and 
population B labelled with heavy amino acids. At this point, a perturbation is introduced to one 
population of cells, which in this case was a knockdown of TDP-43. Then, cells from both 
populations (i.e. A and B) are mixed and their proteomes extracted and measured by means of 
mass spectrometry. Each peptide appears as a pair in the mass spectra and the ratio of the peak 
intensities in the mass spectrometer provides the ratio of the proteins in population A versus that 
in population B. If there is no change in the abundance of a particular protein due to the 
knockdown of TDP-43, then it will appear in a 1:1 ratio. Therefore, the SILAC method represents 
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a powerful approach for identifying multiple targets in a single experiment (Ong et al., 2002, Mann, 
2006, Stalekar et al., 2015). Figure 9 illustrates the concept of the SILAC method.  
  
 
Figure 9: An illustration of the SILAC method. The left-hand side presents a diagrammatic explanation of the 
two cell populations, while the right-hand side is a representative illustration of the peptide presentation by 
means of spectrometry.   
 
 
The result of the SILAC experiment was recently published (Stalekar et al., 2015). In brief, the 
spectrum counts of the peptides were compared in control fractions and fractions of TDP-43 
knocked-down cells. The cells were fractionated into nuclear and cytoplasmic fractions. Some 
106 differentially abundant candidate proteins were identified in the nuclear fraction, 65 of them 
being increased and 50 decreased due to the TDP-43 knockdown. Further, 167 proteins were 
identified in the cytoplasmic fraction, of which 73 were increased and 94 decreased because of 
the TDP-43 knockdown. A list of all the identified proteins can be found in (Stalekar et al., 2015). 
The majority of the differentially expressed proteins are involved in RNA processing and 
intracellular transport (Stalekar et al., 2015).  
In this study, the expression of a number of the identified proteins and their potential role in the 
disease mechanism was investigated using post-mortem human brain and spinal cord samples 
from FTLD and ALS cases with TDP-43 pathology. An initial screening for those proteins in the 
FTLD and ALS brain and spinal cord tissue was performed by IHC, which is recognised as an 
important tool for elucidating a differential diagnosis that cannot be determined by conventional 
analysis. It is considered to be a purely descriptive method, which presents a picture of the 
situation that occurs in vivo. The discovery of antigen retrieval methods allowed for its application 
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in fresh and fixed tissue, which increased its applicability in the diagnosis of pathological anatomy 
(Huang et al., 1976, de Matos et al., 2010). The contribution of IHC to the field of 
neurodegeneration research has advanced far beyond the identification of specific diseases from 
a differential clinical diagnosis. The discovery of protein depositions within degenerating neurons 
taken from the post-mortem tissues of patients has opened a window of opportunity for better 
understanding the underlying pathological mechanisms (Duraiyan et al., 2012, de Matos et al., 
2010). Based on the level of change observed in the SILAC study as well as other previous 
research publications detailing their cellular functions, a number of proteins that could potentially 
interact with TDP-43 pathology were selected for investigation in the present study. The selected 
proteins were RANBP1, ubiquilin-2, hnRNP-M, hnRNP-C1/C2, hnRNP-Q and hnRNP-E2. 
 
3.1.1 RANBP1 
Ran-binding protein 1 regulates the RanGTPase system. Ran is a small GTPase that is 
predominantly located in the nuclear membrane (Ren et al., 1995). The RanGTP gradient controls 
the transport of proteins and other biomolecules through the nuclear envelope. RANBP1 binds 
directly to RanGTP and stimulates its conversion to RanGDP (Melchior et al., 1993) (Bischoff et 
al., 1995). RanBP1 was found to be downregulated by TDP-43 knockdown in the SILAC 
experiment (Stalekar et al., 2015). The downregulation of RanBP1 by TDP-43 knockdown was 
also reported in SK-Hep1 cells, with the same study suggesting that TDP-43 regulation could be 
a possible target for metabolic regulation in hepatic cell carcinoma (Park et al., 2013). TDP-43 
was also reported to promote the silencing of exon 5 in the RanBP1 transcript (Tollervey et al., 
2011b). The depletion of RanBP1 increases the RanGTP in cells, which can arrest protein 
transport through the nuclear envelope (Tedeschi et al., 2007). The loss of RanBP1 is 
embryonically lethal to mice and it is associated with microcephaly by disrupting the cortical 
projection of developing neurons selectively in layers 2/3, which is a critical area for behavioural 
impairments (Paronett et al., 2015).   
 
3.1.2 Ubiqulin-2 
Ubiquilin-2 belongs to the ubiquilin family of proteins that regulate the degradation of ubiquitinated 
proteins. It is encoded by the UBQLN2 gene, which is located on the X chromosome. Five 
missense mutations have been identified in the UBQLN2 gene that are linked to ALS and FTLD. 
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One mutation was found in a large X-linked dominant ALS-dementia family (Deng et al., 2011), 
while two mutations were found in single patients from two small families with classic ALS. The 
other two mutations segregated with the disease in multigenerational ALS-FTD families. Ubiquilin-
2 pathology was described as a component of spinal cord inclusions in a subset of sporadic ALS, 
familial ALS and ALS with dementia cases (Deng et al., 2011, Williams et al., 2012, Fecto and 
Siddique, 2011). Functional studies have shown that defects in ubiquilin-2 cause the impaired 
degradation of misfolded proteins, which implies a common pathogenic mechanism in 
neurodegenerative diseases (Deng et al., 2011).   
 
3.1.3 hnRNPs 
TDP-43 belongs to the very large family of nuclear factors known as hnRNPs (Buratti and Baralle). 
hnRNP is a collective term for the proteins that associate with the pre-mRNAs (hnRNAs). There 
are more than 20 major hnRNPs found in human cells, which are designated hnRNP-A1 to 
hnRNP-U (Table 5) (Chaudhury et al., 2010, Dreyfuss et al., 2002, Ghosh et al., 2008, Weighardt 
et al., 1996). The binding of hnRNPs to hnRNAs strongly affects the fate and processing of 
hnRNAs to mRNAs by influencing their structure and interactions. Steady-state hnRNPs are 
normally localised in the nucleus; however, they shuttle continuously between the nucleus and 
the cytoplasm, which indicates that they play a role in transducing signals between the nucleus 
and the cytoplasm as well as in mRNA export and function in the cytoplasm (Pinol-Roma and 
Dreyfuss, 1992). hnRNPs are important proteins for the nucleocytoplasmic transport of mRNAs 
as well as mRNA localisation, translation and stability. They also play an important role in 
transcription regulation, gene splicing, telomere length maintenance, immunoglobulin gene 
recombination, pre-ribosomal-RNA processing and 3’-end processing (Hoek et al., 1998, 
Michelotti et al., 1996, Mayeda and Krainer, 1992, Tomonaga and Levens, 1995). Several other 
hnRNP proteins were found to interact with TDP-43 in the SILAC experiment (Stalekar et al., 
2015). Therefore, the hnRNPs represent potential TDP-43 interacting proteins in ALS and FTLD 
cases. In the search for TDP-43 candidate partners in ALS and FTLD, a number of hnRNPs that 
were either identified by the SILAC experiment or selected based on other research studies were 
included in the screening section of this study. The investigated hnRNPs were hnRNP-C1/C2, 









hnRNP-M is present in four isoforms (hnRNP-M1-4), which arise from two variable mRNAs by 
means of the alternative splicing of single pre-mRNA and differ in terms of a stretch of 39 amino 
acids. hnRNP-M contains three RRM, a glycine/methionine-rich region and a methionine/arginine-
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rich repeat motif (Dreyfuss et al., 2002, Datar et al., 1993, Kafasla et al., 2002. hnRNP-M depletion 
from nuclear extracts inhibits splicing in early spliceosome assembly {Aidinis,1995 #2193). The 
alternative splicing of transcripts generated from fibroblast growth factor receptor 2 (FGFR2) and 
other mini-genes was found to be regulated by hnRNP-M (Park et al., 2011, Hovhannisyan and 
Carstens, 2007). The splicing regulation function of hnRNP-M can be influenced by interactions 
with specific binding partners (Marko et al., 2010, Lleres et al., 2010).   
One component of the hnRNP-M interaction network is the association of hnRNP-M with the 
Ewing sarcoma protein (EWS). EWS belongs to the highly related RNA/ssDNA-binding proteins 
and transcription factors known as the FET family of proteins (FUS/TLS, EWS and TAF15) 
(Pahlich et al., 2009, Tan and Manley, 2009). The FET family of proteins was initially discovered 
as components of the fusion oncogenes that cause human cancers. The proteins’ normal function 
is predicted to include roles in RNA transcription, processing and transport, microRNA processing 
and DNA repair (Kovar, 2011, Law et al., 2006). Mutations in the FUS/TLS gene have been 
reported to cause of 3% of familial ALS and 1% of sporadic ALS (Mackenzie et al., 2010b, Vance 
et al., 2009). ALS with FUS mutations (ALS-FUS) is characterised by abnormal cytoplasmic 
neuronal and glial inclusions that are immune-reactive for FUS. FUS inclusions were also 
detected in several subtypes of FTLD designated as FTLD-FUS. However, no FUS mutations 
have been reported in any of the FTLD-FUS cases to date (Mackenzie et al., 2010a, Urwin et al., 
2010, Snowden et al., 2011). Interestingly, the abnormal accumulation of all three FET proteins 
in pathological inclusions has been reported as a consistent and specific feature of all subtypes 
of FTLD-FUS. This contrasts with the situation of ALS-FUS, where only FUS was detected in the 
pathological inclusions in all investigated cases, which raises the possibility of subtle differences 
in the pathogenic pathways involved in the different FTLD-FUS subtypes (Neumann et al., 2011). 
Moreover, a study by Marko et al. (2014) reported that hnRNP-M interacts with FUS/TLS and 
TAF15 as well as EWS. However, the selective preferences of the hnRNP-M isoforms associate 
with different FET proteins. Indeed, FUS/TLS preferably interacted with the relatively more 
abundant lower molecular weight hnRNP-M1/2 isoform, while TAF15 showed a greater 
preference for associating with the higher molecular weight hnRNP-M3/4. The complex formation 
of hnRNP-M with FET proteins was found to be based on protein-protein interactions rather than 
RNA-based interactions (Marko et al., 2014). Furthermore, hnRNP-M was found to promote 
SMN2 exon 7 pre-mRNA inclusions in spinal muscular atrophy due to directly contacting an 
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enhancer on exon 7 (Cho et al., 2014). Together, the reported interactions of hnRNP-M suggest 
that it may have involvement in the underlying mechanisms of neurodegeneration, which renders 
it worthy of further investigation in FTLD and ALS cases. 
 
3.1.3.2 hnRNP-C1/C2 
hnRNP-C1/C2 are two alternative splice translation products of the human hnRNP-C1/C2 gene 
(Burd, 1994). hnRNP-C1 is created by the excision of 13 amino acids from the hnRNP-C1/C2 
coding sequence, which makes hnRNP-C1 the smaller of the two variants (Rech et al., 1995, 
McAfee et al., 1996). hnRNP-C1/C2 form the core elements of an hnRNP complex – along with 
hnRNP-A1, hnRNP-A2, hnRNP-B1 and hnRNP-B2 – that acts to handle RNA transcripts for 
intracellular destruction or translation. hnRNP-A, B and C form heterotetrameric complexes that 
assemble as an anti-parallel 4-helix coiled coil on nascent transcripts in order to regulate their 
splicing, turnover and polyadenylation (Dreyfuss et al., 2002). hnRNPC1/C2 were found to 
interact with dengue virus RNA and vimentin (which is an intermediate filament supporting cellular 
integrity) (Dechtawewat et al., 2015). The hnRNP-C1/C2 complex was also identified as a 
competitor with the normally functioning VDR-retinoid X receptor (RXR) dimer for binding to the 
vitamin D response element (VDRE), which causes vitamin-D-resistant rickets (Chen et al., 2006). 
hnRNP-C1/C2 have also been reported to exhibit nuclear actions, including splicing, telomere 
regulation, nuclear retention of hnRNAs, mRNA biogenesis and transport, protein translation and 
nuclear matrix stability (Orphanides and Reinberg, 2000). Both hnRNP-C1 and C2 contain an 
RNA recognition motif and a leucine zipper-like RNA-binding motif. Under basal conditions, 
hnRNP-C1/C2 reside mainly in the nucleus; however, they translocate to the cytoplasm during 
certain cellular conditions such as mitosis, apoptosis and viral infection (Dreyfuss, 1993, Kim et 
al., 2003, Gustin and Sarnow, 2002). The important functions of hnRNPC1/C2 in pre-mRNA 
packaging and processing render them possible candidates for TDP-43 partnership. 
 
3.1.3.3 hnRNP-Q 
hnRNP-Q has three isoforms, which are generated by alternative splicing. hnRNP-Q1 is the major 
isoform and it contains an acidic residue-rich domain at the N terminus. It also contains three 
RNA recognition motifs (RRMs) in the central region and an arginine/glycine (RG)-rich domain at 
the C terminus. hnRNP-Q2 has a truncated RRM2 and an extended C-terminal region. hnRNP-
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Q3 only differs from hnRNP-Q1 in terms of its C-terminal extension, which is the same as that 
seen for hnRNP-Q2, making it the longest isoform (Chen et al., 2008a). hnRNP-Q has been 
reported to play a role in mRNA splicing and mRNA stability (Mourelatos et al., 2001, Grosset et 
al., 2000). In the neurons, hnRNP-Q was found to be a component of the cytoplasmic mRNA 
granules and it has been suggested that it acts with the survival motor neuron (SMN) gene in 
mRNA trafficking (Rossoll et al., 2003, Rossoll et al., 2002). Interestingly, a clinical study reported 
elevated expression levels of hnRNP-Q in spinal muscular atrophy (SMA) patients with mild 
symptoms as well as in their unaffected siblings, which suggests a severity modulation role of 
hnRNP-Q (Helmken et al., 2003). SMA is a common inherited neuromuscular disorder caused by 
the homozygous loss of function of the SMN1 gene. At least one copy of the SMN2 gene, which 
is highly identical to the SMN1 gene, is carried by all SMA patients. A critical nucleotide change 
resulting in alternative splicing and the exclusion of exon 7 is seen in the majority of SMN2 mRNA, 
which results in a lower level of production of the functional SMN protein (Chen et al., 2008a, Yuo 
et al., 2008). The involvement of hnRNP-Q in the pathology of SMA makes it an interesting 
candidate for screening in FTLD and ALS. 
 
3.1.3.4 hnRNP-E2 
The hnRNP-E proteins belong to the hnRNP-K protein family with triple KH domains designated 
KH1, KH2 and KH3. Each of the KH domains is able to interact independently with a target RNA 
sequence, which provides these proteins with a potentially high number of complex-specific RNA 
interactions. They are highly expressed in human tissues and they can bind both poly(C) regions 
and low-C mRNAs. hnRNP-E1 and E2 are the most highly expressed and well-characterised 
isoforms of the hnRNP-E proteins. They have 89% amino acid similarity. It is believed that 
hnRNP-E1 is encoded by an intronless gene that is a product of a retrotransposition event of a 
fully processed minor isoform of hnRNP-E2 (Makeyev and Liebhaber, 2002, Makeyev et al., 1999, 
Woolaway et al., 2007). Woolaway et al. (2007) investigated the effects of the overexpression 
and depletion of hnRNP-E1 and E2 on HIV-1 gene expression. They demonstrated that the 
depletion of either hnRNP-E1 or E2 led to the increased production of the HIV-1 structural 
proteins. Yet, the overexpression of hnRNP-E1 but not of E2 can inhibit the expression of the 
Rev-dependent RNAs encoding gp120 and p24. Therefore, despite the high degree of sequence 
similarities between the hnRNP-E1 and E2 isoforms, they have distinct non-redundant cellular 
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functions. Work conducted by other research groups has corroborated these findings by 
demonstrating the higher affinity of hnRNP-E1 for hnRNP-D than hnRNP-E2 (Kiledjian et al., 
1999). It has also been reported that hnRNP-E1 and E2 exhibit differential regulation in response 
to the hypoxic stress of cortical neurons (Zhu et al., 2002).  
 
3.1.4 Aims of this chapter 
This chapter aims to identify the proteins in human brain and spinal cord tissue that could be 
interacting with TDP-43 pathology by using immunohistochemistry on FTLD-TDP tissue (of 





3.2.1 Immunohistochemistry  
Sections were obtained from FTLD cases with identified TDP-43 pathological subtypes. Formalin-
fixed, paraffin-embedded tissue sections from the frontal cortex of the brain of five subtype A, four 
subtype B, five subtype C, five TDP-43 cases with the C9orf72 expansion and five control cases 
were examined using immunohistochemistry (tissue from the TDP-43 subtype D could not be 
obtained due to its rarity). IHC was performed as described in section 2.1.1 using antibodies 
directed against the proteins selected as candidate TDP-43-binding proteins based on the results 
of the SILAC experiment.   
Initially, each antibody was optimised for use in the IHC technique by testing a number of dilutions 
(and, if necessary, pretreatment techniques) of each antibody on control and FTLD sections. The 
utilised antibodies are detailed in section 2.2.2. 
 
3.2.2 Double-labelling immunofluorescence 
Double-labelling immunofluorescence was conducted as described in section 2.2.3. The primary 
antibodies were the TDP-43 polyclonal antibody (Proteintech) at a 1:250 dilution and the ubiquilin-
2 monoclonal antibody (Abnova) at a 1:150 dilution. The experiment was performed on FTLD-




3.3.1 Initial screening of TDP-43-binding candidate proteins on human brain tissue 
Immunohistochemistry was utilised to screen for the candidate TDP-43-binding proteins identified 
in the SILAC experiment (Stalekar et al., 2015) in the frontal cortex tissue from FTLD-TDP cases 
and controls. Initially, two control cases and two FTLD-TDP cases were used to optimise the 
antibodies and then further investigation was conducted using a number of cases from different 
FTLD subtypes and control cases. 
 
3.3.1.1 RANBP1  
RANBP1 was tested at dilutions of 1:75, 1:100 and 1:200, with the 1:200 dilution being 
demonstrated to be optimal.  
The results of the RANBP1 antibody optimisation are demonstrated in Figure 10. The 
immunostaining of RANBP1 at a 1:200 dilution in the frontal cortex of the control case (A) showed 
strong nuclear reactivity when compared to the frontal cortex of the FTLD-TDP subtype B case 
(B). The cytoplasmic staining looked similar in both the control (A) and the case (B), with only 
very minimal background staining. There were no RANBP1 aggregates detected in any region of 
the frontal cortex of the FTLD-TDP case.  
 
 
Figure 10: RANBP1 IHC at 1:200 in the frontal cortex of a control case (A) and an FTLD subtype B case (B). 
Strong nuclear staining in the control as compared to weak nuclear labelling in FTLD-TDP. 
 
Further IHC for RANBP1 was not performed due to time limitations. We focused on the hnRNPs 





The ubiquilin-2 antibody was tested at dilutions of 1:100, 1:250 and 1:500 (all with citrate buffer 
pretreatment). The optimal dilution was found to be 1:500, with diffuse and very weak cytoplasmic 
staining and stronger nuclear staining being seen in the motor neurons in the frontal cortex of a 
control case (Figure 11A). In the frontal cortex of the FTLD-TDP type B case (Figure 11B), striking 
ubiquilin-2-positive inclusions were detected in the motor neurons’ cell bodies and neurites. 
 
Figure 11: Ubiquilin-2 staining in the frontal cortex of a control case (A) and an FTLD-TDP case (type B) (B). 
Diffuse weak cytoplasmic and strong nuclear staining are seen in the motor neurons of the control case, 
whereas inclusions were noted in the FTLD-TDP case. 
 
The pattern of ubiquilin-2 staining in the different FTLD subtypes was then further investigated 
using the optimal 1:500 dilution. The results from five FTLD type A, four FTLD type B, five FTLD 
type C, five C9orf72 expansion-positive cases and five controls are shown in Table 6 and Figure 
12. Ubiquilin-2 inclusions were detected in the FTLD-TDP subtype B and FTLD-C9orf72 












Diagnosis Subtype UBQLN2 IHC 
9 103/08 FTLD-TDP A Diffuse cytoplasmic and strong nuclear staining 
12 033/08 FTLD-TDP A Diffuse cytoplasmic and strong nuclear staining 
2 029/09 FTLD-TDP A Diffuse cytoplasmic and strong nuclear staining – 
some neurites seen 
1 025/11 FTLD-TDP A Diffuse cytoplasmic and strong nuclear staining 
6 172/12 FTLD-TDP A Weak cytoplasmic and strong nuclear staining 
21 432/12 FTLD-TDP B Nuclear staining only 
19 058/12 FTLD-TDP B Nuclear staining only 
17 157/12 FTLD-TDP B Strong staining with inclusions 
18 169/11 FTLD-TDP B Strong nuclear staining, inclusions and dendrites 
22 013/10 FTLD-TDP C Strong nuclear staining 
25 301/10 FTLD-TDP C Strong nuclear 
28 163/07 FTLD-TDP C Diffuse cytoplasmic and nuclear 
24 061/13 FTLD-TDP C Weak overall – some positive dendrites 
27 409/08 FTLD-TDP C Weak nuclear staining 
31 403/08 FTLD-ALS 
C9orf72 
B Strongly nuclear positivity, inclusions seen 
35 069/02 FTLD-ALS 
C9orf72 
B Weaker overall but strong nuclear and inclusions 
seen 
41 151/08 FTLD-ALS 
C9orf72 
B Strongly nuclear positivity, inclusions seen 
44 163/09 FTLD-ALS 
C9orf72 
A Strongly nuclear positivity, inclusions seen 
45 174/08 FTLD-ALS 
C9orf72 
n/a Strongly nuclear positivity, inclusions seen 
109 158/14 Control n/a Weak nuclear and cytoplasmic staining 
110 278/96 Control n/a Weak nuclear and cytoplasmic staining 
99 048/09 Control n/a Weak nuclear and cytoplasmic staining 
100 063/10 Control n/a Weak nuclear and cytoplasmic staining 







Figure 12: IHC for ubiquilin-2 shown in FTLD-TDP cases: subtype A, case ref. 2, 20x (A) and 40x (B), subtype 
B, case ref. 17, 20x (C) and 40x (D), subtype C, case ref. 28, 20x (E), C9orf72 expansion-positive, case ref. 
45, 20x (F) and 40x (G) and control, case ref. 99, 20x (H). Cytoplasmic staining and strong nuclear positivity 






The hnRNP-E2 IHC showed weak diffuse staining in the cytoplasm and stronger nuclear staining 
in the frontal cortex of the control case (Figure 13A). In the frontal cortex of two FTLD-TDP cases, 
the hnRNP-E2 IHC showed striking crescentic perinuclear and dystrophic neurite inclusions (B). 
The inclusions were detected with all three tested dilutions (i.e. 1:100, 1:250 and 1:500), although 
1:500 was chosen as the optimum dilution. 
 
 
Figure 13: hnRNP-E2 immunohistochemistry. Weak staining in the cytoplasm and stronger nuclear staining 
in the frontal cortex of the control case (A, left). In the frontal cortex of two FTLD-TDP cases, hnRNP-E2 IHC 






Table 7: hnRNP-E2 IHC results 
Case Ref. Case 
No. 
Diagnosis Subtype hnRNP E2 Inclusions 
9 103/08 FTLD-TDP A + 
12 033/08 FTLD-TDP A + 
2 029/09 FTLD-TDP A + 
1 025/11 FTLD-TDP A - 
6 172/12 FTLD-TDP A + 
21 432/12 FTLD-TDP B - 
19 058/12 FTLD-TDP B - 
17 157/12 FTLD-TDP B - 
18 169/11 FTLD-TDP B - 
22 013/10 FTLD-TDP C + 
25 301/10 FTLD-TDP C + 
28 163/07 FTLD-TDP C + 
24 061/13 FTLD-TDP C + 
27 409/08 FTLD-TDP C + 
31 403/08 FTLD-ALS C9orf72 B - 
35 069/02 FTLD-ALS C9orf72 B - 
41 151/08 FTLD-ALS C9orf72 B - 
44 163/09 FTLD-ALS C9orf72 A - 
45 174/08 FTLD-ALS C9orf72 n/a - 
109 158/14 Control n/a - 
110 278/96 Control n/a - 
99 048/09 Control n/a - 
100 063/10 Control n/a - 






Figure 14: IHC for hnRNP-E2 shown in FTLD-TDP cases: subtype A, case ref. 2, 20x (A), 40x (B) and 100x 
(C).  Subtype B, case ref. 17, 20x (D). Subtype C, case ref. 25, 20x (E) and 40x (F). C9orf72 expansion-
positive, case ref. 31, 20x (G).  Control, case ref. 109, 20x (I).  Weak cytoplasmic staining is seen in both 
the FTLD-TDP and control cases. Inclusions matching the pattern of TDP-43 pathology can be seen in 








hnRNP-M was tested at dilutions of 1:100, 1:200 and 1:500, with 1:500 being selected as the 
optimal dilution. The IHC of hnRNP-M in the frontal cortex of the FTLD-TDP case (Figure 15A–
D) showed nuclear immunoreactivity, which did not differ from the frontal cortex staining of the 
control case (Figure 15E). 
 
Table 8: hnRNP-M IHC results 
Case Ref. Case 
No. 
Diagnosis Subtype hnRNP-M IHC 
9 103/08 FTLD-TDP A Nuclear staining 
12 033/08 FTLD-TDP A Weak nuclear and cytoplasmic staining 
2 029/09 FTLD-TDP A Nuclear and cytoplasmic staining 
1 025/11 FTLD-TDP A Weak nuclear staining 
6 172/12 FTLD-TDP A Weak nuclear staining 
21 432/12 FTLD-TDP B Weak cytoplasmic staining 
19 058/12 FTLD-TDP B Nuclear staining 
17 157/12 FTLD-TDP B  Nuclear staining 
18 169/11 FTLD-TDP B           Nuclear and cytoplasmic staining 
22 013/10 FTLD-TDP C  Nuclear and cytoplasmic staining 
25 301/10 FTLD-TDP C Weak cytoplasmic staining 
28 163/07 FTLD-TDP C Nuclear staining 
24 061/13 FTLD-TDP C Nuclear staining 
27 409/08 FTLD-TDP C Weak nuclear staining 
31 403/08 FTLD-ALS C9orf72 B Nuclear staining 
35 069/02 FTLD-ALS C9orf72 B No positivity 
41 151/08 FTLD-ALS C9orf72 B  Nuclear staining 
44 163/09 FTLD-ALS C9orf72 A Nuclear and cytoplasmic staining 
45 174/08 FTLD-ALS C9orf72 n/a  Nuclear and cytoplasmic staining 
109 158/14 Control n/a Nuclear staining 
110 278/96 Control n/a Weak nuclear staining 
99 048/09 Control n/a Weak nuclear staining 
100 063/10 Control n/a Weak nuclear staining 









Figure 15: IHC for hnRNP-M shown in FTLD-TDP cases: subtype A, case ref. 4, 20x (A), subtype B, case 
ref. 11, 20x (B), subtype C, case ref. 2, 20x (C), C9orf72 expansion-positive, case ref. 41, 20x (D), control, 
case ref. 103, 20x (E). Control, case ref. 109, 40x (F). Cytoplasmic staining and nuclear positivity are seen 








3.3.1.5  hnRNP-C1/C2 
hnRNP-C1/C2 were tested at concentrations of 1:100, 1:200 and 1:500, with 1:500 being selected 
as the optimal dilution. Strong staining in the nucleus was detected by the hnRNP-C1/C2 in the 
frontal cortex of both the control (Figure 16A) and the FTLD-TDP case (Figure 16 B). 
Figure 16: hnRNP-C1/C2 immunohistochemistry. Strong staining in the nucleus was detected in the frontal 






















Table 9: hnRNP-C1/C2 IHC results 
Case Ref. Case 
No. 
Diagnosis Subtype hnRNP-C1/C2 IHC 
9 103/08 FTLD-TDP A No immuno-positivity 
12 033/08 FTLD-TDP A Nuclear staining 
2 029/09 FTLD-TDP A Strong nuclear staining 
1 025/11 FTLD-TDP A Nuclear staining 
6 172/12 FTLD-TDP A Nuclear staining 
21 432/12 FTLD-TDP B Nuclear staining 
19 058/12 FTLD-TDP B Nuclear staining 
17 157/12 FTLD-TDP B Nuclear staining 
18 169/11 FTLD-TDP B Strong nuclear staining 
22 013/10 FTLD-TDP C Nuclear staining 
25 301/10 FTLD-TDP C No positivity 
28 163/07 FTLD-TDP C Nuclear staining 
24 061/13 FTLD-TDP C Nuclear staining 
27 409/08 FTLD-TDP C No positivity 
31 403/08 FTLD-ALS C9orf72 B Nuclear staining 
35 069/02 FTLD-ALS C9orf72 B No positivity 
41 151/08 FTLD-ALS C9orf72 B Nuclear staining 
44 163/09 FTLD-ALS C9orf72 A Nuclear staining 
45 174/08 FTLD-ALS C9orf72 n/a Nuclear staining 
109 158/14 Control n/a Nuclear staining 
110 278/96 Control n/a Weak nuclear staining 
99 048/09 Control n/a Weak nuclear staining 
100 063/10 Control n/a Weak nuclear staining 





Figure 17: IHC for hnRNP-C1/C2 shown in FTLD-TDP cases: subtype A, case ref. 12, 20x (A). Subtype B, 
case ref. 19, 20x (B) and 40x (C). Subtype C, case ref. 22, 20x (D) and 40x (E). C9orf72 expansion-positive, 
case ref. 45, 20x (F).  Control, case ref. 109, 20x (G). Diffuse cytoplasmic staining and strong nuclear 
positivity are seen in all the FTLD-TDP subgroups and control cases. There was no obvious difference 







3.3.1.6 hnRNP-Q  
hnRNP-Q IHC at all dilutions (1:50, 1:250 and 1:500) showed no immunoreactivity in either the 
frontal cortex of the control (Figure 18A) or the frontal cortex of the FTLD-TDP case (Figure 18B).  
Figure 18: hnRNP-Q IHC. No immunoreactivity is detectable. 
 
3.3.2 Localisation of ubiquilin-2 within TDP-43 aggregates 
The colocalisation of TDP-43 and ubiquilin-2 was detected in the frontal cortex of FTLD-TDP 
cases #2 and #5. Panel A in Figure 19 shows the colocalisation of ubiquilin-2 within round TDP-
43 inclusions in subtype A FTLD-TDP (case ref. 2). Ubiquilin-2 also colocalised within neuritic 
TDP-43 inclusions in the frontal cortex of subtype C FTLD-TDP (case ref. 22), as depicted in 
Figure 19 (B1–B3). 
 
Figure 19: dIF of TDP-43 and ubiquilin-2 in FTLD-TDP subtype B, case ref. 2, (A1–A3) and in FTLD-TDP 




3.4  Discussion 
The accumulation and aggregation of misfolded proteins is a hallmark of various neurological and systemic 
diseases. The difference between cell types arises from the different protein expressions of the genes rather 
than from the genes themselves, which results in the production of specific sets and amounts of proteins for 
each cell type and often accounts for cellular specificity in disease (Venter et al., 2001, Fagerberg et al., 2011). 
The amino acid sequences of an individual protein determine its specific three-dimensional structures. The 
hydrophobic parts of the protein fold, meeting other hydrophobic parts in the sequence internally and leaving 
their hydrophilic residues on the outside, which allows for their interaction with charged residues of different 
polarity (Tyers and Mann, 2003). The precise organisation of protein complexes and/or individual proteins 
maintains the integrity of cellular function. The correct activity of a network of thousands of proteins is essential 
for cells to function properly. The functions of a protein depend on its structure, which is determined by its 
amino acid sequence, as well as the chaperone proteins, which supervise the folding process of proteins 
(Soto, 2003). A wide range of neurodegenerative diseases have been characterised, sub-classified and 
diagnosed via the identification of misfolded protein aggregates, including Alzheimer’s disease, Parkinson’s 
disease, motor neuron disease and frontotemporal dementia. The aggregated proteins share some structural 
and morphological staining characteristics; however, they may have distinct biological or biochemical features 
(Martin, 1999a). The involvement of misfolded protein aggregates in the neuron death process has been 
supported by a significant amount of evidence. The first step towards understanding the cellular mechanisms 
and/or pathological pathways underlying protein aggregation and neurodegeneration is to identify the 
aggregated proteins, their functions and their interaction partners in certain organelle or cellular compartments 
(Fagerberg et al., 2011, Alberts, 2002). The identification of proteins in human tissues involves a variety of 
techniques, including IHC, microarray IHC, Western blotting and immunofluorescence. IHC has become a 
routine tool for the specific detection and quantification of abnormal protein inclusions in post-mortem human 
tissues since antibodies against specific proteins have become commercially available (Duraiyan et al., 2012).   
Since the identification of TDP-43 as the major component of protein aggregates in MND and FTLD, TDP-43 
has been subject to thorough investigation in order to understand its role in the neuronal degeneration process.  
The identification of TDP-43-interacting networks of proteins would represent a step forward in understanding 
its pathological mechanism and pathway. A list of candidate TDP-43-binding proteins was generated in the 
SILAC experiment described earlier in this chapter. The expression of a number of these proteins was 
investigated in FTLD-TDP brain tissue. The proteins were selected according to the results of the SILAC 
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experiment, while the cases were selected according to the TDP-43 pathological subtype. The optimal dilution 
for each antibody was detected by testing three different dilutions within the range recommended by the 
manufacturer. The dilution that resulted in less background staining and clear cellular staining was used for 
the rest of the experiments.     
Despite the close relationship between RanBP1 and TDP-43 and its downregulation by TDP-43 knockdown 
in the SILAC experiment, there were no aggregates detected in the FTLD-TDP and ALS cases (Stalekar et 
al., 2015). The interaction of RanBP1 with TDP-43 was also demonstrated by several other studies, as 
mentioned in the introduction to this chapter (Park et al., 2013, Tollervey et al., 2011a, Tedeschi et al., 2007, 
Paronett et al., 2015). However, the absence of RanBP1 from the TDP-43 aggregates does not exclude it from 
the TDP-43 interaction network, which has been described by other studies (Tollervey et al., 2011a).   
Ubiquilin-2 inclusions were detected in the FTLD cases with subtype B pathology and cases with 
the C9orf72 expansion. The inclusions were seen in both the cell body and the neurites. In addition, the 
colocalisation of ubiquilin-2 with TDP-43 inclusions was detected using double-labelling immunofluorescence 
techniques. Previously, Brettschneider and colleagues reported that ubiquilin-2 pathology provides a 
characteristic neuropathological signature distinguishing FTLD-TDP cases with and without C9orf72. Their 
study suggested a pathophysiological link between UBQLN pathology and C9orf72 expansion (Brettschneider 
et al., 2012). Our findings correlate with those of Brettschneider et al.’s (2012) report; however, we found 
UBQLN inclusions in FTLD-TDP subtype B without the C9orf 72 mutation, which suggests that it is more 
related to the TDP pathological pattern than C9orf72 expansion. Alternatively, these two cases could contain 
a C9orf72 expansion that was not identified during in-house screening. Further dIF experiments could provide 
a clearer answer regarding the possible relation between UBQLN pathology and TDP-43 pathology in FTLD-
TDP cases, which could not be conducted in the present study due to time limits. In addition, the focus of this 
study is on hnRNPs, although the UBQLN interaction with TDP-43 in FTLD-TDP cases could be the focus of 
future studies. 
The hnRNP-M and hnRNP-C1/C2 immunoreactivity in the FTLD-TDP cases did not differ from that of the 
control cases. No reactivity for hnRNP-Q was detected using any concentration of the available antibody. All 
three hnRNPs share similar functions with TDP-43 in terms of RNA processing and splicing control. The 
reported interaction of hnRNP-M with FUS/TLS may explain the absence of hnRNP-M from the TDP-43 cases 
(Marko et al., 2014). hnRNP-M was not investigated in the FUS cases in this project. hnRNP-C1/C2 clearly 
have a strong nuclear presence, as expected in basal conditions. However, in the FTLD-TDP cases there was 
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weak staining of the cytoplasm around the nuclei when compared to the control case. It has been reported 
that hnRNP-C1/C2 translocate to the cytoplasm during certain cellular conditions such as apoptosis. Despite 
the absence of aggregates, the cytoplasmic presence of hnRNP-C1/C2 may indicate that cells are undergoing 
apoptosis (Dreyfuss, 1993, Kim et al., 2003, Gustin and Sarnow, 2002). Interestingly, hnRNP-Q has a close 
relation to MND, specifically with SMA, as discussed in the introduction to this chapter. The complete absence 
of immunoreactivity could be related to a faulty antibody, which could be investigated further in the future.  
The results of the hnRNP-E2 IHC revealed striking perinuclear and neuritic inclusions in the FTLD-TDP 
subtypes A and C cases, but not in the subtype B or C9orf72 expansion-positive cases. Based on these striking 
results, further investigations were carried out to examine the specificity and pathological importance of this 




The role of TDP-43 in the neurodegenerative process is not yet fully understood despite the intensive study of 
TDP-43 over the past decade. Screening for TDP-43 binding partners and identifying TDP-43 protein networks 
may enhance our understanding of the pathological mechanisms that could lead to TDP-43 aggregation and 
ultimately cause neuronal death. A list of candidate proteins was generated based on those that were 
influenced by the TDP-43 knockdown in a SILAC experiment previously published by our laboratory. A number 
of these proteins were probed using immunohistochemistry in human brain tissue. Inclusions were detected 
with two proteins, namely ubiquilin-2 and hnRNP-E2. Ubiquilin-2 inclusions were seen selectively in the 
subtype B and C9orf72 expansion-positive cases, whereas E2 inclusions were seen specifically in the subtype 
A and C FTLD-TDP cases. The interaction of ubiquilin-2 and TDP-43 in the C9orf72 expansion cases was 
detected by our group in experiments that were running parallel to this project. Therefore, hnRNP-E2, its 





Chapter 4 Investigation of hnRNP-E2 in FTLD and MND Human Brain 
Tissue 
4.1 Introduction 
In 2006, two large-scale studies recognised three distinct histopathological patterns according to the 
anatomical distribution and morphology of the neuronal ubiquitin inclusions in FTLD-U brains (Sampathu et 
al., 2006, Mackenzie et al., 2006). The two studies were conducted independently and simultaneously, which 
led to the non-matching numbering of the subtypes; however, the pathological features that defined the 
subtypes were almost identical (Table 10). Shortly afterwards, the Sampathu group reported the identification 
of TDP-43 as the major protein component of the ubiquitin inclusions in most FTLD-U cases as well as the 
majority of sporadic and some familial ALS (sALS and fALS) cases (Neumann et al., 2006b). Subsequently it 
was reported by other groups that most of their FTLD-U cases exhibited the same pathological pattern of TDP-
43 (Cairns et al., 2007, Davidson et al., 2007). A fourth FTLD-U subtype was described during the same 
period, which was specifically associated with mutations in the valosin-containing protein (VCP) gene. The 
VCP mutation type of FTLD represents the familial syndrome of Paget’s disease of bone with inclusion body 
myopathy and frontotemporal dementia (Forman et al., 2006). This type of FTLD-U also shows TDP-43 
pathology, which led to the recommendation by Mackenzie et al. (2009) that all FTLD-U cases with TDP-43 
pathology be designated as FTLD-TDP (Neumann et al., 2007b, Mackenzie et al., 2009). 
Both Mackenzie et al.’s (2006) and Sampathu et al.’s (2006) classification systems were widely accepted and 
repeatedly validated; however, the use of both systems was a source of confusion. Therefore, the principal 
authors of the original two papers proposed a new harmonised classification of FTLD-TDP pathology to 
replace the previously used classification systems (Mackenzie et al., 2011b). The new classification system 
took into consideration the frequency of the subtypes, with “A” being the most common subtype of FTLD-TDP. 
It also recommended replacing the numbers and orders of the subtypes in the previous two systems with 
letters to avoid confusion. Table 10 summarises the classification systems, while Figure 20 provides an 
illustration of the pathological pattern of the TDP-43 inclusions identified in each subtype. In this study, the 






Table 10: FTLD harmonised classification proposed by Mackenzie et al. (2011)  










Type A Type 1 Type 3 Many NCI 





























bvFTD: behavioural variant frontotemporal dementia, DN: dystrophic neurites, GRN: progranulin gene, IBMPFD: inclusion 
body myopathy with Paget’s disease of bone and frontotemporal dementia, MND: motor neuron disease, NCI: neuronal 
cytoplasmic inclusions, NII: neuronal intra-nuclear inclusions, PNFA: progressive non-fluent aphasia, SD: semantic 







Figure 20: An illustration of the harmonised classification of the FTLD-TDP subtypes. Type A is characterised by moderate 
to numerous TDP43-immunoreactive NCI and short DN predominantly in the upper cortical layers II/III. Type B cases 
typically show moderate to numerous TDP43-immunoreactive NCIs and sparse DNs across all cortical layers. Type C 
cases’ main characteristic is the presence of long dystrophic neurites predominantly in the upper cortices and NCIs. Type 




Many genetic mutations have been reported to be linked to familial FTLD-TDP, as detailed in Chapter 1. In 
brief, mutations have been reported in the granulin gene (GRN), VCP, TARDBP and, most recently, the 
abnormal expansion of a GGGGCC hexanucleotide repeat in a non-coding region of the C9orf72 gene, which 
is considered to be the most common genetic cause of sporadic and familial forms of FTLD and ALS (DeJesus-
Hernandez et al., 2011a, Kaivorinne et al., 2014). The understanding of the molecular basis of FTLD has 
advanced remarkably due to the substantial pathological and genetic findings over the past decade. However, 
there still exists a gap in our understanding of the exact molecular mechanisms that underlie the identified 
pathology. The purpose of this study is to investigate the TDP-43 pathology in FTLD and ALS in order to 
further understand the TDP-43 pathophysiology through its interaction with other proteins. From the screening 
results detailed in the previous chapter, hnRNP-E2 inclusions were detected in the frontal cortex of FTLD 
subtypes A and C cases, but not in subtype B or C9orf72 expansion cases. Therefore, a series of experiments 
were conducted in an effort to characterise the hnRNP-E2 pathology seen in the FTLD-TDP brain tissue 
utilising both human brain tissue and cell biology techniques. This chapter will present the pathological findings 
concerning hnRNP-E2 and its relation to TDP-43 and ubiquitin in human brain tissue from FTLD-TDP cases 
and other neurodegenerative diseases.  
As a first step in confirming this result, different antibodies for hnRNP-E2 were purchased and optimised on 
the same cases as those featured in the screening results. In Chapter 1, details regarding hnRNP-E2 
belonging to the hnRNP-K subfamily of hnRNPs and its great number of similarities with other members of 
that family were given. It has been reported that hnRNP-E2 and hnRNP-E1 share 89% structural homology. It 
is further believed that hnRNP E1 is encoded by an intronless gene that is a product of a retrotransposition 
event of a fully processed minor isoform of hnRNP E2 (Valverde et al., 2008, Waggoner and Liebhaber, 2003, 
Makeyev and Liebhaber, 2002, Woolaway et al., 2007). In addition, Wang et al. (2011b) found that hnRNP-E2 
interacts with the SRp75/hnRNP-G complex to regulate exon 10 splicing. The misregulation of exon 10 splicing 
results in the FTLD-type associated with tau (Wang et al., 2011b). Therefore, it was important that the cases 
that exhibited positive hnRNP-E2 immunoreactivity were screened for hnRNP-E1 and hnRNP-G in order to 
exclude any interaction with the hnRNP-E2 antibody. 
Second, the disease specificity of hnRNP-E2 was investigated by assessing a large number of cases in order 
to include more TDP-43-related cases as well as other neurodegenerative disease cases and controls. At the 
time of this study, there were 30 FTLD-TDP cases without the C9orf72 mutation and 22 FTLD-TDP cases 
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carrying the C9orf72 mutation identified in the Brain Bank at the Institute of Psychiatry, Psychology and 
Neuroscience, King’s College London.   
In addition, to investigate whether hnRNP-E2 plays a general role in neurodegeneration or whether it is specific 
to FTLD, a number of cases of various other neurodegenerative diseases were screened for hnRNP-E2 
pathology. Furthermore, the areas of the brain screened for hnRNP-E2 aggregates were increased to include 
the frontal cortex, hippocampus and spinal cord. For the other neurodegenerative cases, areas with the most 
prominent pathology were selected for screening, which mostly involved the frontal or frontotemporal cortices. 
In cases where there was motor neuron involvement, sections from the spinal cord were investigated. The 
cases and section details are presented in the results section of this chapter. 
Third, the functionality of a protein can be examined by characterising its interactions with other proteins (Rao 
et al., 2014). One way of studying protein-protein interaction in vitro utilises double-labelling 
immunofluorescence of the proteins of interest. Therefore, the colocalisation of hnRNP-E2, TDP-43 and 
ubiquitin was investigated in human brain sections using the dIF technique. Cases that showed positive 
immunoreactivity for hnRNP-E2 in IHC were used and the inclusions of hnRNP-E2, TDP-43 and ubiquitin were 
counted, then the percentage of colocalisation was calculated. The main issue needing to be overcome in this 
experiment was the natural autofluorescence seen in the human brain, which was solved by means of multiple 
washing and the preparation of fresh Sudan Black for each experiment. Higher power magnification images 
of the inclusions were captured using the confocal microscope in order to closely examine the colocalisation 
of hnRNP-E2 with TDP-43 and ubiquitin in FTLD-TDP cases.   
The biochemical signature of pathological TDP-43 in FTLD-TDP cases was identified by Neumann et al. 
(2006b). They sequentially extracted the grey matter from FTLD-TDP brains with buffers of increasing strength 
and ran Western blots of the samples. The hallmark of the pathology described by Neumann et al. (2006b) 
was the presence of detergent-resistant insoluble TDP-43 in the urea fraction, including the presence of the 
45 kDa band, the high molecular weight smear and the presence of the C-terminal cleavage product at 25 
kDa. Thus, the final experiment performed utilising human brain tissue in this study aimed to biochemically 
characterise hnRNP-E2 in FTLD-TDP cases using the Neumann et al.’s (2006 protocol for brain tissue 
fractionation. Four groups of cases were used for this experiment: 1) healthy control brains (control), 2) FTLD-
TDP cases with negative immunoreactivity to hnRNP-E2 (FTLD-TDP -ve hnRNP-E2), 3) FTLD-TDP cases 
with positive hnRNP-E2 immunoreactivity (FTLD-TDP +ve hnRNP-E2) and 4) FTLD-TDP with C9orf72 
expansion cases (C9orf72). Several issues developed in relation to the Western blots, specifically concerning 
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the TDP-43 immunoreactivity on the blots and the consistency of hnRNP-E2 immunoblots with the IHC results. 
Several repeats of the tissue fractionation and Western blots were performed using both the SARK 
fractionation protocol (adopted from Neumann et al. (2006) and the RIPA fractionation protocol (developed by 
Dr Jackie Mitchell for mouse brain fractionation). Different antibodies were used for the TDP-43 on some of 
the samples in order to check the specificity of the TDP-43 antibodies, with the results being presented in 
Appendix C.  
 
4.1.1 Aims of this chapter 
The present chapter aims to: 
1. Confirm the screening results concerning hnRNP-E2 through the application of several commercially 
available hnRNP-E2 antibodies.   
2. Investigate the specificity of the hnRNP-E2 antibodies by applying hnRNP-E1 and hnRNP-G to the 
cases previously identified to have positive hnRNP-E2 inclusions.  
3. Investigate hnRNP-E2 pathology in further brain regions of FTLD-TDP cases and to investigate the 
correlation of hnRNP-E2 pathology with the TDP-43 pathological subtypes and other demographic 
factors. The hnRNP-E2 immunoreactivity was also investigated in other neurodegenerative diseases 
in order to establish the disease specificity of hnRNP-E2 pathology. 
4. Investigate the colocalisation of hnRNP-E2 with TDP-43 and ubiquitin inclusions in the brain tissue 
of FTLD-TDP cases.   







4.2.1.1 hnRNP-E2 antibody optimisation and confirmation 
Three hnRNP-E2/PCBP2 antibodies obtained from three different companies were tested at different dilutions 
on the same cases (both control and FTLD-TDP cases). The first antibody was the mouse monoclonal antibody 
raised against recombinant hnRNP-E2 of human origin (hnRNP-E2 [23 G] code no. sc-101136, Santa Cruz). 
The second antibody was the mouse monoclonal PCBP2 (hnRNP-E2 code no. WH0005094M7, clone 5F12, 
Sigma-Aldrich). The third antibody was the Abnova mouse monoclonal PCBP2 monoclonal antibody (M07, 
clone 5F12, Abnova #H00005094-M07). All the antibodies were tested at dilutions of 1:50, 1:250 and 1:500. 
The IHC procedure was performed as described in Chapter 2. 
 
4.2.1.2 Cases and brain region selection 
The hnRNP-E2 IHC was performed on all the cases listed in section 2.1.1. For the FTLD cases, the frontal 
cortex and hippocampus were examined, as well as the spinal cord where available. For the other 
neurodegenerative disease cases, the regions were selected according to the prominent pathology of each 
disease. The results section of this chapter provides the full case details. 
  
4.2.2 Double-labelling immunofluorescence 
Double-labelling immunofluorescence was performed on several cases that showed hnRNP-E2-positive 
inclusions by IHC in order to check for colocalisation with TDP-43 and ubiquitin. The experiments were 
performed as described in Chapter 2. The primary antibody used to detect hnRNP-E2 was the mouse 
monoclonal antibody hnRNP-E2 (Santa Cruz), which was chosen for ease of experimental design as TDP and 
ubiquitin are polycolonal. Some experiments were performed using the hnRNP-E2 (Abnova) antibody to 
confirm the results. All the hnRNP-E2 antibodies were used at a 1:250 dilution. The TDP-43 antibody was the 
rabbit polyclonal (Proteintech), which was used at a 1:250 dilution. The ubiquitin antibody was the rabbit 
polyclonal anti-ubiquitin obtained from Dako (code no. Z045801), which was used at a 1:100 dilution. All the 
sections were incubated with fluorophore secondary antibodies for 45 minutes in the dark. The secondary 
antibodies used were Alexa Fluor® goat anti-rabbit, which was used to label the polyclonal primary antibodies, 
and Alexa Fluor® goat anti-mouse, which was used to label the monoclonal primary antibodies (Alexa Fluor® 
488 Goat Anti-Mouse IgG [Invitrogen] and Alexa Fluor® 568 Goat Anti-Rabbit IgG [Invitrogen]). The colour of 
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the fluorescent signal was chosen as green (488 nm) or red (568 nm) for each antibody. Following incubation, 
the sections were washed in PBS and incubated with Sudan Black for 10 min. The sections were washed 
multiple times with PBS and the slides were mounted using Vectashield with DAPI and then coverslipped. All 
the sections were visualised using an inverted fluorescence microscope (Zeiss Axiovision) and high-resolution 
images were obtained using the Leica confocal SP system. The processing of the images was performed 






4.2.3 Western blotting  
hnRNP-E2 insolubility in the brain tissue was investigated using the Western blotting technique. A 100 mg 
sample was dissected from the frozen frontal cortex grey matter (Brodmann area 9) of each case and the 
tissue was fractionated using the Sarkosyl fractionation protocol as described in Chapter 2. Details concerning 
the cases used for Western blotting are presented in Table 1. 
 
Table 11: Details of the FTLD-TDP cases and control cases used for Western blotting and the hnRNP-E2 IHC results 





2 029/09 FTLD-TDP A M 108 42 5 + 
3 037/12 FTLD-TDP A F 108 56 6 + 
22 013/10 FTLD-TDP C M 48 6 12 + 
25 301/10 FTLD-TDP C M 108 45 20 + 
9 103/08 FTLD-TDP A F 84 24 11 + 
32 403/08* FTLD-TDP C9orf72 B F 144 15.5 12 - 
7 205/07 FTLD-TDP A M 96 24.5 8 - 
8 229/03 FTLD-TDP A F 156 15 7 - 
1 025/11 FTLD-TDP A M 48 40.5 12 - 
10 294/13 FTLD-TDP A F 24 72 8 - 
18 169/11 FTLD-TDP B M 180 38 12 - 
5 101/09 FTLD-TDP A M 38 5 n/a - 
41 144/12 FTLD-ALS C9orf72 B F n/a 21 10 - 
42 151/08 FTLD-ALS C9orf72 B M 12 73.5 14 - 
44 157/04 FTLD-ALS C9orf72 B M 72 22.5 35 - 
45 163/09 FTLD-ALS C9orf72 A M 11 35 5 - 
17 229/06 FTLD-ALS C9orf72 F 10 34.5 17 - 
98 047/02 CNT F n/a 21.5 150 - 
100 048/09 CNT M n/a 18 17 n/a 
101 063/10 CNT F n/a 50 19 - 
102 066/00 CNT M n/a 53 14 - 
104 123/09 CNT M n/a 24 8 - 





4.2.3.1 Gel electropheresis and Western blotting 
The samples were thawed at room temperature for a few minutes and then spun in the centrifuge for a few 
seconds before loading onto the Western blot gels. Some 10 µl of each of the five fractions (i.e. lysate, low 
salt, Triton, SARK and urea) from each case were loaded onto the 26-well SDS-PAGE polyacrylamide gel 
NuPAGE R Novex R 10% Bis-Tris buffering agent with a neutral pH gel. Each gel was loaded with the five 
fractions of a control case, a FTLD-TDP case with hnRNP-E2 +ve inclusions, a FTLD-TDP with -ve hnRNP-
E2 inclusions and an FTLD-TDP with the C9orf72 expansion. The lysate and urea fractions of one case were 
also loaded onto all the gels as intra-gel controls. In addition to the samples, 1–2 µl of the protein ladder (Bio-
Rad) was loaded onto the gels as a protein size reference. The gels ran at 150–190 volts for approximately 
90 minutes. Once the line reached the bottom of the gel, the run was stopped and the gel was transferred onto 
a nitrocellulose membrane so the proteins could be probed with specific antibodies for band detection as 
described in Chapter 2. The blots were blocked with 5% skimmed milk for 20 minutes before the primary 
antibodies were added to the blots. The primary antibodies were diluted in 1% skimmed milk in 1x TBS-T and 
the blots were incubated overnight on a roller at 4°C. The brain blots were probed with the polyclonal rabbit 
TDP-43 10782-2-AP (Proteintech) and the PCBP2 mouse monoclonal (M07) clone 5F12 (Abnova). The next 
day, the blots were washed three times with TBS-T (10–20 min each wash) on a roller at room temperature.  
The blots were then incubated with the secondary antibodies obtained from Thermo Scientific (Goat anti-
Rabbit IgG [H+L] Secondary Antibody, DyLight 680 conjugate, and Pierce Goat anti-Mouse IgG [H+L] 
Secondary Antibody, DyLight 800 conjugate), which were diluted to 1:5000 in 1% milk for 2–3 hours on a roller 
at room temperature in the dark. The blots were then washed three times with TBS-T as previously described. 
The blots were visualised using the LI-COR Odyssey® scanner and the bands were analysed according to 
both the sample fraction and the band size. The blots were also probed with loading control to ensure that any 
increase or decrease in the size of the bands seen in the cases was not due to differences in sample loading. 
The loading controls used were histone 3, lamin or GAPDH. 
The protein quantification from the blots was performed using the ImageJ software as described in Chapter 2. 
The loading controls were not detected in the insoluble fraction (urea); therefore, the normalisation of the 
quantified results was conducted by taking the ratio of the insoluble/soluble (urea/lysate) fractions of each 
case separately and then calculating the average for each case group. The differences in the insoluble TDP-
43 and hnRNP-E2 levels among the sample groups were determined using a one-way ANOVA followed by a 
Bonferroni post-hoc t-test with a significance level of p < 0.05. The t-test was a two-tailed t-test assuming equal 
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variance between the groups. The mean is presented as (Mean ± SE), with SE representing the standard error 
of the samples.  
 
4.2.4 Correlation of demographic factors with hnRNP-E2 pathology 
A total of 29 FTLD-TDP cases without the C9orf72 mutation were examined for hnRNP-E2 pathology by means 
of IHC. At least two regions of the brain and/or spinal cord were examined for each case. The cases were 
subtyped according to the TDP-43 pathology into four subtypes as previously described. In order to identify 
the factors that may influence the IHC results, for example, the TDP-43 subtype pathology, post-mortem delay 
or fixation time, a Chi-square test was performed to identify any variable significance. All the analyses were 
carried out using SPSS software (IBM SPSS statistics 19).
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Table 12: Details of the FTLD-TDP cases used in the statistical analysis 
 Case Diagnosis Sex PMD (hrs) Fixation time (weeks) 
1 025/11 FTLD-TDP A M 40.5 12 
2 029/09 FTLD-TDP A M 42 5 
3 037/12 FTLD-TDP A F 56 6 
4 063/12 FTLD-TDP A M 36 4 
5 120/11 FTLD-TDP A M 14 8 
6 172/12 FTLD-TDP A M 31 10 
7 205/07 FTLD-TDP A M 24.5 8 
8 229/03 FTLD-TDP A F 15 7 
9 103/08 FTLD-TDP C F 24 11 
10 294/13 FTLD-TDP A F 72 8 
11 334/09 FTLD-TDP A M 11 24 
12 033/08 FTLD-TDP A F 35 10 
13 047/07 FTLD-TDP A F 70 8 
14 097/09 FTLD-TDP A M n/a n/a 
15 099/08 FTLD-TDP A M 7 n/a 
16 030/06 FTLD-TDP B M 43.5 n/a 
17 157/12 FTLD-TDP B M 45 6 
18 169/11 FTLD-TDP B M 38 12 
19 058/12 FTLD-TDP B F 54 8 
20 244/07 FTLD-TDP B M 46 4 
21 432/12 FTLD-TDP B M 31 8 
22 013/10 FTLD-TDP C M 6 12 
23 022/07 FTLD-TDP C M 120 7 
24 061/13 FTLD-TDP C M 16 11 
25 301/10 FTLD-TDP C M 45 20 
26 350/08 FTLD-TDP C M 14 16 
27 409/08 FTLD-TDP C M n/a 12 
28 163/07 FTLD-TDP C M 6.5 12 







Immunohistochemistry was utilised to screen for candidate TDP-43-binding proteins on different areas of the 
human brain from cases of FTLD with positive TDP-43 inclusions, as described in Chapter 3. hnRNP-E2 
showed strong positive cytoplasmic and neritic inclusions in the frontal cortex of a subset of FTLD-TDP cases. 
Details concerning these cases are presented in Table 3 (Chapter 2). 
 
4.3.1.1 Antibody confirmation and optimisation 
In order to confirm the positive results of the hnRNP-E2 IHC on FTLD-TDP cases, further IHC experiments 
were performed using the other two hnRNP-E2/PCBP2 antibodies on the same cases (ref. 2). Antibody 
optimisation was performed by testing gradual dilutions of 1:50, 1:250 and 1:500. The 1:500 dilution showed 
good immunopositivity with less background staining. Figure 21 shows the IHC results using the three different 
hnRNP-E2 antibodies at 1:500 dilutions. Details concerning the utilised antibodies are listed in Table 4 
(Chapter 2). In the control frontal cortex (case ref. 108), the hnRNP-E2 staining was diffusely distributed 
between the nucleus and the cytoplasm; however, the nuclear staining was stronger than that seen in the 
cellular cytoplasm (Figure 21 A). In an FTLD-TDP type A case (case ref. 2), hnRNP-E2 (Santa Cruz) detected 
perinuclear and neuritic inclusions (Figure 21B). The Abnova hnRNP-E2/PCBP2 antibody detected the same 
structures; however, the background staining was much less than that seen for the previous Santa Cruz 
antibody (Figure 21C). The Sigma antibodies detected the same inclusions; however, they produced very 
strong background staining (Figure 21D). Therefore, the Santa Cruz and Abnova antibodies were selected for 
use in further experiments.   
hnRNP-G IHC was performed on those cases with hnRNP-E2-positive inclusions due to the reported 
interaction between the two. The results showed hnRNP-G to be diffusely present in the nuclei and the 
cytoplasm. hnRNP-G did not detect any inclusions or similar structures to those detected with hnRNP-E2 
(Figure 21E). Due to the similarities between hnRNP-E2 and hnRNP-E1, IHC was performed on the same 
FTLD-TDP cases that showed positive immunoreactivity to hnRNP-E2 in order to exclude any cross-reactivity. 
The hnRNP-E1 IHC (Figure 21F) on the frontal cortex of the FTLD-TDP case did not show similar aggregates 







Figure 21: Optimisation and confirmation of the hnRNP-E2 IHC results using different antibodies on the frontal cortex of a 
type A FTLD-TDP case (case ref. 2). The results of the hnRNP-E2 Santa Cruz IHC on a control frontal cortex show hnRNP-
E2 to be diffusely distributed between the nucleus and the cytoplasm, with a stronger nuclear presence than cytoplasmic 
(A) (case ref. 108). Round and ring-shaped perinuclear inclusions were detected in the frontal cortex of an FTLD-TDP 
case with the hnRNP-E2 Santa Cruz antibodies (B) (case ref. 2). The background staining is moderate with this antibody. 
The Abnova hnRNP-E2 antibody produced much less background staining and still detected similar inclusion structures 
to the previous antibody (C) (case ref. 2). The hnRNP-E2/PCBP2 Sigma antibodies produced very strong background 
staining yet detected the same inclusions as the previous two antibodies (D) (case ref. 2). The hnRNP-G/RBMX IHC on 
the frontal cortex of the same case did not detect any inclusions (E) (case ref. 2). The hnRNP-E1 IHC on the frontal cortex 











4.3.1.2 hnRNP-E2 in different regions of the brain of a subset of FTLD-TDP cases 
hnRNP-E2 was investigated in different regions of the brain of FTLD-TDP and MND cases without the C9orf72 
expansion. hnRNP-E2 inclusions were detected in the frontal cortex, hippocampus and spinal cord (Figure 22 
and Figure 23). Figure 22 shows the hnRNP-E2 IHC in different regions of the brain and spinal cord of a type 
A FTLD-TDP case (case ref. 2). The frontal cortex pathology of hnRNP-E2 is predominant in the superficial 
layers, mainly in layer 2 of the neocortex, with numerous cytoplasmic perinuclear and intraneuronal inclusions 
and frequent neuritic inclusions (Figure 22A). In the hippocampus, hnRNP-E2 inclusions were detected within 
the granular cells (Figure 22B). No hnRNP-E2 inclusions were detected in the cerebellum in any FTLD-TDP 
cases without the C9orf72 mutation (Figure 22C). In the spinal cord, sparse inclusions were detected in the 
grey matter of the anterior horn of the thoracic spinal cord region. The spinal cord inclusions were detected in 
only two cases (case ref. 2, Figure 22D–E, and case ref.16, Figure 22F).   
 
Figure 22: IHC of hnRNP-E2 in a type A FTLD-TDP case (ref. 2) (A–E). Numerous cytoplasmic perinuclear and 
intraneuronal inclusions and frequent neuritic inclusions were detected, mainly in layer 2 of the frontal cortex (A).  
Intracellular cytoplasmic inclusions were detected in the pyramidal cells of the hippocampus of the same case (B). In the 
cerebellum of the same case, there was no pathology detected in the granular layer, molecular layer or Purkinje cells (C).  
Sparse inclusions were detected in the grey matter of the anterior horn of the thoracic region of the spinal cord of the same 
case (ref. 2) (D and E). Sparse spinal cord inclusion was detected in another case (ref. 16) in the grey matter of the anterior 








In the type C FTLD-TDP cases, the long neuritic profiles of hnRNP-E2 inclusions were predominantly detected 
in the superficial layers of the frontal cortex (Figure 23A). They were also detected in the pyramidal layer of 
the hippocampus (Figure 23B). Round intracellular inclusions were detected in the granular layer of the dentate 
gyrus in the hippocampus in type C FTLD-TDP cases (Figure 23C). The abundance of the inclusions among 
the positive cases varied from case to case. Figure 24 shows hnRNP-E2 inclusions in the frontal cortex of four 




Figure 23: hnNRP-E2 IHC from a type C FTLD-TDP case (ref. 22). Frequent long neuritic inclusions of hnRNP-E2 were 
predominantly detected in the superficial layers of the frontal cortex (A). They were also detected in the granular layer of 
the hippocampus (B). In the dentate gyrus of the hippocampus, round intracellular inclusions were detected (C). No 









Figure 24: hnRNP-E2 IHC of the frontal cortex from four different type C FTLD-TDP cases showing the variation in the 
hnRNP-E2 abundancy in each case. Very few inclusions were detected in case (A) (ref .25) when compared to the other 





Example IHC results of hnRNP-E2 in the C9orf72 FTLD-TDP cases are presented in Figure 25. Strong nuclear 
staining of the hnRNP-E2 with diffuse cytoplasmic staining was detected in the frontal cortex of the C9orf72 
FTLD-TDP cases (Figure 25A), which did not differ from the frontal cortex staining detected in the control 
cases (Figure 25C). In the cerebellum, diffuse staining within the Purkinje neurons was detected in the C9orf72 
FTLD-TDP cases (Figure 25B), which resembled that detected in the control cerebellum (Figure 25D). No 
inclusions were detected in the molecular layer or the granule cell layers of the cerebellum (Figure 25). Details 
concerning the FTLD-TDP cases, including the C9orf72 expansion cases, are presented in Table 13. To 
conclude, hnRNP-E2 inclusions were detected in one or more regions of the brain and spinal cord in 16 out of 
the 30 cases, which represents 53.3% of the FTLD-TDP cases without the C9orf72 expansion. Six out of 15 
subtype A FTLD-TDP cases showed hnRNP-E2 inclusions in the frontal cortex and hippocampus, while two 
cases had inclusions in the spinal cord (40% of FTLD-TDP A cases had hnRNP-E2 inclusions). One subtype 
B case out of a total of six showed hnRNP-E2-positive inclusions in both the frontal cortex and the spinal cord 






Figure 25: hnRNP-E2 IHC on the frontal cortex and cerebellum of control case ref. 105 (A and B) and on an FTLD-TDP 
case (ref. 42) with the C9orf72 expansion (C and D). 
 
 
Table 13: Details of the hnRNP-E2 IHC results for all the FTLD-TDP cases representing the regions investigated 
forhnRNP-E2 immunoreactivity. (+: inclusions detected, -: inclusions not detected, FCx: frontal cortex, HC: hippocampus, 
SC: spinal cord) 
 
Ref Case Diagnosis hnRNP-E2/PCBP2 IHC    
FCx (E2) HC (E2) SC (E2) 
1 025/11 FTLD-TDP A - - n/a 
2 029/09 FTLD-TDP A + + + 
3 037/12 FTLD-TDP A + - n/a 
4 063/12 FTLD-TDP A + + + 
5 120/11 FTLD-TDP A - - - 
6 172/12 FTLD-TDP A + - - 
7 205/07 FTLD-TDP A - - n/a 
8 229/03 FTLD-TDP A - - n/a 
9 103/08 FTLD-TDP A + + n/a 
10 294/13 FTLD-TDP A - - n/a 
11 334/09 FTLD-TDP A - - n/a 
12 033/08 FTLD-TDP A + - n/a 
13 047/07 FTLD-TDP A - - n/a 
14 097/09 FTLD-TDP A - - - 
15 099/08 FTLD-TDP A - - n/a 
16 030/06 FTLD-TDP B + - + 
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17 157/12 FTLD-TDP B - - - 
18 169/11 FTLD-TDP B - - n/a 
19 058/12 FTLD-TDP B - - n/a 
20 244/07 FTLD-TDP B - - n/a 
21 432/12 FTLD-TDP B - - - 
22 013/10 FTLD-TDP C + + - 
23 022/07 FTLD-TDP C + + - 
24 061/13 FTLD-TDP C + + - 
25 301/10 FTLD-TDP C + + - 
26 350/08 FTLD-TDP C  + + + 
27 409/08 FTLD-TDP C + + n/a 
28 163/07 FTLD-TDP C + - - 
29 295/07 FTLD-TDP C - - - 
30 101/09 FTLD-TDP A - - n/a 
31 088/00 FTLD-TDP C9orF72 B - - - 
32 403/08 FTLD-TDP C9orF72 B - - - 
33 019/95 FTLD-ALS C9orF72 - n/a n/a 
34 050/98 FTLD-ALS C9orF72 - n/a n/a 
35 068/05 FTLD-ALS C9orf72 - n/a - 
36 069/02 FTLD-ALS C9orf72 B - n/a - 
37 095/05 FTLD-ALS C9orf72 - n/a - 
38 112/99 FTLD-ALS C9orf72 - n/a n/a 
39 117/91 FTLD-ALS C9orf72 - - n/a 
40 141/06 FTLD-ALS C9orf72 - n/a - 
41 144/12 FTLD-ALS C9orf72 - n/a - 
42 151/08 FTLD-ALS C9orf72 B - - n/a 
43 156/95 FTLD-ALS C9orf72 B - n/a n/a 
44 157/04 FTLD-ALS C9orf72 - n/a n/a 
45 163/09 FTLD-ALS C9orf72 A - - n/a 
46 174/08 FTLD-ALS C9orf72 - n/a n/a 
47 205/99 FTLD-ALS C9orf72 - n/a n/a 
48 223/08 FTLD-ALS C9orf72 - - n/a 
49 229/06 FTLD-ALS C9orf72 - n/a - 
50 290/10 FTLD-ALS C9orf72 - n/a n/a 
51 311/07 FTLD-ALS C9orf72 - n/a - 
52 315/07 FTLD-ALS C9orf72 A - n/a n/a 
53 400/08 FTLD-ALS C9orf72 - n/a - 
31 088/00 FTLD-TDP C9orF72 B - - - 
32 403/08 FTLD-TDP C9orF72 B - - - 
33 019/95 FTLD-ALS C9orF72 - n/a n/a 
34 050/98 FTLD-ALS C9orF72 - n/a n/a 
35 068/05 FTLD-ALS C9orf72 - n/a - 
36 069/02 FTLD-ALS C9orf72 B - n/a - 
37 095/05 FTLD-ALS C9orf72 - n/a - 
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38 112/99 FTLD-ALS C9orf72 - n/a n/a 
39 117/91 FTLD-ALS C9orf72 - - n/a 
40 141/06 FTLD-ALS C9orf72 - n/a - 
41 144/12 FTLD-ALS C9orf72 - n/a - 
42 151/08 FTLD-ALS C9orf72 B - - n/a 
43 156/95 FTLD-ALS C9orf72 B - n/a n/a 
44 157/04 FTLD-ALS C9orf72 - n/a n/a 
45 163/09 FTLD-ALS C9orf72 A - - n/a 
46 174/08 FTLD-ALS C9orf72 - n/a n/a 
47 205/99 FTLD-ALS C9orf72 - n/a n/a 
48 223/08 FTLD-ALS C9orf72 - - n/a 
49 229/06 FTLD-ALS C9orf72 - n/a - 
50 290/10 FTLD-ALS C9orf72 - n/a n/a 
51 311/07 FTLD-ALS C9orf72 - n/a - 
52 315/07 FTLD-ALS C9orf72 A - n/a n/a 
53 400/08 FTLD-ALS C9orf72 - n/a - 
41 144/12 FTLD-ALS C9orf72 - n/a - 
42 151/08 FTLD-ALS C9orf72 B - - n/a 
43 156/95 FTLD-ALS C9orf72 B - n/a n/a 
44 157/04 FTLD-ALS C9orf72 - n/a n/a 
45 163/09 FTLD-ALS C9orf72 A - - n/a 
46 174/08 FTLD-ALS C9orf72 - n/a n/a 
47 205/99 FTLD-ALS C9orf72 - n/a n/a 
48 223/08 FTLD-ALS C9orf72 - - n/a 
49 229/06 FTLD-ALS C9orf72 - n/a - 
50 290/10 FTLD-ALS C9orf72 - n/a n/a 
51 311/07 FTLD-ALS C9orf72 - n/a - 
52 315/07 FTLD-ALS C9orf72 A - n/a n/a 
53 400/08 FTLD-ALS C9orf72 - n/a - 
49 229/06 FTLD-ALS C9orf72 - n/a - 
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4.3.1.3 hnRNP-E2 in neurodegenerative diseases 
The involvement of hnRNP-E2 in all types of neurodegeneration was investigated in a broad range of 
neurodegenerative diseases, including Pick’s disease, DLB, Alzheimer’s disease and Huntington’s disease. 
Other types of FTLD cases were also examined for hnRNP-E2 pathology, including FTLD with tau aggregates 
(FTLD-Tau), FTLD with ubiquitin only inclusions (FTLD-U) and FTLD with the progranulin mutation (FTLD-U-
PRGN). Due to the close relation between FTLD and ALS, sporadic ALS cases, ALS with the FUS mutation, 
ALS with the SOD1 mutation and ALS with the TARDBP mutation were also investigated for hnRNP-E2 
immunoreactivity by IHC. In addition, argyrophilic grain disease (AGD) and spinocerebellar ataxia (SCA) cases 
were included.  
The results of the hnRNP-E2 IHC on all the cases mentioned above did not reveal any pathological aggregates 
in the brain or spinal cord in any disease other than FTLD-TDP, with all the sections appearing similar to the 
controls. Figure 26 shows the IHC of hnRNP-E2 on the frontal cortex of a control case (case ref. 105) (A), a 
dementia with Lewy bodies case (B) (case ref. 63), an FTLD case with tau (MAPT mutation) (C) (case ref. 86) 
and an Alzheimer’s disease case (D) (case ref. 55). hnRNP-E2 showed diffuse nuclear and cytoplasmic 
staining in all the cases and controls, with no intracellular or extracellular inclusions. The negative control slide 





Figure 26: hnRNP-E2 (Santa Cruz, 1:500) IHC on the frontal cortex of control and neurodegenerative cases. Control case 
(A, ref. 105), dementia with Lewy bodies case (B, ref. 63) an FTLD with tau case (MAPT mutation, C, ref. 86), an 





4.3.2 Double-labelling immunofluorescence 
4.3.2.1 Colocalisation of TDP-43 and hnRNP-E2 in human brain tissue 
In order to examine the relationship of hnRNP-E2 with TDP-43 pathology, double-labelling 
immunofluorescence was performed to investigate any colocalisation within the TDP-43 inclusions.   Inclusions 
were counted as described in the methods chapter (Chapter 2).  A total of 465 TDP-43 inclusions and 393 
hnRNP-E2 inclusions were registered from 1 FTLD-TDP type A case (case #2) and 4 FTLD-TDP type C cases 
(case #22, #23, #25 and #26).  The percentage of the inclusions that colocalised was calculated. It was found 
that hnRNP-E2 colocalised with ~84.5% of TDP-43 inclusions.  Figure 27 is a low magnification image showing 
the density and distribution of TDP-43 (red) and hnRNP-E2 (green) and the ratio of their colocalisation in the 
frontal cortex of an FTLD-TDP case.  Figure 27A, A1 and A2 represent the dIf of both TDP-43 and hnRNP-E2 
in the frontal cortex of a control case, showing that the normal nuclear localisation of TDP-43 and hnRNP-E2 
appears to be shuttling between the nucleus and the cytoplasm, which is a normal distribution (Figure 27A 
and A1). The merged image (Figure 27A2) shows that there is some nuclear colocalisation of TDP-43 and 
hnRNP-E2 in some cells. hnRNP-E2 does not follow the same distribution of TDP-43 in all the cells in the 
frontal cortex in the control case (Figure 27). As previously mentioned, different types of inclusions were 
detected with hnRNP-E2, while similar results were detected with dIF for both TDP-43 and hnRNP-E2. Higher 
magnification images of individual cells were obtained using a confocal microscope, which show the complete 
colocalisation of both TDP-43 and hnRNP-E2 in the perinuclear and neuritic inclusions (Figures 28 and 29). 
Figure 28 also shows the colocalisation of both TDP-43 and hnRNP-E2 in the frontal cortex of an FTLD-TDP 
type A case where both perinuclear and neuritic inclusions are present. The colocalisation was absolute in 
both inclusions types (Figure 28). Images were also obtained from a type C FTLD-TDP case where mainly 
TDP-43 neuritic inclusions are detected in the frontal cortex (Figure 29). Again, the colocalisation of hnRNP-
E2 with TDP-43 in the neuritic inclusions was detected.  It is clear that hnRNP-E2 is related to TDP-43 through 





Figure 27: Double-labelling immunofluorescence of TDP-43 (red) and hnRNP-E2 (green) in the frontal cortex of a control 
case (A, A1 and A2), case ref. 104, which shows mainly nuclear staining of TDP-43. The shuttling of hnRNP-E2 between 
the cytoplasm and the nucleus is clear because it does not colocalise with TDP-43 in the nuclei of all cells. TDP-43 and 
hnRNP-E2 inclusions were detected in the frontal cortex of a type C FTLD-TDP case (B, B1 and B2, ref. 22) and s type A 





Figure 28: Confocal images from the frontal cortex of a type A FTLD-TDP case (ref. 2), which show TDP-43 (A1, B1, C1 
and D1) and hnRNP-E2 (A2, B2 C2 and D2). The colocalisation of hnRNP-E2 within the TDP-43 inclusions is very clear 





Figure 29: Confocal images from the frontal cortex of a type C FTLD-TDP case (ref. 22), which show TDP-43 (A1, B1, C1 
and D1) and hnRNP-E2 (A2, B2, C2 and D2). Immunofluorescence shows the absolute colocalisation of hnRNP-E2 with 




4.3.2.2 Colocalisation of ubiquitin and hnRNP-E2 in human brain tissue 
hnRNP-E2 colocalisation with ubiquitin was also investigated. A total of 551 ubiquitin inclusions and 374 
hnRNP-E2 inclusions were counted from 1 FTLD-TDP type A case (case #2) and 4 FTLD-TDP type C cases 
(case #22, #23, #25 and #26) as described in the methods chapter (Chapter 2).  The colocalisation of hnRNP-
E2 with ubiquitin in the frontal cortex of FTLD-TDP cases accounted for 67% of all ubiquitin inclusions. Figure 
30 shows the distribution of both ubiquitin and hnRNP-E2 in the frontal cortex of a type A FTLD-TDP case. It 
is clear from Figure 30 that not all the ubiquitin inclusions colocalised with hnRNP-E2 and vice versa. It is also 
clear from Figure 30 (B1–C3) that hnRNP-E2 and ubiquitin do not exhibit absolute colocalisation within the 
inclusions such as that seen with TDP-43 and hnRNP-E2 inclusions. Figure 31 shows closer images of the 
ubiquitin and hnRNP-E2 inclusions in the frontal cortex of other type A and type C FTLD-TDP cases.  
 
Figure 30: The distribution of ubiquitin (A1, B1 and C1) and hnRNP-E2 (A2, B2 and C2) inclusions in the frontal cortex of 
a type C FTLD-TDP case (ref. 22). A3 and B3 show that there are some ubiquitin inclusions that do not have hnRNP-E2, 
while some inclusions have hnENP-E2 but not ubiquitin. C1–3 are magnified images of the box area in B3. The 







Figure 31: Closer images of ubiquitin (A1, B1, C1 and D1) and hnRNP-E2 (A2, B2, C2 and D2) in the frontal cortex of type 




4.3.3 Western blotting 
The levels of insoluble hnRNP-E2 were examined in FTLD-TDP cases using Western blotting techniques.  
Results were obtained from FTLD-TDP cases without the C9orf72 expansion, which showed positive hnRNP-
E2 inclusions in IHC. In addition to the control cases, FTLD-TDP cases with C9orf72 that did not show any 
hnRNP-E2 inclusions on IHC were also tested. Figure 32 presents the details of the cases used in the Western 
blotting. Six cases in each group were used (i.e. six FTLD-TDP with hnRNP-E2-positive inclusions in IHC, six 
FTLD-TDP without hnRNP-E2 inclusions in IHC, six FTLD-TDP with the C9orf72 expansion that were all 
negative for hnRNP-E2 in IHC and six control cases). The C9orf72 cases were included to check whether 
there was any insoluble hnRNP-E2 that could be detected with Western blotting not with IHC. All the blots 
were probed with the rabbit polyclonal TDP-43 (Proteintech) antibody and the mouse monoclonal hnRNP-E2 
(Abnova) antibodies. The fractionation protocol is detailed in section 2.1.4.1.  
 
4.3.3.1 hnRNP-E2 Western blots in FTLD-TDP cases and controls 
All the samples were fractionated according to the SARK fractionation protocol described in Chapter 2. The 
Abnova mouse hnRNP-E2 antibody was used at 1:500 dilutions to label the Western blots for hnRNP-E2. The 
hnRNP-E2 bands were detected on the Odyssey® system’s mouse channel at the expected size of ~37kDa. 
The quantification of the blots was performed using the ImageJ software and the graphs were plotted using 
GraphPad software (Figure 32). All five fractions of each case were loaded onto the gels so that each blot had 
a control case, an FTLD-TDP with hnRNP-E2 +ve IHC, an FTLD-TDP with hnRNP-E2 -ve IHC and an FTLD-
TDP with the C9orf72 mutation.   
The presence of the hnRNP-E2 insoluble band was not consistent with all the IHC results; therefore, a definite 
conclusion regarding hnRNP-E2 insolubility could not be drawn by inspecting the Western blots. In Blot A, 
Figure 32, the control case 66/00 had a moderate band of hnRNP-E2 in its urea fraction; however, the hnRNP-
E2 +ve case 13/10 showed a very strong insoluble band of hnRNP-E2 in its urea fraction, which is consistent 
with the IHC results for this particular case. In Blot B, Figure 32, the hnRNP-E2 -ve case showed a stronger 
band for hnRNP-E2 in the urea fraction when compared to the hnRNP-E2 +ve case. In Blots C, D and F, 
Figure 32, all the cases and controls showed a similar moderate hnRNP-E2 band in the urea fraction. In Blot 
E, there is a strong band of insoluble hnRNP-E2 in the urea fraction of the hnRNP-E2 +ve case and a 
moderately strong band in the C9orf72 case when compared to the control and hnRNP-E2 -ve case on the 
same blot (Figure 32).  
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The levels of hnRNP-E2 for all the cases were quantified as described in Chapter 2 using ImageJ software 
and the average for each group of cases was plotted. The levels of insoluble hnRNP-E2 in the urea fractions 
were normalised to the soluble levels in the lysate fraction for each case. The average of the hnRNP-E2 levels 
for each group of cases was calculated and a statistical analysis was performed. A one-way ANOVA test was 
performed to compare the insoluble hnRNP-E2 levels in all the case groups. The ANOVA test showed no 
significant difference in the insoluble hnRNP-E2 levels among the case groups: control cases (0.82 ± 0.21), 
hnRNP-E2 +ve cases (2.26 ± 0.65), hnRNP-E2 -ve cases (2.05 ± 0.55) and C9orf72 cases (1.11 ± 0.27) (one-






Figure 32: Western blots of hnRNP-E2. Each blot has a control case, an hnRNP-E2 -ve case, an hnRNP-E2 +ve case and 
an FTLD-TDP case with C9orf72 expansion. The five fractions of each case were loaded, starting with the lysate fraction 
followed by the low salt, Triton, SARK and, finally, the insoluble urea fraction. The hnRNP-E2 bands were detected at 37 





Figure 33: Levels of soluble hnRNP-E2 in the lysate fraction and the insoluble levels of hnRNP-E2 in the urea fraction in 
the control cases, FTLD-TDP E2 +ve cases, FTLD-TDP E2 -ve cases and FTLD-TDP with C9Orf72 expansion cases. 
 
 
4.3.3.2 TDP-43 Western blots on FTLD-TDP cases and controls 
The same blots were labelled for TDP-43 using the full-length Proteintech TDP-43 rabbit antibody. The TDP-
43 bands were detected on the Odyssey® system’s rabbit channel at the expected size of ~43 kDa. The 
quantification of the TDP-43 bands was performed using the ImageJ software and the graphs were plotted 
using GraphPad software. All five fractions of each case were loaded onto the gels so that each blot had a 
control case, an FTLD-TDP with hnRNP-E2 +ve IHC, an FTLD-TDP with hnRNP-E2 -ve IHC and an FTLD-
TDP with the C9orf72 mutation case.   
The pathological hallmark in TDP-43 proteinopathies is the presence of the insoluble band of TDP-43 in the 
urea fraction of brain lysate. The smearing of TDP-43 in the urea lane is another pathological hallmark of TDP-
43 proteinopathy. The TDP-43 blots were used as a reference in this study in order to try to spot any differences 
between the cases in correlation with hnRNP-E2 pathology. In Blot A, Figure 34, the FTLD-TDP E2 +ve case 
13/10 showed a strong band of TDP-43 at 43 kDa; however, there was no difference in the band seen in the 
other FTLD-TDP cases or the control (Figure 34). By looking at Blots B and C, it is clear there is no band of 
insoluble TDP-43 in the urea fraction in the control case. Furthermore, the FTLD-TDP E2 +ve case has a 
stronger band when compared to the FTLD-TDP E2 -ve and FTLD-TDP C9orf72 cases on the same blots. In 
Blot D, Figure 34, a band of insoluble TDP-43 was detected in the control case; however, there was no 
smearing when compared to the other three FTLD-TDP cases in the blot. Blot E, Figure 34, showed a faint 
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insoluble TDP-43 band in the control case, which is slightly less intense than the band detected in the FTLD-
TDP E2 -ve case. The FTLD-TDP E2 +ve case showed a stronger insoluble TDP-43 band and smearing in 
comparison to the FTLD-TDP C9orf72 case on the same blot. Yet, Blot F, Figure 34, showed a stronger band 
of insoluble TDP-43 in the control case when compared to the FTLD-TDP E2 -ve and E2 +ve cases on the 
same blot. However, the band was larger and stronger in the FTLD-TDP C9orf72 case on the same blot. As 
the presence of the insoluble band was not conclusive, the quantification and statistical analysis of the TDP-
43 insolubility was performed in order to detect any significant results. 
The levels of TDP-43 in all the cases were quantified as described in Chapter 2 using ImageJ software and 
the average for each group of cases was plotted. The levels of insoluble TDP-43 in the urea fractions were 
normalised to the soluble levels in the lysate fraction for each case. The average of the TDP-43 levels for each 
group of cases was calculated and a statistical analysis was performed. A one-way ANOVA test was 
conducted to compare the insoluble TDP-43 levels in all the case groups. The ANOVA test showed no 
significant difference in the insoluble TDP-43 levels among the case groups: control cases (1.03 ± 0.27), 
hnRNP-E2 +ve cases (1.91 ± 0.57), hnRNP-E2 -ve cases (1.56 ± 0.47) and C9orf72 cases (2.1 ± 0.72) (one-





Figure 34: Western blots of TDP-43. Each blot has a control case, an hnRNP-E2 -ve case, an hnRNP-E2 +ve case and 
an FTLD-TDP case with C9orf72 expansion. The five fractions of each case were loaded, starting with the lysate fraction 
followed by the low salt, Triton, SARK and, finally, the insoluble urea fraction. TDP-43 bands were detected at 43 KDa 





Figure 35: Levels of soluble TDP-43 in the lysate fraction and the insoluble levels of TDP-43 in the urea fraction in the 
control cases, FTLD-TDP E2 +ve cases, FTLD-TDP E2 -ve cases and FTLD-TDP with C9orf72 expansion cases. 
 
 
4.3.3.3 Detection of the 25 kDa band of TDP-43 with the phospho TDP-43 antibody  
A comparison of the different TDP-43 antibody signatures on the Western blots was carried out by running the 
samples from the frontal cortex of FTLD-TDP cases fractionated by the SARK protocol Western blot gels as 
previously described. The blots were labelled with the phospho-TDP antibody (Figure 36A) as well as with the 
Proteintech TDP-43 antibody (Figure 36B). The principal difference was the detection of the TDP-43 
pathological 25 kDa band by the phospho TDP antibody, which was absent when the full-length TDP-43 





Figure 36: Western blot of the soluble and insoluble fractions from the frontal cortex of FTLD-TDP cases. A) Represents 
the results with the anti-phospho TDP-43 antibodies at 1:1000. The arrow indicates the pathological ~25 kDa of TDP-43 





4.3.4 Statistical analysis of hnRNP-E2 pathology and demographic data concerning the cases 
4.3.4.1 FTLD-TDP subtypes 
A Chi-square test of independence was performed to examine the relation between the FTLD-TDP 
pathological subtypes and hnRNP-E2 pathology. The relation between these variables was found to be 
significant (X2 [2, N = 29] = 6.139, p < 0.05). hnRNP-E2 pathology depends significantly on the subtype 
of TDP-43 pathology in FTLD cases. FTLD-TDP subtype A and subtype C have a greater frequency of 




Figure 37: FTLD-TDP subtype A and subtype C have a greater frequency of hnRNP-E2-positive immunoreactivity 
than that seen with subtype B. 
 
4.3.4.2 Gender, dementia duration, PMD and fixation time 
hnRNP-E2 pathology is independent of both gender and dementia duration (X2 [1, N = 29] = 1.98, p > 
0.05). The PMD (X2 [22, N = 27] = 23, p > 0.05) and fixation time (X2 [10, N = 26] = 9.85, p > 0.05) also 






hnRNP-E2 inclusions in FTLD-TDP brain tissue were first detected during the hnRNPs screening 
experiment discussed in Chapter 3. Confirmation of this finding was achieved through several 
experiments conducted on human brain tissues utilising IHC, dIF and WB. hnRNP-E2 is an RNA-binding 
protein that belongs to the hnRNP-K family of proteins. They are characterised by triple KH domains 
that can interact independently with target RNA sequences, which allows this protein family to 
potentially form highly complex-specific RNA interactions. hnRNP-E2 shares 89% amino acid similarity 
with hnRNP-E1; therefore, it was important to confirm that the antibody detecting hnRNP-E2 did not 
also detect E1. The IHC of hnRNP-E1 performed on the same cases with positive hnRNP-E2 
immunoreactivity did not detect any inclusions similar to those detected by the hnRNP-E2 antibodies. 
The presence of hnRNP-E2 in the inclusions seen in the FTLD-TDP patients’ brain tissue indicates its 
possible involvement in the underlying pathology of neurodegeneration.  
hnRNP-E2’s disease specificity was investigated by applying hnRNP-E2 IHC to a wide range of 
neurodegenerative cases. The results showed hnRNP-E2 inclusions in a subset of FTLD-TDP cases 
that do not carry the C9orf72 mutation. Of the 30 FTLD-TDP cases, hnRNP-E2 was positive in 16 cases, 
which represented 53.3% of the investigated FTLD-TDP cases. The cases’ demographic data was 
statistically analysed in order to check the dependency of hnRNP-E2 pathology on any of the 
demographic variables. The only significant dependence was found in relation to the TDP-43 
pathological subtype. FTLD-TDP subtypes A and C have a significantly higher frequency of hnRNP-E2 
immunoreactivity than subtype B. Indeed, in subtype B, there was only one positive case for hnRNP-
E2. Alternatively, this case could come under another subtype because of difficulties in subtyping.   
Due to the reported relation between hnRNP-E2 and hnRNP-G, an additional experiment was designed 
to investigate the presence of hnRNP-G in hnRNP-E2 inclusions as well as to confirm hnRNP-E2’s 
antibody specificity. It has been reported that hnRNP-E2 contributes to the regulation of exon 10 by 
interacting with hnRNP-G and SRp75 (Wang et al., 2011a). The same study suggested that the exon 
10 inclusions seen in FTLD-17 are due to the weakened binding of hnRNP-E2/hnRNP-G with SRp75, 
which promotes it as a possible strategy for correcting the imbalance in the exon 10 ratio seen in 
tauopathies (Wang et al., 2011a). Tau is a microtubule-associated protein that aggregates in multiple 
neurodegenerative diseases. The splicing misregulation of the adult-specific exon 10 of tau leads to the 
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expression of abnormal ratios of tau isoforms seen in FTDP-17 and AD (Niblock and Gallo, 2012, 
Broderick et al., 2004b, Wang et al., 2011a).     
hnRNP-G, which is also known as RBMX, is X-linked and it has a different set of co-factors and targets 
from its Y-linked paralogue, RBMY. In this study, the possibility of hnRNP-E2 presenting as a complex 
with hnRNP-G was investigated by applying the IHC of hnRNP-G to the hnRNP-E2-positive cases. The 
results showed that hnRNP-G is not part of the hnRNP-E2 inclusions seen in FTLD-TDP brains. In 
addition, the absence of hnRNP-E2 from other neurodegenerative diseases, including tauopathies such 
as AD, supports the notion that it is more closely related to TDP-43 pathology. Furthermore, the hnRNP-
E2 inclusions followed the course of the TDP-43 inclusions in FTLD-TDP brains according to the new 
pathological classification of FTLD established by Mackenzie et al. (Mackenzie et al., 2011b). Although 
there is no established association between TDP-43 and tau (Robinson et al., 2014), the presence of 
hnRNP-E2 in the TDP-43 inclusions and its identified role in the regulation of tau exon 10 emphasise 
its role in neurodegeneration and the search for new mechanisms.   
The dIf results revealed a strong relation between TDP-43 and hnRNP-E2, with 84.5% of the TDP-43 
inclusions being found to harbour hnRNP-E2. hnRNP-E2 was also present in 67% of the ubiquitin 
inclusions in the same cases. Examining the inclusions with a high resolution revealed that hnRNP-E2 
showed colocalisation within the TDP-43 aggregates. In relation to ubiquitin, hnRNP-E2 was partially 
ubiquitinated, as shown by the high resolution images of the hnRNP-E2/ubiquitin inclusions. A question 
arose at this point concerning whether hnRNP-E2 deposition has any implications for TDP-43’s 
suggested pathological mechanisms and why it is only seen in a subset of FTLD-TDP cases. The 
possible mechanisms of colocalisation will be discussed later in this section.  
Insoluble hnRNP-E2 was detected in the urea fraction of some FTLD-TDP cases; however, the Western 
blotting results were not conclusive for several reasons. The hnRNP-E2 insoluble band was not 
consistent with all the IHC results. The hnRNP-E2 insoluble band in the urea fraction was detected in 
some of the hnRNP-E2-negative cases by IHC, except for the FTLD-TDP cases with the C9orf72 
expansion. hnRNP-E2 was absent from some of the hnRNP-E2-positive FTLD-TDP cases determined 
by IHC. Therefore, hnRNP-E2’s insolubility in brain tissue is not certain. This could be related to the 
abundant variation of the hnRNP-E2 inclusions among the cases or simply the fact that it is present in 
soluble and insoluble forms in different cases. The quantitative results were also inconclusive, which 
could be due to the small number of cases used for fractionation.   
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Several issues arose in relation to the TDP-43 Western blotting. The full-length TDP-43 antibody used 
did not detect the C-terminal fragment at the 25 kDa. However, it was detected with the phospho TDP 
antibodies, as described in Figure 36. A small amount of insoluble TDP-43 was detected in some of the 
control cases; however, the pathological high molecular weight smear was absent from those controls. 
The quantitative results were again not conclusive, which could again be due to the small number of 
cases used. The amount of TDP-43 varied among the FTLD-TDP cases. Interesting, an increasing 
amount of evidence is emerging regarding the heterogeneity of TDP-43 in the brain of FTLD-TDP and 
ALS-TDP patients (Tsuji et al., 2012, Takeuchi et al., 2016, Armstrong et al., 2010). TDP-43 can exist 
as different species with variable solubility, microscopical appearance and mobility profiles, which may 
explain the variation seen among the cases as well as the presence of small amounts of insoluble TDP-
43 in control tissue (Scotter et al., 2015). Additional differences in the TDP-43 pathological bands in the 
Western blots were detected among the different types of FTLD-TDP (Tsuji et al., 2012). Furthermore, 
a recent study investigated the TDP-43 inclusions in the brain of ALS patients, characterising them 
according to the location and abundancy of the TDP-43 aggregates in the brain of ALS patients 
(Takeuchi et al., 2016). The present results of the hnRNP-E2 and TDP-43 Western blotting may suggest 
that there exist different conformations of TDP-43 and hnRNP-E2, which could correspond to the 
pathological phenotype of FTLD-TDP or the histological subtypes of FTLD-TDP.   
Further insight into the functions of hnRNP-E2 could provide an explanation for the colocalisation of 
hnRNP-E2 with TDP-43 and ubiquitin inclusions; however, a definite answer will require rigorous 
investigations. Most prior studies have focused on the post-transcriptional and translational controls of 
hnRNP-E2 in RNA viruses such as poliovirus, rhinovirus and coxsackievirus (Sean et al., 2008, Zell et 
al., 2008, Walter et al., 1999). hnRNP-E2 plays a role in mRNA stability and translation regulation 
through its ability to bind to the poly(C) stretches of both DNA and RNA. It was also reported to bind to 
the 3’ and 5’ UTR of the hepatitis C virus (Tingting et al., 2006). Like other hnRNPs, hnRNP-E2 
participates in protein-protein interactions and it is essential for mouse foetal development, although 
not all of its functions and interactions have yet been identified (Ghanem et al., 2015).   
Both TDP-43 and hnRNP-E2 are present with ubiquitin in FTLD-TDP cases, as shown in the results 
discussed above. Thus, it is possible that ubiquitin could be the link explaining the colocalisation of 
TDP-43 and hnRNP-E2. Scotter et al. (2014) suggested that an impaired cellular ubiquitin proteasome 
system (UPS) results in misregulated soluble TDP-43 levels, which then act as a nucleation for 
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aggregates. The cascade of ubiquitin-mediated protein degradation involves the stepwise action of 
three enzymes, namely the ubiquitin-activating enzyme (E1), the ubiquitin-conjugating enzyme (E2) and 
the ubiquitin ligase enzyme, which provided substrate specificity (E3). E3 ubiquitin ligase recruits the 
ubiquitin-loaded conjugating enzyme E2, recognises a protein substrate and either directly catalyses or 
assists with the transfer of ubiquitin from E2 to the protein substrate (Hershko and Ciechanover, 1998). 
hnRNP-E2 was identified as an adapter between the ubiquitin ligase E3 ITCH and the mitochondrial 
antiviral-signalling protein (MAVS) in cellular studies (You et al., 2009). The overexpression of hnRNP-
E2 led to the degradation of MAVS and abolished the cellular response to viral infection, while the 
knockdown of hnRNP-E2 had the opposite effect. hnRNP-E2 is not a ligase enzyme; however, it 
performs a ligase-enzyme-adapting activity, which recruits the conjugating enzyme to its substrate (You 
et al., 2009). Moreover, a ubiquitin ligase complex has been recently identified by Uchida et al. (2016) 
that is involved in TDP-43 degradation. The ligase complex consists of the von Hippel-Lindau protein 
(VHL), which is a tumour suppressor protein, and the cullin-2 (CUL2) RING, which belongs to the 
hydrophobic family of proteins that provides a temporary complex for ubiquitin ligase E3. The CUL2 
combines with the RING proteins, which contain a zinc-finger domain. VHL was identified as the 
substrate binding part of the complex, which showed the preferential recognition site of Glu246 in the 
RRM2 of misfolded TDP-43. Interestingly, when VHL is overloaded in the cytoplasm, it tends to stabilise 
and aggregate with TDP-43. VHL was detected in TDP-43 inclusions in motor neurons in the spinal 
cord of ALS patients. This suggested that the imbalance between VHL and CUL2 is the key to TDP-43 
aggregation and highlighted the CUL2 E3 ligase as a potential therapeutic target for TDP-43 
proteinopathies (Uchida et al., 2016). Whether or not hnRNP-E2 could be a component or an adaptor 
of this ligase complex is a question requiring further investigation.   
Based on recent studies, another possible explanation for the colocalisation of hnRNP-E2 with TDP-43 
is hnRNP-E2’s apoptosis regulation function. Evidence of neuronal apoptosis was reported in ALS and 
FTLD cases through elevated levels of activated caspase-3 in the patients’ spinal cord and brain tissue 
when compared to the controls (Martin, 1999b, Su et al., 2000). Moreover, caspase-3 was identified as 
the protease responsible for TDP-43 fragmentation (Zhang et al., 2007b). More interestingly, caspase-
3 downregulates TDP-43 in glioma cells (Nan et al., 2014). Many studies have linked hnRNP-E2 to 
caspase-3 activation. hnRNP-E2 is upregulated in human glioma tissue, while the knockdown of 
hnRNP-E2 inhibited glioma growth through the induction of caspase-3-mediated apoptosis and the 
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inhibition of cell-cycle progression (Han et al., 2013). Additionally, it has been reported that the 
overexpression of hnRNP-E2 induces apoptosis in human oral cancer tissue (Roychoudhury et al., 
2007). The reported data provided preliminary evidence of hnRNP-E2’s involvement in neuronal 
apoptosis, which was investigated by Mao et al. (2016) in cases of acute spinal cord injury (SCI). 
Following SCI, both hnRNP-E2 and caspase-3 were upregulated in the neurons (Mao et al., 2016). The 
knockdown of hnRNP-E2 decreased the expression of caspase-3 in the primary neurons. However, the 
levels of cyclin D1 did not change after the hnRNP-E2 knockdown, which suggested that hnRNP-E2-
induced neuronal apoptosis is independent of cell cycle activation (Mao et al., 2016). The detailed 
mechanism of hnRNP-E2 in modulating caspase-3 activity and apoptosis has not yet been clarified. It 
is possible that this mechanism may mediate TDP-43 aggregation; however, this does not appear to be 
true in all cases of FTLD-TDP. Hence, the implications of hnRNP-E2 in TDP-43 pathology and 
FTLD/ALS require further investigation.   
Another possible link could be established through microRNAs (miRNA). miRNAs are small non-coding 
RNAs that possess gene expression regulatory functions. Nuclear and cytoplasmic TDP-43 were 
identified as modulators of miRNAs maturation and it was found that they promote neuronal outgrowth 
by facilitating miRNAs production (Kawahara and Mieda-Sato, 2012). Interestingly, hnRNP-E2 
expression was found to be regulated by miRNA-214; however, the regulatory pathway still needs to 
be determined (Tang et al., 2015). The stress response is another possible explanation for the 
colocalisation of hnRNP-E2 and TDP-43 in the FTLD-TDP brain, which will be discussed in the next 
chapter.     
 
4.5 Conclusion 
Striking hnRNP-E2 inclusions were detected in a subset of FTLD-TDP brain tissue using the IHC 
technique and the colocalisation with TDP-43 was then confirmed using dIF. The hnRNP-E2 inclusions 
were highly specific for FTLD-TDP cases that do not carry the C9orf72 mutation. hnRNP-E2 pathology 
in FTLD-TDP cases is highly dependent on the TDP-43 pathological subtype, showing a significantly 
higher frequency in subtypes A and C. hnRNP-E2 colocalised with 84.5% of TDP-43 inclusions in FTLD-
TDP brain tissue and with 67% of ubiquitin inclusions in the same cases. hnRNP-E2 was not detected 
in any of the other neurodegenerative diseases tested, which suggests that it could be closely related 
to the TDP-43 pathological mechanism. However, the fact that E2-positive inclusions were not detected 
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in any FTLD-TDP cases with the C9orf72 mutation (despite the TDP-43 pathology seen in these cases) 
is intriguing and may suggest the occurrence of different disease mechanisms. hnRNP-E2 has several 
functions in the UPS and programmed cell death, which could directly or indirectly contribute to TDP-
43 pathology. The results presented here emphasise the importance of further investigations into the 




Chapter 5 Utilising Cell Biology to Investigate the Relationship 
Between hnRNP-E2 and TDP-43 
5.1 Introduction  
The human brain tissue results in this study provided strong evidence of a relationship between hnRNP-
E2 and TDP-43 in a subset of FTLD-TDP cases without the C9orf72 expansion. Indeed, we detected 
immunoreactive hnRNP-E2 inclusions in the frontal cortex, hippocampus and spinal cord in 53.3% of 
FTLD-TDP cases without the C9orf72 expansion. Furthermore, in these cases, abundant hnRNP-E2 
was detected in 84.5% of TDP-43 inclusions, as identified by double-labelling immunofluorescence. In 
addition, the hnRNP-E2 inclusions followed the morphological pattern of TDP-43 inclusions seen in 
different pathological types of FTLD-TDP. Moreover, there was a significant dependence between 
hnRNP-E2 pathology and the TDP-43 pathological subtypes. Increased hnRNP-E2 insolubility was 
detected in those cases according to the Western blotting results presented in Chapter 4. Therefore, it 
was important to further investigate the relationship and possible interactions between hnRNP-E2 and 
TDP-43 by utilising cell biology techniques in order to add to our understanding of the TDP-43 
pathological mechanisms in FTLD and MND pathology.   
Since the discovery of TDP-43 as the major component of the ubiquitin inclusions in FTLD and ALS 
(Neumann et al., 2006b), the identification of the pathological mechanisms triggered by its aggregation 
has been the focus of a major research effort. The abnormal TDP-43 aggregates form the basis of an 
extensive network of neurodegenerative diseases that are collectively referred to as TDP-43 
proteinopathies (Geser et al., 2009). TDP-43 represents the master protein in this type of pathological 
mechanism; however, there are other RNA-binding proteins that could be mutated and/or aggregated 
in diseased brains, including FUS/TLS and other hnRNP proteins (Buratti and Baralle, 2012). 
Investigating the pathological mechanism of TDP-43 is complicated by its involvement in a massive 
number of RNA-processing events (Neumann et al., 2006a, Janssens and Van Broeckhoven, 2013). 
As TDP-43 is an RNA-binding protein that belongs to the hnRNP family, most of its functional properties 
are mediated by binding to specific RNA target sequences (Tollervey et al., 2011a, Buratti and Baralle, 
2001). In addition, several proteomic studies have indicated that TDP-43’s interaction with other hnRNP 
proteins is important for RNA maturation (Freibaum et al., 2010). These studies support the nuclear 
loss of function suggested to drive the role of TDP-43 in neurodegeneration (Dewey et al., 2012, Wang 
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et al., 2008)); however, other studies have suggested that cytoplasmic TDP-43 aggregation drives the 
neurodegeneration process through a toxic gain of function (Johnson et al., 2008, Winton et al., 2008). 
More evidence is emerging regarding the involvement of hnRNP proteins in TDP-43 pathology, 
specifically in FTLD and ALS. Recently, hnRNP-A3 was identified as a component of some of the p62-
positive/TDP-43-negative hippocampal inclusions seen in a subset of FTLD/ALS cases with the C9orf72 
expansion. It was also shown to be component of the RNA foci and it has been suggested that it binds 
to the 4G2C repeats in C9orf72 transcripts (Mori et al., 2013b); however, its pathogenic role still needs 
to be determined. In addition, the recent implication of hnRNP-A2/B1 and hnRNP-A1 in ALS and 
multisystem proteinopathy supports the hypothesis of a physical and functional interaction between 
TDP-43 and other hnRNPs (Romano et al., 2014, Calini et al., 2013, Kim et al., 2013). Therefore, the 
relative expression of a specific protein within the TDP-43 interaction network may have a significant 
impact on the function of TDP-43, either through direct interaction or independently by acting on the 
same cellular targets (Mohagheghi et al., 2016, Hanson et al., 2010, Buratti et al., 2013). Accordingly, 
an experiment was designed to knockdown and overexpress hnRNP-E2 and TDP-43 in HEK293T cells 
in order to investigate how changes in the level of one protein affect the levels of the its protein partner. 
The knockdown and overexpression experiments also aimed to determine whether hnRNP-E2 is 
upstream or downstream of TDP-43 pathology. In order to further confirm the interaction, co-
immunoprecipitation was performed; however, the results were not conclusive due to technical issues. 
Several studies have suggested that TDP-43 is a stress responsive protein, although it remains unclear 
whether the TDP-43 aggregates arise from stress granules (SGs) (Wang et al., 2008, Liu-Yesucevitz 
et al., 2010, Colombrita et al., 2009). SGs are defined as transient cytoplasmic structures that are 
formed in response to cellular stress and they are believed to act as a sorting station for mRNAs (Dewey 
et al., 2012). TDP-43 was recruited into the SGs in the motor neuronal cell line NSC34 by oxidative 
assault using 0.5 mM of arsenite for 30 min. Exposure to low concentrations of oxidative stress for 
longer periods of time also resulted in the accumulation of TDP-43 in the SGs (Colombrita et al., 2009). 
It was further shown that osmotic stress can recruit TDP-43 into the SGs in HEK293T cells and primary 
cultured glia. The osmotic stress was applied by elevating the sugar levels using sorbitol, an 
intermediate in the polyol pathway, which is an ATP-independent metabolic route that generates 
fructose from glucose (Dewey et al., 2011). The same study reported that WT-TDP-43 takes a longer 
time to get into the SGs when compared to the mutant forms of TDP-43. In addition, WT-TDP-43 formed 
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more SGs over time than the mutant forms and those granules were relatively smaller and their sizes 
remained relatively unchanged over time (Dewey et al., 2011). The composition and morphology of 
SGs varies according to the cell and stress type. There are core components of SGs such as the T-cell 
intracellular antigen-1 (TIA-1) and the poly(A)-binding protein 1 (PABP1); however, the incorporation of 
other RNA-binding proteins differs according to the cell and stress type (Anderson and Kedersha, 2008). 
Despite the finding that TDP-43 colocalised with TIA-1 in NSC34 cells and with other SG markers in 
HEK293T cells, there was no colocalisation detected in the brains of MND patients (Colombrita et al., 
2009). Another study reported the presence of TIA-1 and PABP1 in the RNA-positive basophilic 
inclusions seen in patients with adult-onset atypical MND (Fujita et al., 2008). Therefore, it is important 
to characterise the SGs’ role in the pathology of neurodegeneration, specifically in relation to TDP-43 
and its possible binding partners. Moreover, the SGs offer a relative model for investigating the toxic 
cytoplasmic gain of function hypothesis concerning TDP-43 pathology by investigating its incorrect 
accumulation within the cytoplasm inside the SGs (Dewey et al., 2011).  
It was also reported that hnRNP-E2 is a novel component of SGs and P-bodies in HeLa cells following 
a yeast two-hybrid screen against TIA-1, while the interaction between hnRNP-E2 and TIA-1 was 
validated by double-labelling immunofluorescence (Fujimura et al., 2008). Both TDP-43 and hnRNP-E2 
are reported to incorporate within SGs under stress conditions and there is evidence of their interactions 
with SG markers such as TIA-1 in different cell lines. As a result, an experiment was designed to 
investigate their interaction in SGs induced within HeLa cells. The HeLa cells were exposed to either 
oxidative or osmotic stress, or a combination of both conditions, and ICC was applied to detect both 
TDP-43 and hnRNP-E2 incorporation within the SGs. In addition, the interaction of both TDP-43 and 





In order to explore any potential physical interactions between the two proteins, hnRNP-E2 was 
overexpressed or knocked down and the resulting changes in the TDP-43 expression levels were 
examined. The same experiment was conducted to examine the impact of TDP-43 overexpression or 
knockdown on the hnRNP-E2 levels. Both TDP-43 and hnRNP-E2 were overexpressed and the cells 
stressed in order to encourage SGs to form and allow the examination of colocalisation between TDP-
43 and hnRNP-E2 in the SGs.   
 
5.2.1 Plasmid cloning  
The HEK293T cells were plated at 50,000 cells/well in 500 µl of media in a 24-well plate and then 
incubated overnight at 37ºC. For the hnRNP-E2 overexpression, the cells were transfected with an N-
terminal FLAG-tagged hnRNP-E2 plasmid. The FLAG-tagged non-transgenic hnRNP-E2 (FLAG-NT-
hnRNP-E2) plasmid was generated in house by Dr Emma Scotter. Briefly, the hnRNP-E2 (transcript 1, 
isoform A) was amplified from normal human cDNA using primers containing AttB sites, with the forward 
primer also encoding a FLAG-tag.  




The resulting amplicon was gel purified using the “freeze and squeeze” method (Tautz and Renz, 1983). 
It was cloned into Gateway® pDONR221 and then the Gateway® pT-Rex™-DEST30 plasmid vector 
using one tube format Gateway® cloning according to the manufacturer’s directions (Thermo Fisher 
Scientific). DNA was prepared from the resulting bacterial clones using a NucleoSpin® plasmid 
miniprep kit (Macherey Nagel, Düren, Germany) and it was sequenced in-house using BigDye® 
Terminator v1.1 on an ABI3130 genetic analyser (Applied Biosystems Pty Ltd, Warrington, UK) (Heiner 
CR, 1998). 
HA-TDP43-WT was used for all the experiments, except for the immunoprecipitation experiment in 
which GFP-TDP43-WT was used. The N-terminal EGFP-tagged TDP-43 wild type (WT) cDNA was 
previously cloned into the 4.7 kb pEGFP-C1 vector (ClonTech Laboratories Inc.) with BamHI and XhoI 
by Dr Agnes Nishimura (Nishimura et al., 2010). The HA-tagged TDP-43 WT (HA-TDP43-WT) cDNA 
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was previously cloned by Dr Hazel Urwin into the 4.7 kb Gateway® pDONRTM221 vector (Thermo 
Fisher Scientific). The cells were also transfected with the pDEST30 vector and the GFP vector as a 
control for each experiment. 
The DNA was transfected into the HEK293T cells using FuGENE® (Promega) according to the 
manufacturer’s directions. Briefly, 125 ng of DNA was mixed with the OptiMEM medium and FuGENE® 
using a DNA to FuGENE® ratio of 1 µg:3 µL. The transfection mixtures were then left at room 
temperature for 15 minutes in order to form liposome complexes before being added to the cells. 
Antibiotic-free media we added to the cells prior to transfection, followed by the introduction of 
transfection mixtures and incubation for 6 hours at 37°C in 5% CO2. The media were then replaced with 
new antibiotic-free media and the plates were returned to the incubator. The cells were harvested or 
fixed after 48–72 hours of transfection. 
 
5.2.2 hnRNP-E2 and TDP-43 knockdown  
For the knockdown experiments, the HeLa cells were transfected with specific small interfering RNA 
(siRNA) using the Lipofectamine™ 2000 (Thermo Fisher Scientific) transfection protocol according to 
the manufacturer’s instructions. The cells were transfected with non-human targeted sequence 
(scrambled sequence [Scr]) or siRNAs targeting hnRNP-E2 or TARDBP. The hnRNP-E2-specific siRNA 
(sihnRNP-E2) was a 27-mer purchased from Eurogentec (Hampshire, UK) and previously validated to 
selectively knockdown hnRNP-E2 but not hnRNP-E1 (Woolaway et al., 2007). The siRNA sequences 
were as follows: 
Scrambled sequence: 5’-CUUCCUCUCUUUCUCUCCCUUGGA-3’.          
sihnRNPE2 sequence: 5’-AGACUGUUGCAUUGCCAACUGGUGCAG-3’.  
Human siRNAs targeting endogenous TDP-43 were obtained from Thermo Fisher Scientific (Carlsbad, 
USA. HSS118767) and will be referred to here as siTDP-43 (Invitrogen Stealth). The scrambled non-
targeting sequence for TDP-43 was also obtained from the same supplier (scrTDP; Invitrogen Stealth, 
low GC content) (Nishimura et al., 2014).  
si TARDBP sequence: 5’-GAAAGATCTTAAGACTGGTCATTCA-3’. 
Different concentrations of siRNAs (30 nM, 50 nM and 100 nM) were added to the cells in order to 
determine a dose response curve. As described above, the liposome complexes were formed by 
combining the siRNAs, LipofectamineTM 2000 and OptiMEM media as directed by the manufacturer’s 
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protocol. The transfection mixture was then left at room temperature for 20 minutes to allow the 
formation of DNA-Lipofectamine™ 2000 complexes before being added to the cells. 
After 6 hrs, the media on the cells were replaced with fresh antibiotic-free media. After 48 hrs of 
transfection, the cells were harvested into a harvesting buffer. The sample quantification, Western 
blotting and analysis were performed as described earlier in this chapter (section 5.2.2) and in Chapter 
2. 
 
5.2.3 Protein quantification and statistical analysis of cell samples 
For the protein quantification, the cells were harvested in 1x SDS loading buffer with PIs and PhoSTOP. 
The protein concentrations were quantified from the cellular lysates using the Bio-Rad DC Protein Assay 
(Bio-Rad, Hemel Hempstead, UK). Approximately 5 µg of total protein was prepared for each sample 
and then loaded onto PAGE Western blot in order to separate the different sized proteins in the samples 
as described in Chapter 2.    
The relative quantitative analysis of the Western blot bands was performed by measuring the density 
of the bands using ImageJ 1.47v software. The quantification values were expressed as a ratio of the 
desired band density to the loading control band in each sample. The protein loading control in this 
experiment was glyceraldehyde-3-phosphate dehydrogenase (GAPDH), which is a housekeeping gene 
whose expression remains constant in the cells and tissues under investigation. GAPDH is a 36 kDa 
protein and it plays many roles in cellular function, including transcription regulation and apoptosis. It is 
integral for glycolysis and it exhibits stable and ubiquitous expression (Barber et al., 2005). It is 
important to use a loading control, not only for the protein quantification, but also to determine equal 
sample loading across all the wells and provide confirmation of the effective transfer of protein during 
Western blotting. The blots were probed with rabbit GAPDH (rGAPDH) after they were scanned for 
rTDP-43 and mhnRNP-E2 because the size of GAPDH is very similar to that of hnRNP-E2. 
In order to measure the band density using ImageJ 1.47v, a rectangular shape should be drawn around 
the band. The shape, size and location of the first selection serves as a guide for the rest of the lanes 
on the gel. The density of the bands was plotted as curves. The peak of each band was detected by a 
straight line connecting the start and the end of the curve’s peak. The area underneath each curve was 
measured using the wand tracing tool in the ImageJ software and then presented as a number. Figure 
8 provides an example of band density quantification using ImageJ 1.47v.   
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Each band value was normalised to its loading control band in the same sample and the averages for 
each sample were determined from three or four independent experiment repeats.   
The difference in the TDP-43 and hnRNP-E2 endogenous levels among the groups was determined 
using a one-way ANOVA followed by a Bonferroni post-hoc t-test with a significance level of p < 0.05. 
The t-test was a two-tailed t-test assuming equal variance between the groups. The mean is presented 
as (Mean ± SE), with SE representing the standard error of the samples.  
 
5.2.4 Immunocytochemistry 
To visualise the physical presence of TDP-43 and hnRNP-E2 in the SGs, the immunocytochemistry 
technique was utilised under basal and stressed conditions. Coverslips were added to a 24-well plate 
and coated with poly-D-lysine (50 µg/ml) for 1 hr in the incubator. The coverslips were rinsed twice with 
PBS before the cells were plated. The HeLa cells were plated on coverslips at 50,000 cells/well and 
then left in the incubator to recover for 24 hrs. The cells were transfected with the same FLAG-NT-
hnRNP-E2 and HA-TDP43-WT plasmids as described in the overexpression section of this chapter. 
Some 48 hrs post-transfection, the cells were treated with different stress conditions to encourage the 
formation of SGs. Different combinations of sodium arsenite (0.5 mM) and/or sorbitol (600 mM) were 
diluted in fresh DMEM media as illustrated in Figure 38. The cells were incubated with stressors for 30 
min before the sorbitol media were removed from the wells, where both sorbitol and arsenite stress was 
to be applied, and the arsenite media were added to them. Arsenite media were also added to the wells 
wherein the cells were exposed to only arsenite stress. The cells were then returned to the incubator 
for another 30 minutes. The cells were fixed by adding 4% PFA (paraformaldehyde) for 10 minutes and 
then replacing it with PBS. Immunocytochemistry was performed immediately or else the plates were 
left at 4°C for later use. 
All the primary antibodies were diluted 1:500 in immunobuffer as detailed in Chapter 2. 
Immunocytochemistry was performed as follows. The cells transfected with only HA-TDP43-WT were 
stained with mouse TDP-43 (Santa Cruz sc-10087) and rabbit PABP1 (Abcam ab69110). The cells that 
were transfected with Flag-hnRNP-E2 were stained with mouse hnRNP-E2 (Abnova) and rabbit PABP1 
(Abcam). The cells that were co-transfected with both HA-TDP-43-wt and Flag-hnRNP-E2-wt were 
stained with polyclonal TDP-43 (Proteintech) and monoclonal hnRNP-E2. The primary antibodies were 
added to the coverslips as detailed above for each specific well and then incubated on a plate rocker 
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overnight at 4ºC. Figure 38 illustrates the stress experiment plan and the antibodies used for each 
condition in the 24-well plate.  
 
Figure 38: A 24-well plate with HeLa cells plated on glass coverslips and transfected with either HA-TDP-43-WT, 
Flag-hnRNP-E2- or a combination of the two. The top arrows demonstrate the antibody combination for each well 
in the column. The arrows on the left represent the stress condition applied to each row. 
 
Next, the primary antibodies were removed and the coverslips were washed three times with PBS. The 
secondary fluorescent antibodies used were donkey anti-mouse 488 and donkey anti-rabbit 549 
(Thermo Fisher Scientific). These antibodies were diluted in immunobuffer at 1:500 then added to the 
cells and incubated for 3 hr on a plate rocker at room temperature in the dark. Then, the secondary 
antibodies were removed and the coverslips were washed with 500 µl per well PBS. DAPI (Sigma) (1.25 
ug/ml) was added to the coverslips for 30 seconds before removal and the coverslips were washed with 
PBS. The coverslips were mounted using mounting media (Dako Fluorescent Mounting Media) on 
microscopic slides and left to dry prior to visualisation using the Leica confocal SP system for high-





5.3.1 Quantification of hnRNP-E2 and TDP-43 levels after gene overexpression and knockdown 
In order to explore the mechanistic connection between TDP-43 and hnRNP-E2 as well as the possible 
role of this interaction in TDP-43 pathogenesis, we used cell biology techniques. Both TDP-43 and 
hnRNP-E2 were overexpressed or knocked down in HEK293T cells. The cell lysate was collected after 
successful transfection and the proteins were quantified in each sample. Western blotting was 
performed to detect both TDP-43 and hnRNP-E2 in the samples. The Western blots were analysed as 
described in the method section of this chapter and the quantification values were expressed as a ratio 
of the integral of band density in a sample to the loading control band in the same sample. The results 
were statistically analysed in order to assess the difference in TDP-43 or hnRNP-E2 levels among the 
control group and the experimental groups. 
 
5.3.2 Statistical analysis of TDP-43 and hnRNP-E2 overexpression results 
5.3.2.1 Changes in endogenous hnRNP-E2 levels according to TDP-43 overexpression 
First, the endogenous levels of hnRNP-E2 were measured in three different sample groups from four 
repeated experiments. The untransfected cells and the PDest30-transfected cells both represent 
sample controls. The experimental group in this analysis was the HA-TDP43-WT-transfected cell group. 
A one-way ANOVA test was performed to compare the effect of HA-TDP43-WT overexpression on the 
endogenous level of hnRNP-E2 when compared to the two control groups.     
The ANOVA showed that the WT-HA-TDP43 overexpressed cell samples (0.61 ± 0.15 n = 4) had 
significantly decreased levels of endogenous hnRNP-E2 when compared to the untransfected sample 
(1.72 ± 0.14 n = 4) and the PDest30 vector only sample (0.14 ± 0.12 n = 4) (one-way ANOVA, F = 26.1, 
d.f. = 2 and 9, p = 0.0001; Bonferroni post-hoc test). The Bonferroni post-hoc t-test revealed that there 
was a significant difference between the HA-TDP43-WT expressed cell samples and the untransfected 
cell samples (p = 0.001). It also revealed that there was a significant reduction in the hnRNP-E2 levels 
in the PDest30 samples when compared to the untransfected samples (p = 0.0003). Yet, there was no 
significant difference in the endogenous hnRNP-E2 levels between the HA-TDP43-WT and PDest30 






Figure 39: A) Representative Western blot of the HEK239T cell samples showing the levels of endogenous hnRNP-
E2 in untransfected control cells, HA-TDP-43-WT-transfected cells and PDest30-transfected cells. B) The graph 
shows the statistical analysis performed using a one-way ANOVA among the three groups: HA-TDP43-WT (0.61 
± 0.15 n = 4), untransfected (1.72 ± 0.14 n = 4) and PDest30 (0.14 ± 0.12 n = 4), which revealed a significant 
difference in the hnRNP-E2 endogenous levels (F = 26.1, d.f. = 2 and 9, p = 0.00018). The Bonferroni post-hoc 
test revealed a significant difference in the hnRNP-E2 levels between the HA-TDP43-WT and untransfected 
samples (p = 0.001) and a significant difference in the hnRNP-E2 levels in the PDest30 samples when compared 
to the untransfected sample (p = 0.0003). However, there was no significant difference in the hnRNP-E2 levels 








5.3.2.2 Changes in  endogenous TDP-43 levels according to hnRNP-E2 overexpression 
Second, the endogenous TDP-43 levels were measured in three different sample groups from four 
repeated experiments. The untransfected cells and the PDest30-transfected cells both represent 
sample control groups. The experimental group in this analysis was the Flag-hnRNP-E2-transfected 
cells. A one-way ANOVA was performed to compare the effect of Flag-hnRNP-E2 overexpression on 
the endogenous TDP-43 levels when compared to the two control groups.  
The ANOVA showed that the cells with Flag-hnRNP-E2 overexpressed (0.27 ± 0.11 n = 4) had a 
significantly decreased level of endogenous TDP-43 when compared to the untransfected cells (0.96 ± 
0.13 n = 4) and the pDEST30 vector only transfected cells (0.28 ± 0.14 n = 4) (one-way ANOVA, F = 
9.88, d.f. = 2 and 9, p = 0.005; Bonferroni post-hoc test). The Bonferroni post-hoc t-test revealed that 
there was significant difference in the endogenous TDP-43 levels between the Flag-hnRNP-E2-
expressed cell samples and the untransfected cell samples (p = 0.006). It also revealed that there was 
a significant reduction in the hnRNP-E2 levels in the pDEST30 samples when compared to the 
untransfected samples (p = 0.011), although there was no significant difference in the endogenous 
TDP-43 levels between the Flag-hnRNP-E2-transfected and PDest30 samples (p > 0.05) (Figure 40). 
Thus, hnRNP-E2 overexpression did not affect the endogenous TDP-43 levels. 
 
Figure 40: A) Representative Western blot of the HEK239T cell samples showing the levels of endogenous TDP-
43 in untransfected control cells, Flag-hnRNP-E2-transfected cells and PDest30-transfected cells. B) The graph 
shows the statistical analysis performed using a one-way ANOVA among the three groups: Flag-hnRNP-E2 (0.27 
± 0.11 n = 4), untransfected (0.96 ± 0.13 n = 4) and PDest30 (0.28 ± 0.14 n = 4), which revealed a significant 
difference in the endogenous TDP-43 levels (F = 9.88, d.f. = 2 and 9, p = 0.005). The Bonferroni post-hoc test 
revealed a significant difference in the TDP-43 levels between the Flag-hnRNP-E2 and untransfected samples (p 
= 0.006) and a significant difference in the TDP-43 levels in the PDest30 samples when compared to the 
untransfected sample (p = 0.011). However, there was no significant difference in the hnRNP-E2 levels between 





5.3.3 Statistical analysis of TDP-43 and hnRNP-E2 knockdown results 
5.3.3.1 hnRNP-E2 and TDP-43 knockdown  
The HEK239T cells were treated with different concentrations (30 nM, 50 nM and 100 nM) of both 
SiRNA for TDP-43 and hnRNP-E2 as detailed in the methods section of this chapter. The cells were 
also transfected with scrambled sequences as a control for the knockdown of both TDP-43 and hnRNP-
E2. The TDP-43 and hnRNP-E2 levels were measured using Western blotting. The blots were analysed 
using ImageJ software as described earlier. A one-way ANOVA test was performed, followed by a 
Bonferroni post-hoc two-tailed t-test to examine whether there was any significant difference in the TDP-
43 and hnRNP-E2 levels.  
The hnRNP-E2 knockdown resulted in a significant reduction in the TDP-43 levels when analysed using 
a one-way ANOVA among all the samples with different sihnRNP-E2 knockdown concentrations (one-
way ANOVA, F = 3.89, d.f. = 4 and 10, p = 0.037; Bonferroni post-hoc test) (Figure 41). The Bonferroni 
post-hoc t-test revealed that there was significant difference in the endogenous TDP-43 levels between 
the untransfected cell samples (1.078 ± 0.074) and si hnRNP-E2 at 100 nM (0.56 ± 0.079) (p = 0.009); 
however, there was no significant difference detected between the other sample groups (p > 0.05) 
(Figure 41). The TDP-43 knockdown did not result in any significant changes in hnRNP-E2 (one-way 
ANOVA, F = 0.51, d.f. = 4 and 10, p = 0.72). The Bonferroni post-hoc two-tailed t-test also revealed no 
significant changes in hnRNP-E2 between all the sample groups (p > 0.05) (Figure 41). Thus, although 
these two proteins are known to interact and colocalise in a subset of FTLD cases, there is no evidence 
related to either the overexpression or knockdown to show that the levels of either protein are regulated 





Figure 41: A) Representative Western blot of the HEK239T cell samples showing the levels of endogenous TDP-
43 and hnRNP-E2 in untransfected (UT) control cells, gradual concentrations of si hnRNP-E2 (siE2) and si TDP-
43 (SiTDP), and scrambled control samples for both hnRNP-E2 (Scr E2) and TDP-43 (Scr TDP). GAPDH was the 
loading control used in this experiment. B) The graph shows the statistical analysis performed using a one-way 
ANOVA among the sample groups to measure the endogenous TDP-43 levels in all sample groups UT (1.078 ± 
0.074, n = 3), Scr E2 100 nM (0.722 ± 0.12, n = 3), SiE2 30 nM (0.63 ± 0.12, n = 3), SiE2 50 nM (0.69 ± 0.10 n = 
3) and SiE2 100 nM (0.56 ± 0.08, n = 3). The endogenous TDP-43 levels were significantly decreased, as shown 
by the ANOVA test (one-way ANOVA, F = 3.89, d.f. = 4 and 10, p = 0.037; Bonferroni post-hoc test). The Bonferroni 
post-hoc two-tailed t-test revealed a significant difference in the endogenous TDP-43 levels (F = 9.88, d.f. = 2 and 
9, p = 0.005). The Bonferroni post-hoc t-test also revealed a significant difference in the endogenous TDP-43 levels 
between the UT cells samples (1.078 ± 0.074) and SiE2 100 nM (0.56 ± 0.079) (p = 0.009); however, there was no 
significant difference in the TDP-43 levels between the other groups of SiE2, UT or Scr E2 (p > 0.05). C) The graph 
shows the statistical analysis performed using a one-way ANOVA among the sample groups in order to measure 
the endogenous hnRNP-E2 levels in all the sample groups: UT (1.86 ± 0.05 n = 3), Scr TDP 100 nM (1.11 ± 0.56, 
n = 3), SiTDP 30 nM (1.01 ± 0.35, n = 3), SiTDP 50 nM (1.36 ± 0.40, n = 3) and SiTDP 100 nM (1.53 ± 0.72, n = 
3). There were no significant changes in the level of TDP-43 (one-way ANOVA, F = 0.51, d.f. = 4 and 10, p = 0.72) 




In order to identify whether hnRNP-E2 directly interacts with TDP-43 as well as to determine whether 
they bind to each other to form a protein complex, co-IP experiments were performed. The HEK293T 
cells were co-transfected with GFP-TDP and Flag-hnRNP-E2 as described in the methods section. 
When the TDP-43 was immunoprecipitated using the Abcam rabbit GFP antibodies, there was no band 
detected for hnRNP-E2 using the Flag antibodies, which indicated that there was no interaction between 
TDP-43 and hnRNP-E2 (Figure 42A). A reverse experiment was also performed by immunoprecipitating 
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hnRNP-E2 using the Flag antibody and then immunoblotting with the rabbit TDP-43 antibody and 
mouse hnRNP-E2 antibody. Figure 42B shows a band of GFP-TDP-43, indicating the possible 
interaction between hnRNP-E2 and TDP-43 (Figure 42B). A further control experiment was performed 
to confirm that TDP-43 interacts with hnRNP-E2 rather than just the beads. The control experiment 
consisted of immunoprecipitating the just beads without any primary antibodies. The results showed a 
weak band for GFP-TDP, suggesting that either TDP-43 is binding to the beads or a contaminant protein 
was transferred into this fraction (Figure 42C). Therefore, the TDP-43 band seen with the hnRNP-E2 
IP was not considered to be a true positive result and hence we found no evidence of protein-protein 
binding between hnRNP-E2 and TDP-43. Protein A Dynabeads were also tested (results not 
presented), which revealed the same false positive results. 
 
Figure 42: A) immunoprecipitation of GFP-TDP in untransfected and co-transfected cells using rabbit GFP 
antibodies. There was no band detected with the Flag antibodies for hnRNP-E2. (B) Immunoprecipitation of 
hnRNP-E2 using the rabbit Flag antibodies. The band for GFP-TDP was detected in the IP fraction; however, this 
was not considered to be a positive result. (C) Immunoprecipitation of beads only and labelled with rGFP and mFlag 






5.3.5 Stress granules and immunocytochemistry 
5.3.5.1 Both TDP43 and hnRNP-E2 colocalise with the SG marker PABP1  
The HeLa cells were transfected with WT-HA-TDP43 as described in the methods section before stress 
was applied to the cells as previously described. Immunocytochemistry was carried out using the SG 
marker PABP1 and the rabbit TDP-43 antibodies. Figure 43A–C show untreated transfected cells 
without any SG formation, with the strong nuclear presence of TDP-43 and the absence of PABP1 from 
the nucleus. The transfected cells show strong nuclear TDP-43 staining and cytoplasmic PABP1 
staining. The transfection rate with the WT-HA-TDP-43 was very low. In each coverslip, only 2–5 cells 
were transfected with WT-HA-TDP-43. When the cells were treated with 0.5 mM of sodium arsenite, 
small SGs were formed and the depletion of nuclear TDP-43 from the nucleus to the SGs was observed 
(Figure 43D, E and F). Treatment with sorbitol did not result in the formation of SGs (Figure 43G, H and 
I). The images obtained by confocal microscopy show large SG formation following exposure to both 
sorbitol and arsenite stress as well as clearly showing TDP-43 colocalised with the SG marker PABP1 






Figure 43: HA-TDP transfected HeLa cells untreated with any stress condition showing strong nuclear staining of 
TDP-43 (green) and normal cytoplasmic distribution of PABP1 (red) (A, B and C). The HA-TDP-transfected cells 
treated with 0.5 mM of sodium arsenite showing small SG formation and the recruitment of both PABP1 and TDP-
43 into the SGs (D, E and F). HA-TDP-43-transfected cells treated for 60 minutes with 600 mM of sorbitol showed 
no SG formation and both PABP1 and TDP-43 were still within their normal cellular distribution (G, H and I). HA-
TDP-43-transfected cells treated for both 60 minutes with 600 mM of sorbitol and 0.5 mM of sodium arsenite for 
30 minutes (J, K and L). Immunocytochemistry for PABP1 (red) and TDP-43 (green) shows large SG formation in 












The HeLa cells were transfected with Flag-hnRNP-E2 before stress was applied as described 
previously. Figure 44 shows the hnRNP-E2-transfected cells without any stress, showing the 
cytoplasmic and nuclear distribution of hnRNP-E2 and the absence of PABP1 from the nuclei (Figure 
44A, B and C). The transfection rate with Flag-hnRNP-E2 was higher than that seen with WT-HA-TDP-
43. The application of arsenite stress for 30 minutes resulted in small SG formation and the 
accumulation of both PABP1 and hnRNP-E2 in the SGs (Figure 44D, E and F). Treatment with sorbitol 
alone for 1 hour did not result in SG formation; however, there was nuclear clearance of hnRNP-E2 
(Figure 44G, H and I). The images obtained by confocal microscopy show large SG formation following 
exposure to both arsenite and sorbitol stress as well as clearly showing that hnRNP-E2 colocalised with 







Figure 44: Flag-hnRNP-E2-transfected HeLa cells untreated with any stress condition showing strong nuclear 
staining of hnRNP-E2 (green) and normal cytoplasmic distribution of PABP1 (red) (A, B and C). The Flag-hnRNP-
E2-transfected cells treated with 0.5 mM of sodium arsenite showing small SG formation and the recruitment of 
both PABP1 and hnRNP-E2 into the SGs (D, E and F). Flag-hnRNP-E2-transfected cells treated for 60 minutes 
with 600 mM of sorbitol showed no SG formation; however, hnRNP-E2 was cleared from the nucleus to the 
cytoplasm (G, H and I). Flag-hnRNP-E2-transfected cells treated for 60 minutes with 600 mM of sorbitol and 0.5 
mM of sodium arsenite for 30 minutes (J, K and L). Immunocytochemistry for PABP1 and hnRNP-E2 shows large 
SG formation in the cytoplasm of the cells and the colocalisation of both hnRNP-E2 and PABP1 within the SGs. All 




5.3.5.2 Colocalisation of endogenous TDP-43 and hnRNP-E2 in SG 
The untransfected HeLa cells were treated with different stress conditions in order to stimulate the 
formation of SGs as described in the methods section. Immunocytochemistry was performed to detect 
the endogenous TDP-43 and hnRNP-E2 proteins in the control and stress conditions. As expected, in 
the non-treated cells there was no formation of SGs, while TDP-43 and hnRNP-E2 were normally 
distributed in the cells (Figure 45A, B and C). The treatment of the cells with 0.5 of mM arsenite for 30 
minutes resulted in the discrete formation of SGs, in which both TDP-43 and hnRNP-E2 were 
colocalised (Figure 45D, E and F). To determine whether osmotic stress interferes in the formation of 
SGs, the cells were treated with 600 mM of sorbitol for one hour and no formation of SGs was observed. 
However, the osmotic stress resulted in an increase in the cytoplasmic TDP-43 and hnRNP-E2 (Figure 
45G, H and I). To increase the number of SGs, the cells were treated with sorbitol for one hour (to 
release TDP-43 and hnRNP-E2 into the cytoplasm) and, subsequently, the cells were treated with 
sodium arsenite (to recruit TDP-43 and hnRNP-E2 into the SGs). Virtually all the cytoplasmic TDP-43 
and hnRNP-E2 was recruited into large SGs. Massive SGs were detected when the cells were treated 
with sorbitol followed by sodium arsenite. Clearly, both TDP-43 and hnRNP-E2 were recruited into the 









Figure 45: Untransfected HeLa cells were plated and left untreated. Immunocytochemistry with TDP43 and hnRNP-
E2 shows the normal nuclear and cytoplasmic distribution of both TDP43 and hnRNP-E2 (A, B and C). 
Untransfected HeLa cells were treated for 30 minutes with 0.5 mM of sodium arsenite. Immunocytochemistry for 
TDP-43 (red) and hnRNP-E2 (green) showed SG formation and the colocalisation of both TDP43 and hnRNP-E2 
within the SGs(D, E and F). When untransfected HeLa cells were treated with 600 mM of sorbitol for 60 minutes, 
the ICC showed no SG formation; however, the cell cytoplasm shows the formation of vacuoles due to the osmotic 
stress (G, H and I). Untransfected HeLa cells that were treated with both 600 mM of sorbitol for 60 minutes and 0.5 
mM of sodium arsenite for 30 minutes showed very clear SG formation and both TDP-43 and hnRNP-E2 showed 












TDP-43 is known to be one of the major components of the ubiquitin-positive inclusions seen in FTLD 
and MND (Neumann et al., 2006b). Following this discovery, the physiological and pathological 
characteristics of TDP-43 have been the focus of intense investigation in order to understand its role in 
the pathology of FTLD and MND. TDP-43 belongs to the hnRNP family of proteins and, like all the 
members of the hnRNP family, it possesses the ability to bind to RNA in a single-strand and sequence-
specific manner. It also has the ability to bind to several proteins that modulate its RNA processing and, 
probably, its aggregation properties (Zhu et al., 2014, Zhang et al., 2013). Further, TDP-43 has the 
ability to bind to other hnRNPs as well as other RNA-binding proteins such as those implicated in SGs, 
for example, TIA-1 (Liu-Yesucevitz et al., 2010) (Buratti and Baralle, 2012).   
We detected the colocalisation of hnRNP-E2 in 84.5% of TDP-43 inclusions in a subset of C9orf72- 
expansion-negative FTLD-TDP cases (Chapter 4). We sought to explore whether there was a link 
between TDP-43 and hnRNP-E2 that might explain this pathology by means of the co-regulation of 
protein levels or direct binding. We therefore used cell biology techniques to investigate this relationship 
and the possible implication of hnRNP-E2 aggregation in TDP-43 pathology.   
In a network of interacting proteins, changes in the relative expression of a protein can have a significant 
impact on other proteins in the network, either directly or by affecting common cellular targets 
(Mohagheghi et al., 2016). Therefore, TDP-43 and hnRNP-E2 were overexpressed or knocked down in 
HEK293T cells and their relative expression was measured and statistically analysed by comparing it 
to controls. Their interaction was further investigated using co-immunoprecipitation to determine 
whether they form a protein complex as a result of their interaction. We also sought to determine 
whether the recruitment of TDP-43 and hnRNP-E2 into the SGs might play a role in their colocalisation 
within inclusions (Monahan et al., 2016, Liu-Yesucevitz et al., 2010, Dewey et al., 2012, Fujimura et al., 
2008, Fujimura et al., 2009). Consequently, we examined the presence of TDP-43 and hnRNP-E2 in 




5.4.1 hnRNP-E2 could be upstream of TDP-43 
The aim of this experiment was to determine whether the levels of TDP-43 and hnRNP-E2 were 
interdependent. WT-HA-TDP43 was overexpressed in HEK293T cells and the levels of endogenous 
hnRNP-E2 were measured. However, there was no significant difference found in the endogenous 
hnRNP-E2 between the WT-HA-TDP43-transfected and pDEST30-transfected cells (p > 0.05). When 
NT-Flag-hnRNP-E2 was overexpressed, no significant difference in the TDP-43 levels was detected 
between the pDEST30- and NT-Flag-hnRNP-E2-transfected cells.  
The knockdown of hnRNP-E2 showed a significant decrease in the TDP-43 levels when a one-way 
ANOVA was performed among all the samples with different sihnRNP-E2 concentrations (p < 0.05). 
However, the Bonferroni post-hoc t-test corrected analysis revealed a significant difference in TDP-43 
expression between the untransfected cell samples and sihnRNP-E2 at 100 nM (p < 0.05). Yet, TDP-
43 knockdown did not result in any significant change in the hnRNP-E2 expression levels. The results 
suggest that hnRNP-E2 is upstream of TDP-43; however, it is not clear whether they interact directly or 
through indirect pathways. 
To determine whether TDP-43 and hnRNP-E2 interact directly as part of a protein complex, we 
performed co-IP, wherein WT-GFP-TDP43 and NT-Flag-hnRNP-E2 were co-transfected into HEK293T 
cells. When WT-GFP-TDP-43 was pulled down, there was no indication of hnRNP-E2 precipitation 
using both the Flag and hnRNP-E2 antibodies in Western blots. When hnRNP-E2 was pulled down 
using Flag antibodies, a band for TDP-43 precipitation was detected. A beads alone control experiment 
was included to eliminate any possible interaction of the WT-GFP-TDP43 with the beads in the absence 
of any antibodies. The interaction of WT-GFP-TDP43 with the beads was detected using Protein G or 
Protein A Dynabeads. The interaction with the beads could be due to the GFP vector rather than TDP-
43, since when the Western blots are labelled with TDP-43 antibodies, the band disappeared from the 
beads’ IP. The TDP-43 antibodies did not detect a band of interaction when hnRNP-E2 was pulled 
down; however, this could be because the endogenous TDP-43 levels were not sufficient to appear on 
the Western blot when compared to the overexpressed levels. The results of the co-IP were not 
conclusive; however, if the TDP-43 band is confirmed, along with the results of the knockdown 
experiment, then hnRNP-E2 could be upstream of TDP-43. Otherwise, we can only conclude that under 




5.4.2 TDP-43 and hnRNP-E2 colocalise within stress granules  
SGs are transient cytosolic structures that are formed when cells are exposed to stress such as hypoxia, 
heat, infection or oxidative stress (Anderson and Kedersha, 2008). They originate from polysomes and 
they store the mRNA of encoding housekeeping proteins as well as prioritising the selective translation 
of stress-response proteins (e.g. chaperons) and heat-shock proteins that are involved in damage 
repair. Therefore, SGs are considered to represent a sorting station wherein transcripts will be stored 
in a silent form for translation re-entry or to be degraded by cellular degradation systems (Bentmann et 
al., 2012). In addition to mRNAs, SGs also contain several RNA-binding proteins, some of which serve 
as specific markers for SGs, for example, PABP1 and TIA-1 (Dewey et al., 2012).   
 
5.4.2.1 TDP-43 colocalises with PABP1 in HeLa cells under oxidative stress and combined 
oxidative and osmotic stress 
TDP-43 has been reported to be a stress-responsive protein in several studies. Further, TDP-43 was 
described as a component of SGs in various cell lines under different stress conditions. The localisation 
of TDP-43 within SGs is determined by the stressor type and the cell type. Previous studies have 
reported that TDP-43 can be recruited into SGs in cell culture using oxidative stress, osmotic stress, 
heat shock, serum deprivation, ubiquitin-proteasome inhibition, endoplasmic reticulum stress and the 
herbicide Paraquat (Colombrita et al., 2009, Liu-Yesucevitz et al., 2010, Meyerowitz et al., 2011, Dewey 
et al., 2011, Freibaum et al., 2010, McDonald et al., 2011). TDP-43 was recruited into the SGs by 
osmotic stress and oxidative stress in mixed primary glial culture and HeLa cells (Dewey et al., 2011) 
as well as in vivo in axotomised mouse motor neurons (Moisse et al., 2009). However, TDP-43 failed 
to localise within SGs in HEK293T and the neural cell line (SH-SY5Y and Neuro2a) (Ayala et al., 2011a, 
Dewey et al., 2011). Bentmann et al. (2012) performed a thorough study on the requirements for TDP-
43 recruitment into SGs. They analysed the effect of different TARDBP mutations seen in ALS on 
directing TDP-43 into the SGs. They also mapped the TDP-43 domains required for SG recruitment 
and investigated the presence of SG markers within TDP-43 inclusions in ALS/FTLD-TDP patients 
(Bentmann et al., 2012). They reported that both the RRM1 and the C-terminal glycine-rich domain are 
required for TDP-43 localisation within SGs. SG marker proteins such as TIA-1, elF3 and PABP1 were 
reported to label the pathological TDP-43 inclusions in post-mortem brains of ALS and FTLD patients 
(Dormann et al., 2010, Bentmann et al., 2012, Colombrita et al., 2009, Kim et al., 2014). This could be 
150 
 
due to the presence of different TDP-43 species in the aggregates seen in various regions of the central 
nervous system, as Bentmann et al. (2012) suggested. Their data also suggested that the PABP1 
labelling of TDP-43 inclusions depends on the presence of full-length TDP-43, which may explain the 
controversy surrounding the SG marker labelling within TDP-43 aggregates in human tissue (Bentmann 
et al., 2012). McGurk et al. (2014) detected PABP1 within TDP-43 inclusions in the spinal cord of ALS 
patients without mutations, as well as in ATXN2-ALS, FUS-ALS and C9orf72 hexanucleotide repeat 
expansion ALS. They suggested that PABP1 tends to colocalise with mature TDP-43 inclusions rather 
than preinclusions. They also reported that it is more frequently present with TDP-43 in the spinal cord 
of C9orf72 ALS patients than any other subset of ALS, which is consistent the findings of Bentmann et 
al. (Bentmann et al., 2012, McGurk et al., 2014). PABP1 was also reported to modulate TDP-43 toxicity 
in drosophila as well as to play an important role in mediating TDP-43 toxicity in model systems (Kim 
et al., 2014). 
In this study, endogenous TDP-43 was recruited into the SGs in untransfected HeLa cells treated with 
arsenite (oxidative stress) and with combined stress treatment (oxidative and osmotic). This data are 
consistent with previously reported findings. The SGs were larger with the combined stress treatment 
when compared to the arsenite stress alone, since the osmotic stress recruits TDP-43 to the SGs, 
thereby allowing more protein to be incorporated within the SGs (Dewey et al., 2011). 
In order to examine the transfection levels of WT-HA-TDP43 and NT-Flag-hnRNP-E2, as well as to 
confirm the localisation of TDP-43 and hnRNP-E2 within the SGs, labelling with the SG marker PABP1 
was performed and the colocalisation was examined. The transfection rate for both WT-HA-TDP43 and 
NT-Flag-hnRNP-E2 was very low, with only 2–5 cells for WT-HA-TDP-43 and 4–10 cells for NT-Flag-
hnRNP-E2 in each coverslip. However, the endogenous and overexpressed TDP-43 and hnRNP-E2 
colocalised with the SG marker PABP1 under both stress conditions. Contrary to previous reports, 
osmotic stress on the HeLa cells failed to induce well-defined SGs formation; however, the combination 
of osmotic stress and stress caused by transfection increased the formation of vacuoles in the 
cytoplasm. Although there was a diffusion of TDP-43 from the nucleus into the cytoplasm, the loss of 






Despite the evidence of TDP-43 interaction with multiple proteins within the SGs, not all of the proteins 
have been identified. As the TDP-43 C-terminal domain was reported to be a requirement for its 
localisation within SGs, protein-protein interactions could contribute to TDP-43 recruitment into SGs. 
Therefore, it is important to investigate the interaction of TDP-43 with other proteins in an effort to 
understand the process involved in TDP-43 pathology. 
 
5.4.2.2 hnRNP-E2 colocalises with PABP1 in SGs under oxidative stress and combined oxidative 
and osmotic stress 
hnRNP-E2 was first identified as a component of the α-complex of the human α-globin mRNA that 
enhances mRNA stability (Kiledjian et al., 1999). hnRNP-E2 plays an important role in biological 
processes such as transcription regulation and translation silencing. Further, hnRNP-E2 plays a central 
role in DNA repair, telomere biogenesis and cell signalling, which indicates its potential role in tumour 
development and progression (Eversole and Maizels, 2000). Currently, hnRNP-E2 is characterised as 
a facilitator of the internal ribosomal entry site (IRES)-mediated translation of both cellular and viral 
transcripts (Evans et al., 2003, Bedard et al., 2004). hnRNP-E2 was described as a shuttling protein 
between the nucleus and the cytoplasm; however, it was found to reside within a subset of processing 
bodies (P-bodies) in cells at a resting state. P-bodies are conserved cytoplasmic foci enriched with 
RNA-degrading enzymes, which serve as a storage site for mRNAs and could be involved in micro-
RNA (miRNA)-dependent translational repression and short-interfering RNA (SiRNA) (Fujimura et al., 
2009). Interestingly, hnRNP-E2 was not found in all the Dcp1a- and elF4E-T-positive P-bodies, which 
suggests a specific mechanism that targets hnRNP-E2 into only certain P-bodies (Fujimura et al., 2009). 
In addition, it was reported that hnRNP-E2 localises to the SGs while still present within P-bodies. Yet, 
the knockdown of hnRNP-E2 did not affect the structural integrity of the SGs and P-bodies, while its 
overexpression does not affect the expression of the SG marker TIA-1. Fujimura et al. (2009) suggested 
that when cells are under stress, hnRNP-E2 shuttles between the P-bodies and SGs due to their close 
association. Additionally, they suggested that hnRNP-E2 may play an important role in transferring 
specific mRNA species from the SGs to P-bodies for degradation or mRNPs remodelling in SGs 
(Fujimura et al., 2009, Fujimura et al., 2008). They also investigated the important domains for hnRNP-
E2 localisation within SGs and P-bodies, and they found that the KH1 domain is essential for hnRNP-
E2 incorporation into the SGs. They also reported that the deletion of both KH2 and KH3 abolished 
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localisation to the P-bodies, although it did not affect the accumulation within the SGs (Fujimura et al., 
2009) 
The results of this study showed that hnRNP-E2 is recruited into the SGs, which was confirmed by the 
localisation of the SG marker PABP1 within HeLa cells under stress conditions. With oxidative stress, 
small SGs were formed when compared to those formed with the combined stress condition. More 
hnRNP-E2 was recruited into the SGs after the combined stress with both arsenite and sorbitol. The 
colocalisation of hnRNP-E2 with TDP-43 was further investigated in the HeLa cells after the application 
of stress conditions. 
 
5.4.2.3 hnRNP-E2 colocalises with TDP-43 in SGs 
The previous two experiments confirmed the presence of both TDP-43 and hnRNP-E2 within the SGs 
with the SGs marker PABP1. In this experiment, the colocalisation of endogenous TDP-43 with 
endogenous hnRNP-E2 within the SGs was confirmed in HeLa cells under various stress conditions. 
The SGs in this experiment appeared smaller and fewer than when TDP-43 or hnRNP-E2 was 
overexpressed in the HeLa cells. This could be due to the amount of both that was present 
endogenously being much less than in the case of overexpression. 
Fujimura et al. (2009) also suggested that the presence of hnRNP-E2 is not important for SG formation 
and that it does not play a role in the structural basis of SGs and P-bodies. However, they did manage 
to demonstrate that the P-bodies that contain hnRNP-E2 are actively associated with the SGs and that 
hnRNP-E2 shuttles between the two. Their observations suggest the role of hnRNP-E2 in mRNA 
degradation. At this point in the present study, it is not clear how hnRNP-E2 interacts with TDP-43 within 
the SGs or whether hnRNP-E2 leads TDP-43 into the SGs.  
Recently, Mao et al. (2016) reported the upregulation of hnRNP-E2 expression in the spinal cord after 
spinal cord injury in adult rats. They found that it modulates the caspase-dependent apoptosis pathway 
by interacting with caspase-3, since the knockdown of hnRNP-E2 resulted in a significant decrease in 
the caspase-3 expression in the primary neuronal cells. Furthermore, they reported that the knockdown 
of hnRNP-E2 inhibits the astrocyte proliferation and glutamate-induced apoptosis of the primary 
neurons in vitro. Their results support the hypothesis that hnRNP-E2 may be involved in neuronal 
apoptosis and cell cycle activation (Mao et al., 2016). 
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Given the results concerning the expression and Co-IP experiments, it appears that TDP-43 and 
hnRNP-E2 may interact indirectly, while the SG experiment suggests that hnRNP-E2 does not enhance 
the cellular toxic effect of the pathological TDP-43. Nevertheless, it suggests that TDP-43 could be 
escaping a clearance mechanism that is associated with hnRNP-E2. At this point, it remains unclear 
how and why hnRNP-E2 is colocalised with TDP-43 in a subset of FTLD-TDP cases as well as whether 
it is involved in the pathology of TDP-43. The study by Mao et al. (2016) provided evidence of its 
involvement in neuronal apoptosis, but at this stage, the mechanism of hnRNP-E2 in modulating 
neuronal repair remains unclear.    
 
5.4.3 Conclusion 
Our experiments manipulating the levels of TDP-43 and hnRNP-E2 showed that these two proteins do 
not interact or influence each other under basal conditions. Following oxidative stress, however, they 
are both recruited into the SGs. Once the stressor has resolved, the SGs are broken up and RNA-
binding proteins and RNA are either released or degraded. It is possible that TDP-43 and hnRNP-E2 
form aggregates that fail to be degraded and hence form a seed for further aggregation, which in turn 
either sequesters TDP-43 from the nucleus, thereby causing neurodegeneration by means of a loss of 
nuclear function mechanism, or implies that cytoplasmic aggregates are directly neurotoxic through a 
gain of function. At this point, it is not clear how and why hnRNP-E2 interacted with TDP-43 in a subset 
of FTLD-TDP cases, although our findings do provide further evidence for the role for SGs in acting as 




Chapter 6 Discussion and Conclusion 
6.1 Discussion  
FTLD is a clinically, genetically and pathologically heterogeneous group of disorders characterised by 
a change in language, behaviour and personality which can be accompanied by the signs of MND.  
FTLD is the second most common form of dementia with an onset before the age of 65 years and is 
characterised pathologically by atrophy of the frontal and anterior temporal lobes. The prevalence of 
FTLD is estimated to be between 10 and 30 per 100,000 and shows a strong familial component with 
30-50% of patients reporting at least one family member with the same symptoms {Borroni, 2010 
#983;Zarow, 2012 #700;Sieben, 2012 #709;Cairns, 2007 #1212}, with predominantly an autosomal 
dominant pattern of inheritance {Goldman, 2007 #2253}.  Mutations in many different genes have been 
associated with FTLD, most of which also cause ALS.  It is now recognised that FTLD and ALS share 
common genetic, clinical and pathological characteristics and are now considered to form the ends of 
a phenotypic spectrum.  Mutations that exclusively or predominantly cause an FTLD phenotype include 
those in the genes MAPT, GRN, VCP, CHMP2B and the G4C2 expansion in the C9orf72 gene which 
is the most common mutation in FTLD and ALS. FTLD is a complex disorder and combined 
characterisation of the clinical and biological biomarkers is essential for diagnosis {Sieben, 2012 #709}.   
Clinically, FTLD is classified into three major types; progressive non-fluent aphasia, semantic dementia 
and frontotemporal dementia (FTD) {Mitsuyama, 2009 #1058}.   FTLD is further classified pathologically 
based on the composition, morphology and distribution of the protein inclusions detected in the brain of 
FTLD patients.  FTLD is classified into three major pathological subtypes; FTLD-Tau, FTLD-TDP and 
FTLD-FUS but a small proportion of cases show ubiquitin only, or p62 only, inclusions or show no 
aggregation pathology at all {Mackenzie, 2010 #227}.  The identification of TDP-43 as the major 
component of the neuronal protein inclusions seen in FTLD and ALS provided a strong molecular link 
between the two syndromes.  There is evidence that the mis-accumulation of TDP-43 is directly 
mechanistic in causing neurodegeneration however, the downstream events are not clearly understood.  
A major forward step in understanding the pathological mechanisms underlying the TDP-43 
proteinopathies would be mapping out a network of its interacting proteins.  This project aimed to identify 
TDP-43 binding partners in the brain and spinal cord tissues of FTLD and ALS patients.  A list of 
candidate TDP-43 interacting proteins was previously generated by colleagues in our lab using the 
SILAC technique and the expression levels of a number of these proteins was examined in the brain 
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and spinal cord tissue of FTLD-TDP and ALS cases using the IHC technique, these proteins included; 
RanBP1, Ubiquilin-2, hnRNP-M, hnRNP-Q, hnRNP-C1/C2 and hnRNP-E2.  Immunoreactive 
perinuclear inclusions and dystrophic neurites for Ubiquilin-2 and hnRNP-E2 were detected in the frontal 
cortex of FTLD-TDP cases.  From this point forward hnRNP-E2 became the focus of the project and 
further experiments were designed to investigate the role of hnRNP-E2 in the pathogenesis of FTLD-
TDP.   
Ubiquilin-2 inclusions were detected in the frontal cortex of FTLD-TDP type B cases and C9orf72 FTLD-
TDP cases.  Ubiquilin-2 pathology has since been reported to be characteristic for C9orf72 pathology 
in FTLD-TDP cases {Brettschneider, 2012 #2272}.  The findings of this project correlate with the 
reported study however, Ubiquilin-2 inclusions were also detected in 2 FTLD-TDP subtype B cases 
which do not carry the C9orf72 expansion.  This could mean that Ubiquilin-2 pathology is related more 
to the TDP-43 pathology subtype rather than the presence of the C9orf72 expansion. There is also a 
possibility that the two subtype B cases have an unrecognised C9orf72 expansion – or indeed a different 
mutation. Analysis of further numbers of FTLD-TDP subtype B cases could aid in determining the 
specificity of Ubiquilin-2 inclusions.  From this point forward hnRNP-E2 became the focus of the project 
and further experiments were designed to investigate the role of hnRNP-E2 in the pathogenesis of 
FTLD-TDP. 
 
6.1.1 hnRNPs in health and disease. 
Neurons are non-dividing cells therefore they need tight mRNA homeostasis regulation as they are 
highly vulnerable to RNA binding protein dysfunction. hnRNPs, play a major role in gene expression 
regulation.  The discovery of pathological mutations in many hnRNPs makes them the central focus in 
several neurodegenerative disorders such as ALS, FTLD and spinal muscular atrophy (SMA).  Because 
of the growing repertoir of RNA binding proteins, it is still not clear how and when they are triggered to 
interact and complement each other’s function.  It has become clear that hnRNPs contribute to the 
development of many cancers as well as neurodegenerative disorders.  However, the underlying patho-
mechanisms for many hnRNPs remains to be explained and study of their common and specific disease 
related functions is needed.  hnRNP dysfunction is also implicated in patients carrying the C9orf72 
repeat expansion as the sequestration of RNA binding proteins including hnRNP A3, F, H and K, which 
colocalise with intranuclear neuronal RNA foci in ALS/FTLD patient tissues {Mori, 2013 #19;Davidson, 
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2017 #2392;Cooper-Knock, 2014 #446;Lee, 2013 #2387}.  Furthermore, mutations in several hnRNPs 
were identified as causative for ALS/FTLD which support the idea of altered RNA metabolism as the 
underlying patho-mechanism.  Examples of identified mutations are hnRNP-A1 and A2/B1, TARDBP 
and FUS (which is also known as hnRNP-P2).  Interestingly, most of the mutations in FUS are clustered 
around the NLS but for TDP-43, hnRNP-A1 and A2/B1 they are located in the low complexity, prion-
like domain which increases its intrinsic tendency to self-aggregate {Kim, 2013 #18;Le Ber, 2014 
#2395;Mohagheghi, 2016 #2396;Waibel, 2010 #2397;Gami-Patel, 2016 #2398}.  In addition, APP 
mRNA translation was found to be regulated by hnRNP-C and fragile X mental retardation protein 
(FMRP), which both act competitively and influence APP translation in an opposing way.  The cleavage 
product of APP is amyloid-beta, plaques of which are the hallmark of AD {Borreca, 2016 #2399}.  
Moreover, hnRNPs (A1, G, M, Q and R) are linked to SMN and shown to localize with TDP-43 and FUS 
in nuclear speckles which may function in spliceosome maintenance {Tsuiji, 2013 #23;Chen, 2008 
#1818;Cho, 2014 #2184;Kashima, 2007 #2400;Moursy, 2014 #2401;Dombert, 2014 #2402}.  
Furthermore, hnRNPs are essential for coordinating the transport of stabilized mRNAs along the axonal 
skeleton to the presynaptic translation sites {Bekenstein, 2013 #2403}.   
  
6.1.2 hnRNP-E2 in FTLD-TDP cases. 
Characterisation of hnRNP-E2 in the brain and spinal cord of different FTLD-TDP subtypes and other 
neurodegenerative diseases was an essential step in identifying the specificity of hnRNP-E2 pathology.  
hnRNP-E2 IHC was performed on FTLD-TDP without the C9orf72 expansion, FTLD-TDP with the 
C9orf72 expansion, FTLD-Tau, FTLD-U-PRGN, ALS-FUS, ALS-SOD1, sALS, ALS with TDP-43 
Mutation, CIDP, DLB, AGD, SCA, Pick’s disease, Huntington’s disease, Alzheimer’s disease cases and 
healthy controls.  hnRNP-E2 immuno-reactive inclusions were only detected in a subset of FTLD-TDP 
cases without C9orf72 mutation but not in any of the other neurodegenerative disorders.  This group of 
cases with positive hnRNP-E2 inclusions accounted for 53.3% of total FTLD-TDP cases without a 
C9orf72 mutation.  hnRNP-E2 pathology was detected in FTLD-TDP subtype A (6/15 cases) and 
subtype C (7/8 cases) and in one subtype B case.  hnRNP-E2 inclusions were predominant in the 
superficial layers, particularly layer 2, of the neocortex with numerous perinuclear and intra-neuronal 
inclusions and frequent neuritic inclusions.  hnRNP-E2 inclusions were also detected in the 
hippocampal pyramidal cells, dentate gyrus and in the grey matter of the anterior horn of the thoracic 
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region of the spinal cord.  There were no inclusions detected in the cerebellum of any FTLD-TDP case 
with or without the C9orf72 mutation. 
These hnRNPE2 inclusions showed a similar pattern of inclusion type to the TDP-43 inclusions – indeed 
they were seen to colocalise with TDP-43 aggregates when analysed by double immunofluorescence 
labelling. hnRNP-E2 colocalised with 84.5% of TDP-43 inclusions and with 67% of the ubiquitin 
inclusions in the same cases.  Closer examination of the inclusions by high resolution confocal 
microscope revealed absolute colocalisation of hnRNP-E2 with TDP-43, in contrast to the ubiquitin 
inclusions which suggest partial ubiquitination of hnRNP-E2. This strongly suggests that hnRNPE2 and 
TDP-43 are interacting, or depositing by the same mechanism. Why this is only seen in some of the 
FTLD-TDP subtypes is of interest and lends support to the hypothesis that the aggregation of TDP-43 
in the different subtypes is occurring by different mechanisms. It also suggests that TDP-43 aggregation 
may not be the main biological event occurring in these diseases, but may be a reflection of neuronal 
dysregulation.  The differing mechanisms of TDP-43 aggregation may also explain the clinical variability 
seen between the subtypes.  
hnRNP-E2 was reported to regulate exon 10 splicing of the MAPT gene.  Mis-splicing of exon 10 leads 
to an imbalance in the ratio of 3repeat and 4repeat tau, causing aggregation of 4repeat tau into 
neurofibrillary tangle-like structures linked to FTLD-tau, which is also known as FTDP-17 
(Frontotemporal Dementia with parkinsonism linked to chromosome 17) {Broderick, 2004 #1428}.  It 
was also reported that hnRNP-E2 interacts with SRp75/hnRNP-G complex to regulate the splicing of 
exon10 of the Tau gene.  The authors of the paper suggested that a weak binding to the SRp75 might 
be the main reason behind the exon 10 inclusions in FTLD cases {Wang, 2011 #180}.  Absence of 
hnRNP-E2 pathology in FTLD-tau cases (5 cases) and other tauopathy related cases in this study 
suggests that hnRNP-E2 is associated to TDP-43 pathology and that the imbalance in tau 3R and 4R 
ratio is not due to malfunctioning hnRNP-E2.  Furthermore, hnRNP-E2 shares 89% structural homology 
with hnRNP-E1 which is believed to be encoded by an intron-less gene that is a product of a 
retrotransposon of a fully processed minor isoform of hnRNP-E2 {Valverde, 2008 #2019;Makeyev, 2002 
#219;Woolaway, 2007 #185}.  hnRNP-E1 and hnRNP-G involvement with hnRNP-E2 pathology was 
investigated in hnRNP-E2 positive cases.  The IHC for both hnRNP-E1 and hnRNP-G revealed normal 
distribution compared to the control cases, which suggests the involvement of hnRNP-E2 is through a 
158 
 
different mechanistic pathway that could be more closely related to TDP-43, leading to its deposition in 
the brain of FTLD-TDP cases. 
Characterisation of hnRNP-E2 insolubility in the brain of FTLD-TDP cases was carried out using WB 
on serially fractionated brain tissues from the following four groups; FTLD-TDP cases without C9orf72 
mutation with and without hnRNP-E2 inclusions, FTLD-TDP cases with C9orf72 mutation as well as 
control cases.   Bands of insoluble hnRNP-E2 were not detected in three FTLD-TDP cases with positive 
hnRNP-E2 inclusions.  Moreover, an insoluble hnRNP-E2 band was detected in one FTLD-TDP case 
without the C9orf72 expansion which was negative for hnRNP-E2 inclusions by IHC.   This result could 
be due to the variation in the abundancy of hnRNP-E2 inclusions in the brain among cases or simply 
due to differences in the TDP-43 pathological signature within FTLD-TDP subtypes {Tsuji, 2012 
#692;Armstrong, 2010 #239}.  The inconsistency of the WB results with the IHC results made the 
biochemical characterisation of hnRNP-E2 in FTLD-TDP cases inconclusive.  However, increasing the 
case number and carrying out further quantitative studies could give better insight into the biochemical 
characteristics of hnRNP-E2 in FTLD-TDP pathology. 
The effect of gender, disease duration, PMD and fixation time were statistically analysed using a Chi-
squared test to identify any significant variable effect among the hnRNP-E2 positive and hnRNP-E2 
negative FTLD-TDP cases.  None of the variables were shown to affect hnRNP-E2 positivity in FTLD-
TDP cases.  It would be interesting to further investigate the clinical presentation of disease in the E2 
positive and negative cases to establish if there was a correlation with any specific clinical variable 




6.1.3 hnRNP-E2 role in neurodegeneration. 
To date, there is little knowledge in the literature concerning specific hnRNP-E2 functions in the nervous 
system in health or neurodegenerative disease.  There could be many possible explanations for hnRNP-
E2 colocalisation with TDP-43 in degenerating neurons which could form the focus of future studies.  
Firstly, both TDP-43 and hnRNP-E2 may be present within ubiquitinated inclusions due to impairment 
of ubiquitin proteasome or autophagy pathways associated with aging, which lead to cytoplasmic TDP-
43 accumulation and aggregation {Scotter, 2014 #2122;Uchida, 2016 #2112}.  hnRNP-E2 is recognised 
to play a role as an adapter between the ubiquitin ligase E3 ITCH and the MAVS protein in cellular 
studies {You, 2009 #1487}.  A recent study suggested that the key for TDP-43 aggregation is an 
imbalance between the substrate VHL and the ligase E3 CUL2 complex {Uchida, 2016 #2112}.  hnRNP-
E2 could provide a potential component or adapting activity for this complex which could be investigated 
in future studies.  A second possible explanation of hnRNP-E2 colocalisation with TDP-43 is its 
involvement in the caspase-3 neuronal apoptosis pathway, which has been reported in ALS and FTLD 
cases {Martin, 1999 #2113;Su, 2000 #2116;Zhang, 2007 #1500;Han, 2013 #39}.  Knockdown of 
hnRNP-E2 induces caspase-3 mediated apoptosis which was investigated in neuronal apoptosis after 
acute spinal cord injury and in primary neuronal cell lines.  Levels of both hnRNP-E2 and caspase-3 
were upregulated in neurons following acute spinal cord injury and when hnRNP-E2 was silenced in 
primary neurons, caspae-3 was down regulated {Mao, 2016 #1960}.  The exact mechanism of hnRNP-
E2 mediated neuronal apoptosis is not yet clear however, it provides a possible mechanism for TDP-
43 aggregation in FTLD and ALS which could be a target for future studies. A third explanation is that 
miRNAs might form a link between TDP-43 and hnRNP-E2.  TDP-43 is an identified modulator of 
miRNA maturation and it facilitates miRNA production to promote neuronal outgrowth {Kawahara, 2012 
#786}.  The levels of hnRNP-E2 expression were found to be regulated by miRNA-214 to supress 
proliferation and growth of glioma cells {Tang, 2015 #2125}.  The exact regulatory mechanism has not 
been identified however, the regulatory functions of TDP-43 in miRNA production could be investigated 
in relation to hnRNP-E2 expression in the future.  Furthermore, the cellular stress response could 
provide a possible explanation for TDP-43 and hnRNP-E2 aggregation in FTLD-TDP cases as both are 
reported to be stress responsive proteins {Colombrita, 2009 #1059;Dewey, 2012 #772;Moisse, 2009 
#1955;Bentmann, 2013 #17}.   
160 
 
6.1.4 hnRNP-E2 and TDP-43 interaction. 
The possible interaction between hnRNP-E2 and TDP-43 was investigated in this project through a 
series of cell biology experiments which aimed to determine whether hnRNP-E2 accumulation is 
upstream or downstream of TDP-43 accumulation and to investigate any physical interaction between 
hnRNP-E2 and TDP-43.  Changes in the relative expression levels of one protein can have a significant 
impact on other proteins in its interacting network, either directly or indirectly by affecting common 
cellular targets {Mohagheghi, 2016 #1674}.  To investigate if hnRNP-E2 is upstream of TDP-43 
pathology, hnRNP-E2 was overexpressed and silenced in HEK293T cells and TDP-43 expression 
levels were measured and compared to controls.  To investigate if hnRNP-E2 is downstream of TDP-
43 pathology, a similar experiment was performed but with overexpressing and silencing TDP-43 and 
the levels of hnRNP-E2 were measured compared to controls.  The knockdown of hnRNP-E2 showed 
a significant effect in reducing TDP-43 levels, in contrast knock down of TDP-43 did not affect hnRNP-
E2 levels significantly.  The overexpression experiments did not reveal significant changes either way.  
The results suggested that hnRNP-E2 is upstream of TDP-43 however, it is not clear if they are 
interacting directly or through an indirect pathway.  To further investigate TDP-43 and hnRNP-E2 
interaction, Co-IP was performed in HEK293T cells.  The pull down of hnRNP-E2 showed a band for 
TDP-43 however it was shown that this band is due to the non-specific binding of GFP-TDP with the 
sepharose beads as it occurred in the absence of any antibodies. The IP results support the previous 
finding of hnRNP-E2 being upstream of TDP-43. 
It was also shown that TDP-43 and hnRNP-E2 were both recruited into stress granules under stress 
conditions - as had previously been described by other groups {Fujimura, 2009 #224;Fujimura, 2008 
#218;Dewey, 2011 #931;Monahan, 2016 #1921}. Following oxidative stress endogenous TDP-43 and 
hnRNP-E2 colocalised with each other within SGs as well as with the SG marker PABP1, an effect that 
was greatly enhanced by the sequential addition of an osmotic challenge. hnRNP-E2 has been 
identified as a facilitator of the IRES and to have an important role in remodelling mRNAs in the SGs 
and transferring specific mRNAs from SGs to P-bodies for degradation {Fujimura, 2009 #224;Fujimura, 
2008 #218}.  This study showed that TDP-43 and hnRNP-E2 colocalise within the SGs during cellular 
stress, however the exact mechanism of recruitment and evidence of direct/indirect interaction could 
not be deduced.  The investigation of hnRNP-E2 and TDP-43 interaction in cell lines aimed to identify 
any direct or indirect interaction between hnRNP-E2 and TDP-43, initial results suggested that hnRNP-
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E2 is upstream to TDP-43 pathology however, the results were not reproducible and therefore this part 
of the study was inconclusive.  Under stress condition both proteins are recruited to stress granules, 
however further studies, including in vitro and in vivo models are required to fully explore the relationship 
of hnRNP-E2 to TDP-43 and its pathological significance. 
 
6.2 Therapeutic Strategies for FTLD-TDP 
FTD has traditionally been overshadowed by other neurodegenerative diseases, such as AD, in regard 
to therapeutic modifiers.  Currently FTD treatment is based on symptom management rather than 
targeting the underlying cause of the neurodegeneration.  Furthermore, the rational of using such 
therapeutics is based on efficacy in treating other neurodegenerative disorders or psychiatric conditions 
with similar behavioral phenotypes.  Generally, FTD patients with behavioral disturbances are treated 
with serotonin or norepinephrine reuptake inhibitors and antipsychotics.  However, there is no definitive 
treatment for FTD and there is an extreme need for novel therapeutics which target underlying 
pathological pathways {D’Alton, 2014 #2273}.  The two pathological hallmarks of FTLD are 
hyperphosphorylated tau protein in neurons and glial cells (FTLD-tau) and TDP-43 inclusions which 
constitute 80-95% of FTLD-ubiquitin (FTLD-U) {Li, 2016 #2275}.  The rapid advances in genetic and 
pathological discoveries over the past decade have provided a greater understanding of FTD and a 
potential approach for developing therapeutics.  However, FTD remains a highly complex condition and 
the roles of tau and TDP-43 in the resulting neurodegeneration are still unclear {Sieben, 2012 #2276}.  
 
6.2.1 FTLD-TDP genetics as driver for therapeutic strategies 
FTD, is a clinically and pathologically heterogeneous condition and by the time the clinical phenotype 
and atrophy is diagnosed it is probably too late to reverse the neuronal changes already set in motion.  
Interestingly, structural and cognitive changes can be identified 5-10 years prior to presentation of 
symptoms in patients with a genetic FTD risk {Rohrer, 2015 #2277}.  Therefore, understanding the 
presymptomatic stage and disease progression is crucial for future therapeutic development.  As 
discussed earlier in this thesis, familial mutations in the MAPT gene encoding tau protein which explain 
a subset of FTLD cases also provide compelling evidence for the involvement of tau in sporadic cases 
which share some of the same pathological hallmarks {Hutton, 1998 #2278;Hutton, 1998 #2279}.  
However, TDP-43 genetics are more complicated in FTLD cases.  TARDBP mutations are not found in 
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heritable FTLD despite it existing in familial ALS (which is considered to be at the opposite end of the 
disease spectrum to FTLD).  Therefore, the connection seems justified on biological levels in addition 
to the reports of TARDBP mutations in sporadic FTLD cases {Borroni, 2009 #2280;Synofzik, 2014 
#2281}.  Familial FTLD has been linked to mutations in the VCP, C9ORF72 and GRN genes. Other 
rare mutations have also reported to cause FTLD, including those in CHMP2B, SQSTM1, and UBQLN2.   
 
6.2.1.1 TDP-43 and PGRN 
Although GRN mutations are widely accepted as being related to TDP-43 pathology, the mechanisms 
connecting progranulin haploinsuffeciency and TDP-43 aggregation remain unclear.  PGRN possesses 
neurotrophic activity and it has roles in the periphery including inflammation and wound healing {Ahmed, 
2007 #2283;Laird, 2010 #2282}.  Animal model studies provided some insight into TDP-43 pathology 
related to GRN mutations.  Elevated levels of hyperphosphorylated full-length TDP-43 were recovered 
from detergent-insoluble brain fractions from GRN knockdown mice although phosphorylated TDP-43 
was not detected in the ubiquitinated inclusions {Wils, 2012 #2377}.  Reduction of PGRN enhances 
caspase-3 activation which make the neurons vulnerable to sublethal doses of N-methyl-D aspartic acid 
(NMDA) and hydrogen peroxide which may contribute to TDP-43 pathology.  Some GRN knockdown 
mice do not exhibit accumulation of TDP-43 C-terminal fragments or only show TDP-43 accumulation 
at a late stage {Wils, 2012 #2377;Guo, 2010 #2378;Ahmed, 2010 #2379}.  The current explanation is 
that TDP-43 pathological fragment aggregation may be a late event in FTLD pathogenesis or that the 
mice model cannot stimulate the full extent of the human pathology. 
PGRN is a particularly attractive target for treatment development. The strategies targeting PGRN are 
mainly divided into two groups.  The first group focuses on increasing the levels of PGRN and the 
second group focuses on targeting its receptors.   An example of medications used to elevate PGRN 
level is Suberoylanilide hydroxamic acid (SAHA), a histone deacetylase inhibitor (HDACi) which has 
been identified as an enhancer of GRN transcription and subsequently shown to increase PGRN 
expression in a neuro-2a cell line derived from pathogenic GRN mutation carriers {Cenik, 2011 #2380}.  
Another example is Bafilomycin A1 (Baf A1), which is a vascular ATPase inhibitor shown to increase 
PGRN levels, however the exact mechanism remains undetermined {Capell, 2011 #2381}.  Sortilin1 
and TNF are examples of group two therapeutics targeting PGRN receptors, which reduce GRN-
induced endocytosis resulting in increased PGRN levels {Hu, 2010 #2382;Tsai, 2014 #2383}. These 
163 
 
data suggest that the development of specific PGRN modulation compounds might be a key to treat 
TDP-43 pathologic FTLD. 
hnRNP-E2 is reported to regulate caspase-3 levels and play a role in cellular apoptosis {Mao, 2016 
#1960}.  This study could have provided a further explanation if it considered hnRNP-E2 in FTLD-TDP 
with GRN mutation.  Here, only one case with GRN mutation has been investigated by IHC which was 
negative for hnRNP-E2 inclusions.  Increasing the cases number and running western blots on brain 
lysate could have advanced this study regarding PGRN role in FTLD-TDP pathology.  Also investigating 
hnRNP-E2 in the GRN knockdown mice model may provide more insight into the TDP-43 pathological 
mechanism. 
 
6.2.1.2 TDP-43 and C9ORF72 
In patients with C9orf72 expansion, both TDP-43 and p62 inclusions can be detected.  The p62 
inclusions core could contain DPRs surrounded by TDP-43.  In addition, p62 overexpression 
antagonizes TDP-43 cytosolic aggregation, however reports suggest that TDP-43 may also tackle and 
trap p62, decreasing its autophagy functional component and reducing its capability to remove 
abnormal aggregates {Brady, 2011 #2384;Wang, 2013 #2385}.  Rapamycin is a macrolide compound 
obtained from Streptomyces hygroscopicus which acts by selectively blocking the transcriptional 
activation of cytokines thereby inhibiting cytokine production.  Studies in FTLD-U mice models with 
TDP-43 proteinopathies showed that rapamycin treatment effectively rescues the learning/memory 
impairment of these mice at 3 months of age and significantly slows down the age-dependent loss of 
their motor function.  In addition, rapamycin decreased caspase-3 levels and neuronal loss in the 
forebrain of FTLD-U mice.  Furthermore, it significantly decreased the number of cells with positive 
TDP-43 inclusions and the amount of full length TDP-43 and its cleavage products in the urea-soluble 
fraction of the cellular extract.  The TDP-43 changes after rapamycin treatment is believed to be due to 
inhibition of rapamycin mammalian target (mTOR) which induces reduction in mTOR-regulated 
phospho-p70 S6 kinase (P-p70) and the p62 protein {Wang, 2013 #2385}.  For future work, it would be 
interesting to look at the levels of hnRNP-E2 in FTLD-U mice brain considering its caspase-3 regulation 
activity and the effect of rapamycin on hnNRP-E2.  
In patients with the C9orf72 intronic expansion mutation, both the antisense and sense strands are 
transcribed from the expanded hexanucleotide (G4C2) locus and form nuclear RNA aggregates (RNA 
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foci) which may cause cellular death by sequestering functional RNA binding proteins {DeJesus-
Hernandez, 2011 #831;Lee, 2013 #2387}.  The expanded RNA also undergoes repeat associated non-
ATG translation (RAN translation) which produces aggregation prone polypeptides that form inclusions 
in human FTD {Mori, 2013 #658}.   Targeting the expanded (G4C2) transcripts is another therapeutic 
concept which has already proven successful in vitro {Donnelly, 2013 #2386}.  In addition, antisense 
efficacy in motor neurons derived from C9orf72 carriers was demonstrated by another study {Sareen, 
2013 #2388}.  A promising research on C9orf72 transgenic mice showed decreased levels of mutant 
pathogenic mRNAs by the administration of antisense oligonucleotide drugs (AODs) therefore, 
decreasing RNA toxicity and disease symptoms {Lagier-Tourenne, 2013 #2404;Riboldi, 2014 #2405}.  
However, future studies are essential to clarify the mechanistic link of RNA foci and RAN proteins to 
neurodegeneration as well as to determine if such approach is likely to address the neurotoxicity in 
C9orf72 cases.   
In this study hnRNP-E2 was investigated in FTLD-TDP cases with the C9orf72 expansion.  Interestingly, 
hnRNP-E2 was not detected in any of the brain regions (frontal cortex, hippocampus and cerebellum) 
where TDP-43 and/or p62 pathology are detected.  This finding increases the evidence for a different 
underlying mechanism of TDP-43 aggregation in different types of FTLD-TDP and specifically that TDP-
43 may not be the driving force behind the neurodegeneration seen in C9orf72 expansion cases (a 
hypothesis backed up by recent publications investigating the role of DPRs in C9 ALS and FTLD 
{Gomez-Deza, 2015 #2248}{Davidson, 2014 #208}. The results also support the idea that therapeutic 
implications would need to be targeted rather than extrapolated to the FTD population at large.  In the 
case of C9orf72 expansion, where a genetic test could be carried out, this would be viable but currently 
the only way to distinguish between the other subtypes is by clinical phenotype. The possibility that 
interacting proteins such as E2 might be detectable in CSF or blood would be an exciting move forward 







6.2.2 Targeting TDP-43 
The TDP-43 pathogenesis perspective of FTLD could be summarised in two main hypotheses, a toxic 
gain of function related to accumulation of cytosolic inclusions or a loss of function mechanism linked 
to depletion of endogenous nuclear TDP-43.  Currently, TDP-43 proteinopathy and its endogenous 
function is not fully understood, thus the development of targeted therapeutics has not developed to 
expectations.  Logical therapeutic suggestions would be restoration of TDP-43 nuclear function and 
decreasing the formation, or increasing the clearance, of TDP-43 aggregates.  Loss of TDP-43 has 
significant implications on cellular integrity thus reduction of expression of TDP-43 is not a therapeutic 
option.  Preventing cytoplasmic accumulation and retaining nuclear function may prove beneficial if their 
mechanisms are defined.  Methylene blue (MB) and Dimebon (Latreperdie), which have proven 
successful in Phase II clinical trials for AD, have been shown to decrease TDP-43 aggregation in cellular 
studies.  In SH-SY5Y cells, the number of TDP-43 aggregates was reduced by 50% and 45% following 
treatment with 0.05 μM MB or 5 μM Dimebon respectively. Meanwhile, the combined use of MB and 
Dimebon resulted in an 80 % reduction in the number of aggregates, which indicates that MB and 
Dimebon may be useful for the treatment of FTLD-U {Yamashita, 2009 #2389}.  Another concept for 
lowering TDP-43 levels is through enhancing its clearance as it is demonstrated that TDP-43 inclusions 
are degraded by both autophagy and the ubiquitin-proteasome system. Disrupting the interaction of 
Heat Shock Protein 90 (Hsp90) with co-chaperone 37 (Cdc37) facilitated caspase-mediated TDP-43 
nuclear retrotranslocation, leading to TDP-43 autophagic clearance, suggesting Cdc37/Hsp90 complex 
might hold promise as a potential therapeutic target {Jinwal, 2012 #2390}.  Currently, our knowledge 
about TDP-43 biology is limited, which consequently limits the development of TDP-targeted therapies.  
Increased knowledge of basic TDP-43 functions and interactions should provide greater understanding 
of potential therapeutic target pathways.  This project provided some insight into TDP-43 possible 
interaction with hnRNP-E2.  However, further investigations using more sophisticated research tools 
such as animal models recapitulating TDP-43 pathology and patient specific induced pluripotent stem 
cells (iPSCs) should provide better understanding of FTLD-TDP pathology and hence a step forward 





In conclusion, this project investigated several candidate TDP-43-binding proteins in the brain tissue of 
FTLD and ALS cases with confirmed TDP-43 pathology.   Of the proteins investigated (RANBP1, 
Ubiquilin-2, hnRNP-M, hnRNP-C1/C2, hnRNP-Q and hnRNP-E2), Ubiquilin-2 and hnRNP-E2 showed 
striking and disease specific perinuclear and neuritic inclusions in the frontal cortex in FTLD-TDP 
pathological subtypes A and C.  The role of hnRNP’s in neurodegenerative conditions is an emerging 
area of research, with many hnRNPs linked to ALS and/or FTD through pathogenic mutations or their 
sequestration within the C9orf72 G4C2 expansion RNA foci, however, their disease specific 
mechanisms are poorly understood. This study is the first to show a direct association of an hnRNP 
with specific FTLD-TDP subtypes.  The results increase the evidence that there are different pathways 
involved in TDP-43 aggregate formation and hence different underlying disease mechanisms occurring 
in the different pathological subtypes of FTLD. This could have implications for both further research 
directions for understanding of the mechanisms of neurodegeneration and the role of TDP-43 and for 
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